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Abstract 
 
Successful gene therapy depends upon specific gene delivery into the cells and tissues of 
interest. Nanomagnetic gene transfection is a relatively new gene delivery technique that 
has attempted to meet that need and has been effectively used with both viral and non-viral 
vector systems.   
It uses magnetic nanoparticles (MNPs) in assisting and directing specific delivery of 
reporter or therapeutic genes on a single cell basis, in the presence of an externally 
introduced oscillating magnet. The novelty of the lateral oscillation further stimulates 
endocytosis of MNP:plasmid complexes with improved in vitro transfection efficiency 
compared to the static magnet application and other non-viral gene delivery approaches. 
This work’s purpose was to contribute in the optimisation of this tool for safe and efficient 
gene delivery, and to investigate the applicability of the method in a wider range of cell 
types used for regenerative medicine purposes, improving transfection efficiency and 
duration. Novel transfection experiments using commercially available MNPs coupled to a 
reporter gene, demonstrated higher levels of transfection efficiency (differing among cell 
types) and cell viability (80-94%), at the lowest reagent concentrations across all post-
transfected cell types, compared with the most widely used cationic lipids (Lipofectamine) 
and/or electroporation. 
  
In particular, using human lung mucoepidermoid carcinoma cells (NCI-H292), the 
magnetic field requirements for transfection were evaluated; using human osteosarcoma 
fibroblasts (MG-63), a nanomagnetic transfection protocol at shorter transfection times (30 
min) was established for increased transfection efficiency (53% oscillating and 49% static 
  
II 
 
magnet, 7% at 30 min and 24% at 6 hr Lipofectamine, and 21% electroporation); using 
mouse embryonic fibroblasts (NIH-3T3), the 30 min-protocol was applied further (25% 
oscillating and 22% static magnet, 2% at 30 min and 22% at 6 hr Lipofectamine); using 
human mesenchymal stem cells (hMSCs), the ability of the method to transfect primary 
cells and to retain key markers for multipotency was demonstrated; using human 
embryonic stem cells (hESCs), the transfection capability in additional types of primary 
cells was shown, along with indications of retention of key markers for pluripotency and 
differentiation, although further work is required to confirm this finding. 
Nanomagnetic gene transfection shows promising results for in vitro and in vivo non-viral 
gene delivery and biomedical engineering applications. Data from this study could to be 
used for MNP drug delivery strategies, ultimately for clinical translation.    
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1.1 Preface and chapter synopsis 
The purpose of regenerative medicine is to develop new therapies for the repair or 
regeneration of human cells, tissues or organs and to restore or enhance normal function 
(Mason, 2008; Couto et al., 2012). This field is fast expanding and by its definition largely 
multidisciplinary. One of several well known, high impact advances of regenerative 
medicine that build our hopes and future expectations include the Nobel Prize winning 
discovery that mature cells can be reprogrammed back to pluripotent stem cells (Takahashi 
& Yamanaka, 2006). Furthermore, and reaching the clinic, lifesaving technologies have led 
to the first successful transplantation of a human tissue engineered trachea (Macchiarini et 
al., 2008), followed by successful transplantation of the first tissue engineered organ, a 
trachea (Jungebluth et al., 2011).   
Such breakthroughs are multifactorial tasks, and scientists along with clinicians are 
working closely to face the many challenges and needs in human cell therapies, gene-based 
methods and molecular biology, engineering, biomaterials and advanced surface chemistry. 
Gene therapy has been proven a useful tool for the delivery of needed growths factors or 
biomolecules that traditionally hold an essential part in multiple regenerative medicine 
applications (Harrison et al., 2014). 
 
This chapter aimsin providing the reader with the essential understanding of the general 
background of this study. The focal point and this work’s primary interest, the 
nanomagnetic gene transfection method as a magnetic nanoparticle (MNP)-based gene 
delivery tool, has been introduced and discussed. In addition, and as a requirement in order 
to understand the series of progressions that led to the development of the method, the key 
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terms of gene therapy and its significance as a potential breakthrough therapeutic 
approach, as well as the major currently available viral and non-viral approaches for gene 
delivery were described. Furthermore, the physical background of magnetism, magnetic 
materials and magnetic nanoparticles related to nanomagnetic gene transfection has been 
introduced along with some of their multiple applications. Finally, the human and mouse 
cell culture systems (primary cells and cell lines) used in this study for the application of 
the method and evaluation of the qualitative and quantitative results were presented in this 
chapter. 
 
1.2 Overview of gene therapy 
Genes are heritable units controlling identifiable traits in every organism and for a long 
time have been considered as medicines (Mammen et al., 2007; Wirth et al., 2013). Living 
beings rely on genes coding for all proteins, following the central dogma of molecular 
biology to ensure specific transcription from DNA to RNA and translation from RNA to 
protein
 
(Crick, 1970;). In September 1966, Joshua Lederberg talked about the necessity of 
evolutionary theory to model a self-modifying system and the potential of genetic therapy 
to repair any “genetic-metabolic” disease (Lederberg, 1966). Nowadays, gene therapy is 
considered as a method to insert genetic material into an individual’s cells and tissues in 
order to replace a defective gene, or by introducing a new function into cells to attempt to 
treat complex diseases at a genetic level (Kay, 2011; Soleimani et al., 2015). The diseases 
targeted by gene therapy are some of the most complex and deadly such as cancers, 
inherited or acquired genetic deficiencies, autoimmune diseases, cardiovascular disease 
and Parkinson’s (Ginn et al., 2013). Gene therapy as a potential therapeutic tool requires 
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effective gene delivery via vectors, such as viruses and plasmids, which are agents used as 
vesicles to carry foreign genetic material into the target cells and tissues
 
(Giannoukakis et 
al., 1999; Grigsby & Leong, 2010). Gene therapy is usually divided into the two main 
classes of somatic gene therapy (SGT) and human germ line gene therapy (HGLGT) that 
are fundamentally different with respect to long-term consequences. HGLGT involves 
intervention at the embryonic stage in order to tackle inherent genetic disorders, potentially 
with the transgene (the transferred gene), being passed on to future generations, which has 
given rise to numerous ethical issues and controversies over time (Nielsen, 1997; Jones, 
2006; Soleimani et el., 2015). The next paragraphs will focus on SGT and its significant 
input in regenerative medicine. 
 
1.2.1 Somatic gene therapy (SGT)  
Somatic gene therapy is the only technique that is currently considered appropriate for use 
in humans. It involves the insertion of  genes into somatic cells of an individual with a life-
threatening genetic disease that is intended only to eliminate the clinical consequences of 
the disease. The genetic intervention affects only a subset of patient’s cells and passes no 
genetic information to the next generation. Therefore, it does not directly affect any 
descendents
 
(Mountain, 2000; Mavilio & Ferrari, 2008).  
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1.2.1.1 Criteria for SGT candidates   
In SGT, gene transfer systems are chosen and modified based on each therapeutic target’s 
particular needs. The multiple criteria which enable a particular disorder to be an 
appropriate candidate for SGT include the following:  
 Severity and frequency of the disease that can have a dramatic impact on patient’s 
quality of life. 
  Nature of the genetic defect or abnormality. For example, monogenic diseases are 
appealing due to the need of replacing well-defined defective genes (Ginn et al., 
2013).   
  Lack or ineffectiveness of already existing treatments (Mavilio & Ferrari, 2008). 
  Existence of a suitable experimental animal model to enable research and develop 
safe protocols. 
 Availability of a suitable gene transfection system for the affected cell type. 
 Ability to isolate and clone the defective gene. 
 Introduction of the normal gene into a significant subfraction of the affected target 
tissue, to ensure sufficient gene expression for the desirable effect) (McBain et al., 
2008a). 
 
1.2.1.2 The ex vivo approach 
In SGT, genes can be delivered by two different approaches, the ex vivo and the in vivo: 
The ex vivo approach is the most common where all genetic alterations of patients target 
cells are performed outside the body. Firstly, the physiologically accessible target cells are 
removed from the patient. These cells are manipulated in the laboratory in order to 
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incorporate the vector containing the transgene or recombinant vector and then are 
introduced back into the patient (Figure 1.1)
 
(Mammen et al., 2007). This approach is 
likely to be more efficient due to the accumulation of a higher vector to target cell ratio 
present in cell culture, and because it allows the reintroduction only of those cells back into 
the patient that have incorporated the transgene, improving efficacy (Naldini, 2011). 
Additionally, viral and non-viral delivery systems that have been extensively developed for 
gene therapy applications are being used for the vector reintroduction back to the patient 
(Cox et al., 2015). Furthermore, there is better control over the dosage of therapeutic 
molecules to be delivered to cells (Hsu et al., 2013).  
However, there are two main disadvantages of the ex vivo approach. First, invasive 
procedures are used for the extraction and reintroduction of cells, with a potentially poor 
engraftment following reintroduction back into the patient that could compromise the 
effectiveness of the treatment (Tuszynski, 2007; Cox et al., 2015). Second, the use only of 
cells capable of surviving outside the body, being manipulated in cell culture and 
transplanted back to target tissues while retaining their properties and function (Cox et al., 
2015). 
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Figure 1.1: Flow chart of key steps during ex vivo somatic gene therapy. (1) Target 
cells are removed from patient with biopsy and (2-3) cultured and manipulated in the 
laboratory to incorporate the therapeutic gene or recombinant vector. (4) Cells with 
incorporated transgene are reintroduced back into the body to produce the desired protein 
encoded by the inserted gene.  
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 1.2.1.3 The in vivo approach 
The in vivo approach allows direct administration of gene transfer vectors to patients in 
their native tissues, called in situ, that are still part of a living organism (Figure 1.2). This 
is contributing in the simplicity of the system and repeatability of administration in the 
same location (Tuszynski, 2007).  s. This method is less invasive compared to ex vivo and  
advantageous for working with less accessible cells or cell types which do not easily 
survive for long outside the body
 
(Duan et al., 2004).  
Thetechnique comprises two major limitations. The first lies with  immune system 
response and rejection of therapeutic vector or toxic reactions (Raper et al., 2003; Bessis et 
al., 2004; Manno et al., 2006; Mavilio & Ferrari, 2008; Naldini, 2011). The second refers 
to non-specific gene targeting, when this is not the aim, which is a significant challenge 
since the vector moves around the body until it reaches the target tissue that could lead to a 
number of consequences such as: (i) the possibility of the vector infecting other tissues or 
the germ line , (ii) the insufficiently controlled vector distribution and dosage, and (iii) the 
potential for insertional mutagenesis or off-target mutations (Tuszynski, 2007; Howe et al., 
2008; Cox et al., 2015). 
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Figure 1.2: Flow chart of key steps during in vivo somatic gene therapy. (1) The 
therapeutic gene or recombinant vector carrying the gene of interest is manipulated in the 
laboratory and (2) introduced directly into the patient’s body. (3) Inside the body and in 
contact with the specific tissue’s cells the transgene is incorporated into the target cells to 
produce the desired protein encoded by the inserted gene.  
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1.2.2 Success stories in clinical trials 
Gene therapy by its definition, and due to the ability of acting on a single cell basis, has a 
wide therapeutic potential that could provide more effective treatment in some existing 
therapeutic options or alleviate and even cure  previously untreatable diseases. The input of 
gene delivery for gene therapy in the preclinical research is truly extended and diverse. 
However, there are several gene therapy success stories that have come a long way from 
basic science in being translated to therapies in the clinic, some of which were presented in 
this section. 
 
1.2.2.1 Adenosine Deaminase-Severe Combined Immuno-deficiency (ADA-SCID)In 1990, 
the first gene therapy trial was conducted treating successfully but temporarily a 4-year-old 
girl diagnosed with Adenosine Deaminase-Severe Combined Immuno-deficiency (ADA-
SCID), by ex vivo retroviral-mediated introduction of the normal ADA gene into T 
lymphocytes (Blaese, 1993). Since 2000, more than 30 patients with ADA-SCID have 
been treated worldwide, with reconstruction of immune function and no observed adverse 
events related to the gene transfer technology (Ferrua et al., 2010; Ginn et al., 2013).  
 
1.2.2.2 X-linked Severe Combined Immuno-deficiency (SCID) 
In 2000, the first successful treatment of 2 infants suffering from X-linked SCID (SCID-
X1) was reported (Cavazzana et al., 2000). Since then another 17 infants in two clinical 
trials have been treated by ex vivo retroviral-mediated restoration of the missing IL2RG 
gene, experiencing full immunological reconstruction that highlighted the therapeutic 
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alternative for patients with no suitable matching donor (Hacein-Bey-Abina et al., 2002; 
Gaspar et al., 2004; Ginn et al., 2005; Ginn et al., 2013). 
 
1.2.2.3 Melanoma and Sarcoma  
In 2006, objective regression of metastatic melanoma in 2 patients and sustained levels of 
engineered cells’ circulation one year later were reported, following successful 
immunotherapy with ex vivo retroviral transduction of autologous T lymphocytes capable 
of tumour recognition (Morgan et al., 2006). By extending this strategy, in 2011, a similar 
clinical trial reported objective clinical responses in 4 patients with synovial cell sarcoma 
and in 5 patients with melanoma, indicating the effectiveness of T-cell receptor-based gene 
therapies (Robbins et al., 2011).     
 
1.2.2.4 X-linked Adrenoleukodystrophy (X-ALD)  
In 2009, following long term follow-up, significant clinical benefit was reported for 2 boys 
treated for X-linked adrenoleukodystrophy (X-ALD), a severe brain demyelinating disease 
caused by ALD protein deficiency encoded by ABCD1 gene. Lentiviral-mediated ex vivo 
gene transduction in haematopoietic cells demonstrated the stoppage of progressive 
demyelination, which was comparable to the results from allogeneic haematopoietic cell 
transplantation (HCT) as the only other available treatment (Cartier et al., 2009).  
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1.2.2.5 Leber’s Congenital Amaurosis (LCA) 
In 2010, gene therapy for Leber’s congenital amaurosis (LCA), an inherited retinal 
blinding disease, was reported as safe and effective using sub-retinal administration of 
adeno-associated (AAV) virus encoding the mutated RPE65 gene. The underlying 
improvement of both objective and subjective vision measures was supported by three 
independent studies (Simonelli et al., 2010).      
 
1.2.2.6 β-thalassaemia 
Also in 2010, in a trial for β-thalassaemia which is characterised by reduced synthesis of 
haemoglobin, an adult patient following ex vivo lentiviral β-globin gene transfer became 
transfusion independent for 21 months, while since childhood monthly transfusions were 
required (Cavazzana et al., 2010).    
 
1.2.2.7 Chronic Lymphocytic Leukaemia (CLL) 
In 2011, the treatment of 3 patients with chronic lymphocytic leukaemia (CLL) was 
reported using autologous genetically modified T lymphocytes to express chimeric antigen 
receptors (CAR) that target tumour-associated cell surface antigens, indicating potent 
antitumor effects (Kalos et al., 2011). 
 
1.2.2.8 Heart Failure 
Also in 2011, in a trial with 39 patients suffering from advanced heart failure, the 
upregulation of calcium (Ca
2+
) by administration of AAV-mediated sarcoplasmic 
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reticulum Ca
2+
-ATPase, alleviated considerably heart failure symptoms (Jessup et al., 
2011; Hammoudi et al., 2015).    
 
1.2.2.9 Haemophilia B 
In 2012, gene therapy for Haemophilia B was reported as safe and effective for 2 patients 
treated with AAV-mediated transduction of the lacking factor IX controlling blood 
clotting. Additionally, all 7 patients of this trial showed no acute or long-lasting toxicity, 
and experienced the beneficial effects of factor IX levels elevation eliminating or reducing 
the need for regular factor IX infusion (Tuddenham, 2012).     
 
1.2.2.10 Lipoprotein Lipase (LPL) deficiency 
Also in 2012, Glybera was recommended from the European Medicines Agency (EMA) as 
the first gene therapy product to receive authorisation and reach the clinic for the treatment 
of lipoprotein lipase (LPL) deficiency, in patients with severe or multiple pancreatitis 
attacks (Ylä-Herttuala, 2012). 
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1.2.3 Hurdles and prospects 
Success stories such as the above required decades of efforts and countless hurdles to be 
overcome. In some cases, disappointments could not be prevented that even affected 
patients’ welfare. Some of these cases described non-responding patients and specifically 
15 with metastatic melanoma, 2 with synovial cell carcinoma and 6 with melanoma 
(Morgan et al., 2006; Robbins et al., 2011), while 4 patients had developed leukaemia but 
eventually treated in SCID-X1 trials (Hacein-Bey-Abina et al., 2008; Howe et al., 2008). 
However, the most disheartening were the 3 cases of patient deaths; (i) the first, in 1999 4 
days following adenoviral transduction for X-linked ornithine transcarbamylase (OCT) 
deficiency (Raper et al., 2003); (ii) the second, who developed leukaemia 30 months out of 
treatment for SCID-X1 following the gene-therapy protocol stoppage in 2002 (Howe et al., 
2008; Hacein-Bey-Abina et al., 2010); and (iii) the third, in 2016 7 days following 
repeated higher doses of a drug aiming to treat anxiety and motor disorders associated with 
Parkinson’s disease as well as chronic pain in people with cancer (Butler & Callaway, 
2016).  
 
Nevertheless, and quite rightly, the scientific world has invested resources and hopes in 
gene therapy, and a long list of treatment schemes for various target diseases have reached 
the stage of clinical trials. The vast majority of clinical trials has been devoted to cancer 
(64.4%), followed by monogenic, cardiovascular and infectious diseases addressing 
approximately another 25% of the trials (Figure 1.3) (Ginn et al., 2013). 
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Figure 1.3: Diseases targeted by gene therapy in clinical trials. The figure is indicative 
of the range and proportion of diseases addressed by gene therapy clinical trials worldwide 
up to 2012 (Adapted from Ginn et al., 2013).   
 
Furthermore, there are diseases such as Cystic Fibrosis (CF) and Parkinson’s disease (PD) 
where no cure is yet available, but they are considered good candidates for gene therapy 
and might be possible to be addressed using cell-therapies (Mason & Dunnill, 2008).  
CF is caused by a single gene mutation of the cystic fibrosis transmembrane conductance 
regulator (CFTR) and clinically leads to inflammation and lung disease due to airways 
blockage by mucus build-up and decreased mucociliary clearance. Related clinical trials 
have began more than 20 years ago employing viral and non-viral vectors, extending our 
Chapter 1 – Literature Review 
 
 - 16 - 
 
understanding and marking the difficulty of gene delivery into the lungs (Griesenbach et 
al., 2006; Flotte, 2007; Mueller et al., 2008; Mimoto et al., 2010). More recently, it was 
reported that lentiviruses may be capable of evading the immune system which offers new 
hope for CF gene therapy prospects (Griesenbach et al., 2011).  
PD presents several features with the major motor symptoms being associated with 
dysfunctions in brain cells’ nuclei that can be effectively targeted by viral vectors (Lim et 
al., 2010). Extended research has been devoted and progress has been made up to date, 
were multiple clinical trials have used viral vectors to deliver therapeutic transgenes to 
neurons, as it is believed that not only the correction of motor symptoms, but also the 
delivery of neuroprotective genes to specific brain cells nuclei could possibly be a way to 
stop the disease progression (Kaplitt et al., 2007; Goune et al., 2012; Palfi et al., 2014; 
Soleimani et al., 2015). Despite the progress made so far and the significant clinical 
successes, a greater understanding of the technical barriers and true benefits of gene 
therapy is essential to provide optimized clinical treatments that could address more 
diseases.  
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1.3 Overview of gene delivery  
Until this day, many different viral and non-viral gene delivery methods have been 
developed, the most popular of which are illustrated in Figure 1.4. These protocols initially 
have being tested in vitro for their gene transfer efficiency and have proved to be an 
invaluable tool for understanding genetic pathways, diseases and drug screening
 
(Dykxhoorn et al., 2003; Ostedgaard, et al., 2005; Nishijima et al., 2007). In addition, 
reporter DNA constructs, such as firefly luciferase and green fluorescent protein (GFP), are 
often incorporated into the vector sequence to facilitate sensitive monitoring of gene 
transfer and validate transfection efficiency following their expression into the target cells
 
(Baldwin, 1996; Welsh & Kay, 1997; Nightingale et al., 2006; Fouriki et al., 2014; Wang 
et al., 2014). Further in vivo experiments using many of these gene transfer methods have 
been applied in animal models
 
(Mikata et al., 2002; Shi et al., 2006; Horimoto et al., 2006; 
Callejas et al., 2013) to extend our understanding and ensure safety prior to human testing 
(Kalka & Baumgartner, 2008; Aiuti et al., 2009). The criteria for choosing the most 
suitable gene delivery vector (Section 1.3.1), as well as the major currently available 
methods for gene transfer divided into two main classes of viral (Section 1.4) and non-viral 
gene delivery (Section 1.5) will be described in the following sections. 
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Figure 1.4: Flowchart of major gene delivery approaches. The outline of viral and non-
viral gene delivery approaches as a result of the need for gene therapy.  
 
1.3.1 Gene delivery challenges and the choice of vector 
The need for further improvement of the currently available gene delivery systems 
remains, as there are multiple barriers to be overcome described by several research groups 
that include: (1) the off-target effect, related to the need for increased target tissue 
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specificity; (2) the host immune response including enzyme degradation of the transgene in 
serum and reticuloendothelial system (RES) recognition; (3) the insufficient vector 
accumulation at the target sites that lead to insufficient transgene gene delivery into the 
cells; (4) the vector uptake by the target cells; (5) the endosomal escape; (6) the nuclear 
entry and transgene expression (Scherer et al., 2002; McBain et al., 2008a; Al-Dosari & 
Gao, 2009; Kay, 2011; Naldini et al., 2011; Zhang et al., 2012; Mingozzi & High 2013).  
 
As expected due to the complexity of the topic, there is no perfect vector or gene delivery 
system of any kind that can provide a cure that is safe without any limitation or side effect. 
The choice of the vector is often dictated by the therapeutic need or the experimental 
objective. Theoretically, an ideal gene therapy vector could combine characteristics of both 
viral and non-viral systems in order to meet the many gene delivery challenges (Figure 
1.5). Several properties of these systems would need to be brought together as the vector 
has to be efficient, specifically targeted, biodegradable or easy to remove, stable in the 
blood stream and non-toxic (Munoz et al., 2012). Additionally, it is of high importance to 
be safe and to initiate no inflammatory or immunogenic response, to be able to protect 
genetic materials against degradation during transport and be stable for storage
 
(Kay et al., 
2009; Grigsby & Leong, 2010; Kay et al., 2011).  
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Figure 1.5: Ideal gene transfer vector characteristics for gene therapy. The schematic 
illustrates the major characteristics desired from a gene delivery vector suitable for in vitro 
and in vivo gene therapy. 
 
1.3.1.1 Stable or transient transfection of the vector    
Furthermore, the ability of a vector to stably or transiently transfect the target cells is to be 
considered. For stable transfection the inserted gene is incorporated into the host genome 
and transgene expression is sustained, affecting cell function and/or regulatory pathways, 
while for transient transfection the transgene is expressed for only a limited time period 
(Kim & Eberwine, 2010). The choice for stable or transient transfection is dictated by the 
short- or long-term experimental objective and/or the therapeutic need. For example, in 
cases of cell-based gene therapy stable transfection would be needed to ensure that the 
beneficial modification will not be lost along cell expansion (Wang & Gao, 2014). On the 
other hand, transient transfection is suitable for short-term applications such as gene 
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knockdown or silencing with inhibitory RNAs and targeted genomic editing in a sequence-
specific way, repairing or disrupting the target region (Mali et al., 2013; Li et al., 2014).  
 
1.4 Viral gene delivery approaches 
Viruses (Latin for toxin or poison) are microscopic infectious agents unable to grow or 
reproduce outside a host cell. Each viral particle, also known as virion, consists of nucleic 
acid genome (DNA or RNA) that may be single- or double-stranded
 
(Mountain, 2000). 
They can be considered as packages used to transfer viral genes into host cells
 
(McBain et 
al., 2008a). Once these small parasites infect a cell by receptor-mediated endocytosis, they 
employ its cellular machinery to maintain their survival in terms of metabolism and 
nutrient supply and to target the nucleus for the delivery of their genes and regulatory 
proteins for initiation of transcription and replication ( Kay et al., 2011; Wang et al., 
2014).. Due to such properties, it was a DNA-based polyomavirus SV40 (Simian 
vacuolating virus 40) that was employed for the first successfully transfected functional 
gene, thyamidine kinase, into a mammalian cell line (Anderson et al., 1980).   
Increasing knowledge about the viral replication mechanism has enabled researchers to 
modify viruses for distinct scientific uses such as vaccine development
 
(Randrianarison-
Jewtoukoff & Perricaudet, 1995; Goedegebuure & Eberlein, 1997). For gene transfer 
purposes, most viral genes have been replaced within the therapeutic gene cassette to 
prevent virus replication into the target cell’s genome, minimising virulence and to create 
space for the transgene (Wang et al., 2014). Then, in a process known as transduction, 
these viral vectors are directed into the target cells and express their functional genetic 
information
 
(Kay et al., 2011) (Figure 1.6). 
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Figure 1.6: Schematic representation of the target cell transduction by an adenoviral 
vector. The recombinant adenovirus carrying a therapeutic gene binds specifically to the 
surface of the host cell via a CAR receptor and enters the target cell by receptor-mediated 
endocytosis. Inside the cytoplasm, endosomal escape and viral capsid disassembly follows. 
The viral genome is inserted into the nucleus through the NPC and following specific 
modifications can remain as an episome or be integrated into the host genome. Using the 
host cell machinery, viral DNA is transcribed and translated completing gene expression. 
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(CAR; Coxsackievirus and adenovirus receptor, NPC; Nuclear pore complex). (Adapted 
from Fouriki & Dobson, 2012; Pankajakshan & Agrawal, 2013).     
 
 
Viral vectors have shown to be important for somatic gene therapy due to their increased 
overall transduction rate compared to non-viral vectors (Mah et al., 2002; Bhattarai et al, 
2008; Wang et al., 2014). Further molecular engineering of these systems, including 
protein engineering approaches to generate viral vectors with novel gene delivery 
capabilities, have been employed trying to meet complicated human therapeutic needs
 
(Schaffer et al., 2008). The most commonly used viral vectors for gene delivery as outlined 
in Figure 1.4, as well as the limitations of their systems are presented in the following 
paragraphs.  
 
1.4.1 Retroviruses 
Retroviruses consist of a linear homodimer of single-stranded RNA (ssRNA) packaged 
within a lipid-enveloped coat, and normally do not exceed 100nm in diameter. Including 
the recently developed lentiviruses, retroviruses have high transduction efficiency in many 
dividing and non-dividing cell types, they can accommodate a transgene size of 7-8kb (and 
stably integrate the transformed ssRNA to double-stranded DNA (dsDNA) into the host 
genome (Barton & Medzhitov, 2002; Anson, 2004; Lentz et al., 2012). They have been 
used successfully in many in vitro and in vivo studies and clinical trials over the years 
(Section 1.2.2) (Miller et al., 1983; Kay et al., 2001; ; Swift et al., 2001; Gaspar et al., 
2004; Ginn et al., 2005; Aiuti et al., 2009; Ferrua et al., 2010). However, a decline in the 
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use of retroviral vectors in clinical trials from 28% in 2004 down to 19.7% in 2012 has 
been observed, probably due to the severe adverse events in the SCID trials (Section 1.2.3) 
(Ginn et al., 2013). 
 
1.4.2 Adenoviruses 
Adenoviruses are non-enveloped dsDNA viruses and do not exceed 100nm in diameter. By 
receptor-mediated endocytosis the virus is inserted into the target cell and reaches the 
nucleus to initiate transcription and replication (Breyer et al ., 2001; Kay et al., 2011). 
Adenoviruses are similar to retroviruses in terms of the wide variety of dividing and non-
dividing cell types that are able to transduce as well as their efficiency, and they are 
considered more advantageous due to their capacity to accommodate larger pieces for 
foreign DNA (5-36 kb)
 
(Breyer, 2001; Lentz et al., 2011), although their transgene 
capacity is still limited for certain genes required for clinical applications (Ginn et al., 
2013). Adenoviruses have been successfully used in many anti-cancer therapy studies 
(Breyer, 2001; Molnar-Kimber et al., 1998; Jie et al., 2007; Yanagie et al., 2009; Ginn et 
al., 2013), neurodegenerative and cardiovascular diseases and pulmonary hypertension 
(Breyer, 2001; Horimoto et al., 2006). They are the most commonly used vectors in 
clinical trials covering the 23.3% of all trials (Section 1.2.2) (Ginn et al., 2013).  
 
1.4.3 Adeno-associated viruses (AAV) 
Adeno-associated viruses are human parvoviruses that contain single-stranded DNA 
(ssDNA) packaged into a lipid envelope. They transduce a wide variety of dividing and 
non-dividing cell types accommodating transgenes 4-5 kb in size and so far they have a 
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good safety record causing no known human disease (Ostedgaard et al., 2005; Kay et al., 
2009; Qiao et al., 2010). They selectively integrate into the host genome and are generally 
stable (Mulligan, 1993; Carter & Samulski, 2001; Qiao et al., 2010). The successes of 
AAVs in vitro and in vivo among others include: the microsphere-mediated delivery of 
recombinant AAV2 for improved vector transduction efficiency (Mah et al., 2002; Mah et 
al., 2000), the self-complementary (sf) AAV for intra-articular gene delivery
 
(Kay et al., 
2009) and the AVV6 use for gene transfer in skeletal muscle
 
(Qiao et al., 2010). They have 
been less widely used in clinical trials (Section 1.2.2) covering the 4.9% of all trials 
(Simonelli et al., 2010; Tuddenham, 2012; Ginn et al., 2013).  
 
An outline of the characteristics, main advantages and disadvantages of retroviruses, 
adenoviruses and adeno-associated viruses frequently used for gene delivery is presented 
in Table 1.1. 
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Table 1.1: Main characteristics of frequently used viral vectors for gene delivery 
(Adapted from Lentz et al., 2011 and Soleimani et al., 2015). 
Viral 
Vector 
Vector 
Size 
(nm) 
Genome Insert 
Size 
(kb) 
Advantages Disadvantages 
Retrovirus 
(eg. 
including 
lentivirus) 
 100 ssRNA  8 >High transduction 
efficiency 
>Prolonged 
expression 
>Dividing &  
non-dividing cell 
transduction 
>Possible 
pathogenicity at 1st 
exposure 
>Insertional 
mutagenesis 
Adenovirus 70-100 dsDNA  36 >High transduction 
efficiency 
>Dividing &  
non-dividing cell 
transduction 
> Pathogenicity 
>Transient 
expression 
Adeno-
associated 
virus (AAV) 
 20 ssDNA  4.5 >Prolonged 
expression 
>Low 
immunogenicity 
>Dividing &  
non-dividing cell 
transduction 
 
>Low transduction 
efficiency 
ssRNA = single stranded RNA, dsDNA = double stranded DNA, ssDNA = single 
stranded DNA. 
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1.4.4 Limitations of viral vectors   
Despite the fact that viral vectors have provided invaluable results for gene delivery and 
gene therapy, and they have increased significantly our understanding about the field, some 
general unresolved problems associated with their use include:  
(i) safety issues (excluding the AAVs) (Verma, 2000; Hacein-Bey-Albina et al., 2003; 
Klink et al., 2004; Hacein-Bey-Albina et al., 2010; Cox et al., 2015).  
(ii) the host inflammatory or immunogenic response that viruses initiate from the infusion 
of foreign materials (Lu, 2001; Spack & Sorgi, 2001; Raper et al., 2003; Davies, 2006; 
Pickard & Chari, 2010; Mingozzi & High, 2013). 
(iii) the target tissue specificity which can cause tissue damage in undesired tissues and 
organs (when delivery and transduction is non-specific)
 
(Verma, 2000; Naldini et al., 
2011).  
(iv) recombination incidents that can lead to the production of a replicating virus causing a 
direct threat (Hacein-Bey-Albina et al., 2003; Klink et al., 2004; McBain et al., 2008a). 
(v) the limited capacity to accommodate large transgenes and manufacture sufficient stable 
vector stocks (Breyer et al., 2001; Qiao et al., 2010; Pickard & Chari, 2010; Kotterman & 
Schaffer, 2014).  
(vi) the inefficiency in transferring the engineered gene into suspension cell lines
 
(Bhattarai 
et al., 2008).   
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1.5 Non-viral gene delivery approaches 
Despite the extensive research and successes in the use of the most popular viral vectors 
for gene delivery, several limitations and risks remain as discussed (Section 1.4.4), causing 
the need for further development of non-viral alternative methods.  
In general, there are many reasons to explain why non-viral carriers are advantageous and 
promising some of which are: (i) the simplicity of use and potential for large-scale 
production, (ii) the low cost of manufacturing and (iii) the large capacity of transgene 
uptake (Wang & Gao, 2014). Also to their advantage are (iv) their safety in comparison to 
viral vectors since they contain no disease-causative viral genes, eliminating any chance of 
viral replication) and (v) the high cell viability following gene transfer depending on the 
specific non-viral technique used (Martin et al., 2005; Guo & Huang, 2012). 
Although several hurdles specific to each approach have to be overcome, the main 
limitation preventing non-viral gene delivery approaches from being more widely used is 
their considerably lower transfection efficiency compared to the equivalent for viral 
vectors. Recent advances in the field improving transfection efficiency are shifting the 
focus towards the potential of non-viral gene delivery approaches that can be divided into 
three main categories as outlined in Figure 1.4:  
 Delivery of genetic materials by the use of physical methods, presented in Section 
1.3.3.1 (Villemejane & Mir, 2009; Wang et al., 2013). 
 Delivery of encapsulated genes mediated by chemical approaches, presented in 
Section 1.3.3.2 (Midoux et al., 2009; Lian et al., 2014). 
  Delivery of the gene of interest by the use of multifunctional hybrid systems that 
combine physical and chemical characteristics, such as magnetic micro- and 
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nanoparticle-based gene delivery, presented in Sections 1.3.3.3 and 1.5 (Pankhurst et 
al., 2003; Dobson, 2006a; Corchero & Villaverde, 2009; Fouriki et al., 2010; Pickard 
& Chari, 2010; Guo & Huang, 2012; Zhang et al., 2012; Subramanian et al., 2013; 
Fouriki & Dobson, 2014).   
 
1.5.1 Physical approaches 
There are several physical approaches that are being used in the field of non-viral gene 
delivery. The two most popular approaches of direct injection of DNA and electroporation 
are described in the next paragraphs. Additionally, other less frequently used physical 
approaches such as gene gun, ultrasound and hydrodynamic gene delivery are briefly 
outlined.   
 
1.5.1.1 Direct injection of naked DNA 
This method is the simplest non-viral gene delivery system currently in use for gene 
therapy purposes. It was used for the first non-viral gene therapy clinical trial in 1992 to 
successfully enhance the immune response against tumours in vivo
 
(Nabel, 1992), and 
remains the most popular non-viral gene delivery system in clinical trials covering the 
18,3% of all trials with an increasing trend since 2004 (Ginn et al., 2013). It involves the 
injection of naked DNA directly into target tissues (eg. skeletal muscle, thyroid, liver, heart 
muscle, skin and tumour) or into the systemic circulation via a needle or jet that generate 
pores on the target cell membrane allowing intracellular gene transfer (Niidome & Huang, 
2002; Schmidt-Wolf & Schmidt-Wolf, 2003; Gao et al., 2007). The benefit of jet injection 
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relies on the high-pressure stream of liquid that penetrates the skin and targets the tissue of 
interest. As shown recently, this minimizes patients’ discomfort and increases gene 
expression (Andre et al., 2006 ; Villemejane & Mir, 2009). The advantages of naked DNA 
injection comprise the absence of a biological vector and immunogenicity (Al-Dosari & 
Gao, 2009). Finally, the limitations include; (i) the low transfection efficiency, (ii) the 
possibility of some tissue damage or increase of the pressure on the surface of the target 
cell following injection (Felgner et al., 1987; Villemejane & Mir, 2009) and finally, (iii) 
during systemic circulation the rapid enzymatic degradation due to the action of nucleases 
and clearance by the uptake of phagocyte system
 
(Schmidt-Wolf & Schmidt-Wolf, 2003; 
Pankajakshan & Agrawal, 2013).  
1.5.1.2  Electroporation 
Electroporation (or electropermeabilization) is a versatile, well-studied method by which 
genetic materials and other molecules can be introduced into cells by a pulsed electric field 
(Figure 1.7)
 
(Schmidt-Wolf & Schmidt-Wolf, 2003). The short and intense electric shock 
of electrocompressive forces makes the cell membrane temporarily permeable allowing the 
DNA to enter the cell (Niidome & Huang, 2002; Villemejane & Mir, 2009;). 
Electroporation has achieved high transfection efficiency in many tissues and shown good 
reproducibility in vivo compared to other non-viral vectors (Andre & Mir, 2004; Marti et 
al., 2004). However, the method is limited by a restricted range of electrodes and the lack 
of accessibility of the electrodes to the internal organs in vivo (Al-Dosari & Gao, 2009). In 
addition, the use of high intensity electric fields can cause permanent changes in the cell 
membrane structure, resulting in substantial apoptosis or necrosis (Gao et al., 2007; 
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Villemejane & Mir, 2009;). Despite the progress made so far, more research and 
technological advancements are needed for a wider use in clinical applications.   
 
 
Figure 1.7: Schematic representation of the electroporation process. 
(A) A typical cuvette loaded electroporator schematic, where cell suspension is pipetted 
into the cuvette which has attached one aluminium electrode in each side. (B) Before 
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electroporation, the target cell membrane lipid bilayer is intact, and (C) the externally 
applied electrical field causes an increase in electrical conductivity and permeability of the 
plasma membrane allowing the plasmid DNA to enter the cell.  
 
1.5.1.3 Other methods 
Finally, this paragraph briefly summarizes some physical approaches that are less 
frequently used but research is devoted for their further improvement:  
(a) Gene gun transfection, involves the targeted tissue being bombarded with heavy metal 
particles (eg. gold particles) with plasmid DNA deposited on their surface. It has been used 
in animal studies and a few clinical trials (Al-Dosari & Gao, 2009), with the main 
limitation being the low penetration of the metal particles. Subsequently, low efficiency in 
reaching the entire tissue is observed leading to the requirement for surgery to access non-
superficial tissues
 
(Villemejane & Mir, 2009).  
(b) Ultrasound, also known as sonoporation, is a non-invasive suitable for clinical 
research method that enables gene transfection by generating irradiating ultrasonic waves 
that temporarily increase cell membrane permeability and allow the internalization of large 
macromolecules such as plasmid DNA
 
(Niidome & Huang, 2002; Gao et al., 2007; Al-
Dosari & Gao, 2009). However, it has been reported that it can induce cellular morphology 
changes, mechanical shear and breakdown of the cytoskeleton causing alterations in 
cellular mechanisms such as DNA trafficking (Skorpikova et al., 2001; Schlicher et al., 
2010).  
(c) Hydrodynamic gene delivery, allows naked DNA to be introduced into the cells in 
highly perfused internal organs such as the liver and it has been applied only in vivo in 
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animal models with encouraging results
 
(Villemejane & Mir, 2009). The limitation of the 
method is the high volume of DNA solution required for injection often beyond an 
acceptable level for patients, and the frequently lethal effects of rapid injection
 
(Gao et al., 
2007).  
1.5.2 Chemical approaches 
1.5.2.1 Lipid-mediated gene delivery  
Lipid-mediated gene transfer, also known as lipofection, was first developed in 1987 
(Felgner et al., 1987). It has been successful with in vitro and in vivo gene therapy 
experimental models (Schmidt-Wolf & Schmidt-Wolf, 2003; Mintzer & Simanek, 2009), 
and is the most commonly used non-viral chemical approach. The method has been tested 
in clinical trials for the treatment of cancer and cystic fibrosis (Schmidt-Wolf & Schmidt-
Wolf, 2003; Al-Dosari & Gao, 2009), and currently is the second most frequently used 
non-viral gene delivery system covering the 5.9% of all clinical trials, after direct nucleic 
acid injection (Section 1.5.1.1) (Ginn et al., 2013). 
Lipid-mediated gene delivery (Figure 1.8) occurs via endocytosis (Mintzer & Simanek, 
2009)
 
and involves the assembly of cationic lipids that form liposomes, which are spherical 
vesicles with one (unilamellar) or more (multilamellar) lipid bilayers surrounding an 
aqueous core. Its principle relies on the ability of liposomes to encapsulate nucleic acids 
forming complexes known as lipoplexes that fuse with the cell membrane of the target cell, 
followed by endosomal escape, release of the gene of interest and its distribution in the 
appropriate cellular compartment (Guo & Huang, 2012). In case of DNA therapy, DNA 
has to enter the nucleus for transcription, while for RNA interference (RNAi), small 
interfering RNA (siRNA) has to remain in the cytoplasm and reach the RNA-induced 
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silencing complex (RISC) (Huang et al., 2012). Following on from previously mentioned 
benefits that several non-viral vectors have in common (Section 1.5), this method can 
protect DNA against enzymatic degradation
 
(Guo & Huang, 2012), as it is released from 
the intracellular vesicles before being broken down by lysosomal compartments
 
(Gao et 
al., 2007).  
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Figure 1.8: Schematic representation of lipid-mediated DNA delivery principle. 
Cationic lipids that form liposomes, mix and associate with DNA to form spherical 
lipoplexes, internalized by receptor-mediated endocytosis. Inside the cytoplasm, amounts 
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of lipoplexes can be degraded by the lysosomes or nucleases, and following endosomal 
escape the DNA is released and transported into the nucleus through NPC. Inside the 
nucleus the gene of interest is transcribed followed by translation to complete gene 
expression. (NPC; Nuclear pore complex). (Adapted from Fouriki & Dobson, 2012; 
Pankajakshan & Agrawal, 2013).     
 
 
Cationic-lipid transfection has many advantages but there are drawbacks that require 
further improvement such as: (i) further increase of transfection efficiency (a common 
drawback among non-viral systems), (ii) the transient expression that requires repeated 
doses (when stable transfection is required), (iii) the extended required time for treatment 
and incubation of cells (4hr to 6hr), (iv) the toxic side effects reported with high doses of 
lipoplexes administration, (v) the administration route-dependent transfection efficiency in 
vivo, requiring individualized optimization of the vector for distinct target cells, (vi) the 
potentially high clearance rate from blood stream when positively charged lipoplexes 
interact non-specifically with serum proteins resulting in their volume increase, (vii) the 
uptake by the reticuloendothelial system (RES) (Templeton, 2004; Martin et al., 2005; 
Lian et al., 2014).  
Multiple studies have attempted to overcome these barriers covered in several review 
articles (Morille et al., 2008; Guo & Huang, 2012; Zhang et al., 2012). Many cationic 
headgroup manipulations have been tested and different cationic lipids have been used 
with two of the most popular being dioleylpropyl trimethylammonium chloride (DOTMA) 
and dioleoyl trimethylammonium propane (DOTAP) (Al-Dosari & Gao, 2009; Guo & 
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Huang, 2012). However, modification of cationic lipid molecules has been relatively 
saturated retaining the need for improved synthetics vectors. 
 
1.5.2.2 Polymer-mediated gene delivery and Polyethylenimine (PEI) 
Another actively studied class of synthetic vectors are the cationic polymers that have 
positively charged groups in their backbone and can interact with negatively charged 
genetic materials (Fishbein et al., 2010). These polymers mix with DNA or siRNA to form 
nanosized complexes known as polyplexes, which then enter the target cell by endocytosis 
employing similar mechanisms described for lipid-mediated gene delivery (Section 
1.5.2.1). Generally, polyplexes have some advantages in comparison to lipoplexes  that 
include their small size, narrow distribution and better stability and efficiency in 
condensing DNA s (Al-Dosari & Gao, 2009; Midoux et al., 2009; Dijaj et al., 2014).  
Many types of polymers have been developed with the cationic polymer poly-L-lysine 
(PLL) being one of the first to be used for gene transfer in vivo (Gao et al., 2007). 
Additionally, natural biopolymers such as the polysaccharides chitosan and dextran exhibit 
unique properties such as biodegradability and biocompatibility that increase attention in 
their gene delivery potential (Raftery et al., 2013).  
 
Among cationic polymers,  the most widely investigated   polyethylenimine (PEI), is 
considered one of the most effective polymer-based transfection agents and its ability to 
promote gene transfection in vitro and in vivo was first demonstrated in 1995 (Boussif et 
al., 1995). PEI exists in linear or branched structures, can undergo functionalized group 
modifications and can transfect a broad range of cell types (Thomas et al., 2007; Morille et 
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al., 2008; Dijaj et al., 2014). It is advantageous due to its strong DNA condensation 
capacity, intrinsic endosomal activity and endosomal escape, due to a unique buffering 
property known as the ‘proton sponge effect’ that facilitates the release of the transgene 
into the cytoplasm through osmotic swelling and burst of endosome (Lian et al., 2014; Yin 
et al., 2014).  
Most of the studies have proposed that cationic polymers with high buffering capacities 
between 4.5 to 7.0 such as PEI, can mediate endosomal escape and ultimately avoid 
degradation in lysosomes, by transporting protons and chloride ions into the endosome 
with subsequent osmotic pressure increase and vesicle rupture. The proton sponge 
mechanism was first proposed in 1997 (Behr, 1997) and despite being debated it remains 
the most generally accepted mechanism of endosomal escape (Figure 1.9) (Putnam et al., 
2001; Akinc et al., 2005; Midoux et al., 2009; Benjaminsen et al., 2012; Richard et al., 
2013). Following endosomal escape the plasmid DNA/siRNA is released and distributed in 
the appropriate subcellular compartment. In the case of DNA therapy, translocation of the 
DNA into the nucleus for transcription is needed, while for RNAi, siRNA must be 
delivered to the RNA-induced silencing complex (RISC) in the cytoplasm (You & 
Auguste, 2010; Guo & Huang, 2012).  
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Figure 1.9: Schematic representation of the proton sponge effect of PEI polymer.  (A-
B) PEI coated nanoparticles mix and associate with DNA to form polyplexes which enter 
the cell via endocytosis. (C) Inside the cytoplasm, the buffering capacity of PEI induces the 
pumping of protons into the endosomes, (D) that increases osmotic pressure and endosome 
swelling, (E) rupturing the endosome and facilitating endosomal escape. The DNA is 
released into the cytoplasm and transported into the nucleus through NPC (Adapted from 
Restani et al., 2014).     
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It has been observed with PEI depending on the choice of its isoform (linear or branched) 
and molecular weight (MW) complexed with DNA, that different levels of transfection 
efficiency and toxicity can be obtained both in vitro and in vivo (Al-Dosari & Gao, 2009). 
Therefore, PEI transfection efficiency and toxicity are MW- and structure-dependent, with 
reports showing that high MW PEI can be toxic, while polyplexes made of linear PEI 
appear more efficient in terms of transfection efficiency and significantly less toxic 
(Gosselin et al., 2001; Wightman et al., 2001; Zhang et al., 2012). Additional strategies for 
the improvement of polyplexes can be achieved by conjugation with an inert polymer, for 
example polyethylene glycol (PEG), or dextran to reduce specific interactions and overall 
cytotoxicity of PEI-based polyplexes, although transfection efficiency can be compromised 
(Al-Dosari & Gao, 2009; Tsai et al., 2011). In case of PEG polymer use that can protect 
particles from agglomeration and macrophage uptake, PEG coating can inhibit fusion with 
the cell or endosomal membrane reducing the potential for particle cellular uptake and 
endosomal escape, decreasing transfection efficiency in case of DNA or silencing effect in 
case of siRNA (Zhang et al., 2012), although several strategies have been employed trying 
to handle this limitation (Walker et al.,2005; Hatakeyama et al., 2007; Hatakeyama et al., 
2011).      
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1.5.3 Hybrid Systems: Magnetic micro- and nanoparticle-based gene delivery  
As it was shown in section 1.5, a range of non-viral systems has become available for in 
vitro and in vivo gene delivery purposes that due to their physical or chemical 
characteristics, as well as their acquired technical advances, can eliminate some viral 
drawbacks, offer significant results and clinical applications. However, their system-
specific limitations addressed previously, the lower transfection efficiency compared to 
some viral vectors, and the challenge of specific targeting to the sites of interest in the 
body, retain the need for further development of improved carriers for gene delivery for in 
vitro investigations and in vivo therapeutic applications.  
As illustrated in Figure 1.4 (Section 1.3), a third class of non-viral gene delivery 
approaches is the emerging field of hybrid systems that includes the magnetic micro- and 
nanoparticle-based gene delivery combining both physical and chemical characteristics 
(Pankhurst et al., 2003; Dobson, 2006b; Corchero & Villaverde, 2009). This approach 
involves the use of inorganic (iron oxide) magnetic nanoparticles (MNPs) which are 
extensively used in biomedicine, easily prepared and surface-functionalized in many ways 
(Sokolova & Epple, 2008; Prijic & Sersa, 2011; Lian et al., 2014), coated with 
biocompatible polymers (McBain et al., 2008a; Dijaj et al., 2014), and the presence of 
externally applied magnetic fields directing gene delivery (Scherer et al., 2002; Plank et 
al., 2003; Dobson, 2006a; McBain et al., 2008b; Peng et al., 2008; Pickard & Chari, 2010; 
Fouriki et al., 2012).    
In the following sections the background of magnetism and MNPs (Section 1.6) related to 
magnetic gene/drug delivery and targeting (Section 1.7) will be described, as the basis for 
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magnetic nanoparticle (MNP)-based gene delivery approach and specifically the 
nanomagnetic gene transfection system (Section 1.8).  
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1.6 Magnetics in biomedicine – the foundation for MNP-based gene 
delivery 
1.6.1 Magnetism and magnetic materials 
A magnetic field is produced due to the motion of charged particles. Therefore, a field is 
produced each time an electrical charge is in motion (Jiles, 2015). Magnetic fields based 
on the SI system are usually measured in units of Tesla (T) and Gauss (G). The 
phenomenon of magnetism involves the interaction of two magnetic fields and arises from 
the motion of electrical charges and the interaction between electrons with atoms. 
Therefore, all materials can be affected by magnetic fields in different ways, and the type 
of magnetism of each material can be different based on the electronic configuration 
(Dobson et al., 2007). As all materials interact in some way with externally applied 
magnetic fields, they are categorised based on their magnetic susceptibility as: (a) 
diamagnetic, (b) paramagnetic, (c) ferromagnetic, (d) antiferromagnetic and (e) 
ferrimagnetic.  
 
 Diamagnetic materials have all their electron spins paired and a very weak negative 
magnetic susceptibility. They are considered a very weak type of magnetism displayed 
by all materials (Dobson et al., 2007; Faraji et al., 2010).  
 Paramagnetic materials have some uncompensated spins in the absence of a magnetic 
field and are magnetized only in the presence of a magnetic field were the spin 
moments are aligned. Similarly, when removed from the applied magnetic field 
paramagnets have zero net magnetization. The strength of the magnetic field is 
Chapter 1 – Literature Review 
 
 - 44 - 
 
proportional to the degree of alignment (Figure 1.10) (Barnes et al., 2007; Dobson et 
al., 2007).    
 
 
Figure 1.10: Schematic representation of spin moments of paramagnetic materials.  
(A) Paramagnets have non-aligned spin moments in the absence of a magnetic field and  
(B) are magnetised in the presence of a magnetic field were their spin moments are aligned 
(Adapted from Dobson et al., 2007).    
 
 On the other hand, ferromagnetic materials have a strong, positive magnetic 
susceptibility and aligned spin moments. Unlike paramagnets, ferromagnets remain 
magnetised even after the applied field is removed (Figure 1.11A) (Barnes et al., 2007; 
Hofmann-Amtenbrink, et al., 2010).  
 Antiferromagnetic materials are special cases of ferromagnetic substances with 
uncompensated spin moments of equal magnitude coupled antiparallel to one another 
exhibiting no net magnetization (Figure 1.11B) (Dobson et al., 2007; Hofmann-
Amtenbrink, et al., 2010).  
Chapter 1 – Literature Review 
 
 - 45 - 
 
 Ferrimagnetic materials like antiferromagnets, have uncompensated spin moments 
antiparallel to one another, but with unequal magnitude giving rise to strong net 
magnetization which is also retained after the magnetic field has been removed (Figure 
1.11C). An example of ferrimagnet is magnetite (Fe3O4) (Dobson et al., 2007; 
Hofmann-Amtenbrink, et al., 2010).    
 
 
Figure 1.11: Schematic representation of spin moments of ferromagnetic, 
antiferromagnetic and ferrimagnetic materials. (A) Ferromagnets are permanently 
magnetised with aligned spins moments. (B) Antiferromagnets have antiparallel spin 
moments of equal magnitude and no net magnetization. (C) Ferrimagnets are permanently 
magnetised with antiparallel spin moments of unequal magnitude (Adapted from Dobson 
et al., 2007).    
 
 Superparamagnetic materials are an unusual case of magnetism. Their particles are 
very small, in the order of approximately 20 nm in diameter. They have 
uncompensated spins but the orientation of their individual spin moments can be 
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ferromagnetic, ferrimagnetic or antiferromagnetic. Their spins are coupled but they 
can randomly flip direction caused by thermal energy fluctuations. Superparamagnets 
behave as paramagnets, therefore they retain no magnetization when the magnetic 
field is removed (Dobson et al., 2007; Jiles, 2015). This characteristic is important and 
superparamagnetic properties are desirable for biomedical applications as the MNPs will 
not be attracted to each other reducing the risk of agglomeration for in vivo therapeutic 
purposes (Dobson, 2006; Getzlaff, et al., 2008; Mahmoudi et al., 2011).    
 
1.6.2 Magnetic nanoparticles (MNPs) 
Nanoparticles are organic or inorganic particles in the nanosize range (10
-9
m) that display 
unique electronic, optical and magnetic properties due to their small size and surface 
characteristics (Wahajuddin & Arora, 2012). These properties enable them to be 
specifically controlled and targeted to the biological component of interest and interact on 
a cellular, subcellular, protein or genetic level (Pankhurst et al., 2003; Krishnan, 2010). 
Some examples of nanoparticles include MNPs, liposomes, polyplexes, quantum dots and 
carbon-based nanoparticles (Guo & Huang, 2012; Lian et al., 2014). Nanoparticles have 
exhibited a wide range of biomedical applications that include cell isolation and imaging, 
gene/drug delivery, diagnostics and magnetic hyperthermia (Pankhurst et al., 2003; 
Banerjee et al., 2010; Krishnan, 2010). 
Magnetic nanoparticles (Figure 1.12) can serve as multifunctional engineering platforms 
which can be harnessed to meet many technical requirements (Marszall, 2011). Their 
applications in drug delivery, diagnostics combined with therapeutics such as magnetic 
resonance imaging (MRI)-guided stem cells are well documented (Cores et al., 2015). The 
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term magnetic particle refers to a variety of synthetic particles or aggregates of micro- or 
nanometer size, with distinct physicochemical properties, all sharing a magnetic 
component (Plank et al., 2003; McBain et al., 2008a). There are many magnetic materials 
that could be used as the magnetic nanoparticle core such as iron, nickel, cobalt or 
chromium, but all excluding iron have been found highly toxic for the cells eliminating 
their use for biomedical applications (McBain et al., 2008a; Berry, 2009; Hofmann-
Amtenbrink, 2010). The magnetic cores are coated with a variety of polymers as described 
in section 1.5.2.2, in order to improve handling and be surface-functionalized in terms of 
charge and binding capacity of biomolecules and proteins, facilitating gene delivery 
(Sokolova & Epple, 2008; Yiu, 2011; Lian et al., 2014). The biocompatible polymers serve 
also the essential purpose of minimizing toxicity preventing the direct contact between 
cells and magnetic core (Hughes et al., 2005; Kievit & Zhang, 2011; Dizaj et al., 2014).    
 
Figure 1.12: Schematic representation of a typical magnetic nanoparticle for 
biotechnology. The MNP consists of a magnetic core that is coated with a protective layer 
such as polymer and is surface-functionalized with an organic linker and an active 
molecule such a protein (McBain et al., 2008a). 
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1.6.3 Superparamagnetic iron oxide nanoparticles (SPIONs) 
Superparamagnetic iron oxide nanoparticles constitute a special category of MNPs. They 
are small synthetic particles coated with a charged polymer, with magnetic cores composed 
of clusters of magnetite (Fe3O4) or maghemite (γ-Fe2O3) crystallites which are 
ferromagnetic in nature and permanently magnetized (Jiles, 2015). When these materials 
remain smaller than 30 nm they exhibit their superparamagnetic characteristics described 
in section 1.6.1, and retain their strong magnetization only in the presence of a magnetic 
field, being suitable for magnetically guided targeted delivery (Peng et al., 2008; Kievit & 
Zhang, 2011; Mahmoudi  et al., 2011). When the magnetic field is removed the 
magnetization is lost. This characteristic is desirable for gene/drug delivery vesicles 
allowing SPIONs to be remotely manipulated by external fields (including MRI), but 
preventing particle agglomeration and evading uptake by phagocytes while also increasing 
their half-life in the circulation. Additionally, due to their negligible tendency of 
aggregation the risk of thrombosis within the vasculature is minimised (Dobson 2008; 
Hofmann-Amtenbrink, 2010; Wahajuddin & Arora, 2012). 
 
SPIONs can be coated with biocompatible polymers and surface-functionalized as MNPs 
described previously, or precipitated through a larger porous polymer generating larger 
particles with superparamagnetic properties (Cortajarena et al., 2014). In the field of 
medicine and biology, superparamagnets are broadly classified by size were SPIONs range 
between 50-100 nm, ultra small SPIONs between 10-50 nm and very small SPIONs are 
<10 nm (Singh  et al., 2010; Cortajarena et al., 2014). SPIONs have been well studied for 
biomedical applications such as gene/drug delivery, medical imaging and regenerative 
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medicine (Lin et al., 2008; Naqvi et al., 2010; Mahmoudi  et al., 2011; Tassa et al., 2011; 
Thu et al., 2012; Cores et al., 2015). Particles ranging between 10-100 nm are considered 
optimal as they evade reticuloendothelial system having longer circulation times, and are 
still able to penetrate through small capillaries (Singh et al., 2010; Mahmoudi et al., 2011). 
There is an extended market of commercially available SPIONs used in the laboratory in 
vitro and in vivo (Hofmann-Amtenbrink, 2010), but only a few are FDA approved for 
clinical use (Cromer Bermen et al., 2011; Jasmin et al., 2011).  
 
In summary, SPIONs have to posses the following characteristics in order to be suitable for 
biomedical applications (Mahmoudi et al., 2011; Wahajuddin & Arora, 2012).  
 Biocompatibility 
 Biodegradability 
 Low toxicity 
 Physiochemically stable for storage and physiological conditions 
For the purpose of this thesis two commercially available SPIONs have been used, nTMag 
and PolyMag, sharing all the advantageous characteristics of SPIONs for gene delivery as 
described above, with identical physiochemical specifications (shape, size, surface coating) 
according to their manufacturers. They will be further described in materials and methods 
in Section 2.3.3.   
1.6.3.1 Cellular uptake of SPIONs  
Generally, cells internalize SPIONs by endocytosis (Shapiro et al., 2005). It is understood that 
SPION parameters such as particle size, shape and surface modifications affect the rate of 
particle internalization, the specific endocytic pathway used by the cell, and the cellular 
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location that the particle will end up (Singh et al., 2010; Cores et al., 2015). The manipulation 
of particle surface using polymer coatings, antibodies and peptides can increase the rate of 
internalization (Cortajarena et al., 2014). There are several endocytic uptake pathways shown 
in Figure 1.13, such as: (i) macropinocytosis for particles <5 μm, (ii) micropinocytosis that 
includes clathrin-mediated endocytosis for particles <300 nm and caveolae-mediated 
endocytosis for particles <80 nm, and (iii) phagocytosis for particles up to 20 μm (Gu et al., 
2011; Canton & Battaglia, 2012).  
 
 
Figure 1.13: Schematic representation of available endocytic pathways for SPION 
cellular uptake. (Adapted from Cores et al., 2015). 
 
1.6.3.2 Toxicity and clearance of SPIONs  
Generally, no acute toxicity of SPIONs has been reported and are considered as inert and 
biocompatible due to the naturally occurring iron (ferritin) in the human body (Chen et al., 
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2010; Markides et al., 2012; Cores et al., 2015). The body is adapted for iron metabolism 
with SPIONs having a good safety profile and some being FDA approved for clinical 
translation, for use as contrast agents (Schafer et al., 2010), for the treatment for iron-
deficiency anaemia (Rosner & Auerbach, 2011) and for tumour therapy with magnetic 
hyperthermia (Johannsen et al., 2010).  
However, at high quantities or concentrations and at various oxidative states iron can be 
damaging for the cells affecting cell viability and morphological changes in DNA and 
proteins (Kim et al., 2010; Wang et al.2011). Iron exists in the two main oxidative states of 
Fe (II) and Fe (III), with Fe (II) being responsible for free radical generation and 
consequently cellular damage (Markides et al., 2012). The imbalance between damaging 
oxidants known as reactive oxygen species (ROS) causes oxidative stress, which is 
considered as the main reason of toxicity in MNPs (Kim et al., 2010). Furthermore, SPION 
physiochemical characteristics such as size, shape and surface properties hold an important 
role in a potentially toxic response causing aggregates and coagulation which are shape- 
and size-dependent (Wahajuddin & Arora, 2012). It is clear that there is a need for 
extensive SPION testing in primary cells and relevant models, followed by pre-clinical 
animal studies in order to reach clinical trials.  
 
In terms of SPIONs elimination from biological systems, both metabolism and excretion 
are to be considered. Once internalized, degradation of SPIONs is mediated by 
lysosomes, as generally considered the primary intracellular metabolic mechanism (Levy 
et al., 2010). Similarly once internalized, three more mechanisms for the metabolic fate of 
SPIONs have been proposed by a study in macrophage-like mouse cells suggesting that (i) 
macrophages can eliminate SPIONs during mitotic cell division and passage of those to the 
Chapter 1 – Literature Review 
 
 - 52 - 
 
daughter cells; (ii) low lysosomal pH can induce SPIONs degradation and release of Fe 
(III) in the intracellular medium that can be stored in the body reserves assisted by iron-
regulating proteins such as ferritin; (iii) SPIONs could be exocytosed even though limited 
evidence is available (Gu et al., 2011; Wahajuddin & Arora, 2012).    
 
In terms of excretion the kidney route is considered the most desirable involving minimal 
intracellular catabolism and reducing the potential of reactive oxygen species generation 
and therefore associated toxicity (Wahajuddin & Arora, 2012). The safest route is via renal 
excretion, however the shape and size of particles affects significantly the route of 
clearance. More specifically regarding the particle shape, it was shown that long rod-
shaped particles which have a longer blood circulation time were distributed in the spleen, 
whereas short rod-shaped and spherical particles were distributed in the liver showing 
rapid clearance via urine and feces (Huang  et al., 2011). Regarding the particle size which 
determines their half-life circulation, particles <10 nm are removed by renal clearance 
while particles >200 nm accumulate in the spleen or taken up by phagocytic cells leading 
to decreased plasma concentrations (Chouly et al., 1996; Wahajuddin & Arora, 2012). As 
mentioned previously, particles in the range of 10 to 100 nm are considered optimal as they 
evade reticuloendothelial system and their circulation time is longer (Singh et al., 2010; 
Mahmoudi et al., 2011).  
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1.7 Magnetic drug delivery as the basis for MNP-based gene transfection 
and targeting 
1.7.1 The principle of MNP-based drug delivery 
Magnetic micro- and nanoparticle-based drug delivery is a chemical and physical 
combination that offers potential for in vitro and in vivo gene delivery (Dobson, 2008). 
Coated and functionalized MNPs can be used as gene carriers and targeted to specific sites 
in vitro and in vivo by the application of external, focused magnetic fields
 
(Scherer et al., 
2002; Corchero & Villaverde, 2009; Polyak et al., 2009; Lian et al., 2014), forming the 
basis of magnetic nanoparticle-based gene transfection and targeting. In addition, since 
systemic drug delivery requires larger doses of circulating drug with associated deleterious 
side effects in healthy cells, the potential of specific magnetically targeted drug and gene 
delivery using lower amounts of the therapeutic agent concentrated at the target tissue of 
interest attracts growing interest
 
(Pankhurst et al., 2003; Peng et al., 2008; Corchero & 
Villaverde, 2009; Pankhurst et al., 2009). 
 
Magnetic particles are capable of coupling and responding to an applied magnetic field. In 
order to generate a force on the magnetic particle the field much have a gradient, as in the 
presence of a homogeneous field the particle will experience no force (Pankhurst et al., 
2003). This is the reason that high-gradient, rare-earth magnets are frequently used for 
magnetic drug delivery and MNP-based gene transfection purposes (Dobson et al., 2006).   
In magnetically targeted therapy in vivo, a cytotoxic drug or a gene is bound to 
biocompatible magnetic micro- or nanoparticles, which then are injected into the patient’s 
blood stream or, in some cases, directly into the target tissue. By the use of externally 
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applied magnetic fields the drug-particle complexes can be pulled from circulation and 
targeted to a region within the body or held in place at the target (Figure 1.14) (Pankhurst 
et al., 2003). Subsequently, the therapeutic agent is slowly released from the magnetic 
carrier by heat, enzymatic activity or degradation of the linker compounds, and a local 
effect of the agent released is initiated (Nishijima et al., 2007; Guo & Huang, 2012). 
 
Figure 1.14 Schematic side view section of magnetic nanoparticle-based gene 
targeting in vivo. Gray rings represent the lines of magnetic flux due to externally applied 
magnetic field. Fmag represents the magnetic force vector applied on the particles as they 
flow through the bloodstream
 
(Dobson, 2006a). 
 
1.7.2 Clinical applications of MNP-based drug delivery 
The first clinical application of MNPs was demonstrated in 1957 by Gilchrist et al when 
maghemite (γFe2O3) particles were injected and selectively heated using an alternative 
current (AC) magnetic field to treat lymph nodes and metastases
 
(Gilchist et al., 1957). The 
principle of magnetically guiding particles into specific target areas was introduced in 
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1963, when intravenously injected iron particles were accumulated into the veins of dog 
legs by the application of an externally applied magnet
 
(Meyers et al., 1963). A few years 
later, in 1979, the first well defined magnetic microspheres were constructed for the 
purpose of magnetic targeting
 
(Widder et al., 1979). Following on, several groups have 
successfully applied magnetically targeted cytotoxic drug delivery in multiple small animal 
studies (Pankhurst et al., 2003) including swine (Goodwin et al., 2001), rabbits (Alexiou et 
al., 2000) and rats (Pulfer et al., 1999; Lubbe et al., 2001). 
 
Although this approach has been successfully used in many studies the clinical potential of 
the method has not yet been realized, with a small number of clinical trials up to date.  
In the first clinical trial, epirubicine was complexed with nanoparticles to target advanced 
solid liver tumours in 14 patients, with effective targeting to the tumour site for 6 patients. 
Additionally, the particles that were not attracted to the tumour site were accumulated in 
the liver with no abnormal effects (Lubbe et al.1996a; Lubbe et al.1996b). In a second 
clinical trial, doxorubicin hydrochloride was coupled to magnetic particle carrier and 
delivered intra arterially to the tumour site in 30 out of 32 patients with hepatocellular 
carcinoma. In the analysis of the first 17 patients, 15 of them showed stable or decreased 
tumour size (Koda et al., 2002). In a third similar clinical trial, with 4 patients with 
hepatocellular carcinoma, doxorubicin was coupled to magnetic particle carrier and 
delivered via the hepatic artery using MRI simultaneously. The particle/doxorubicin 
complex was well focused, inducing a tumour volume decrease ranging between 64% to 
91% (Wilson et al., 2004). Finally, additional data from clical trials in Phase I and II 
reported targeted intra-arterial hepatic delivery and low cytotoxicity levels of doxorubicin-
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transdrug
®
 via biodegradable magnetic polycyanoacrylate nanospheres (Merle et al., 2006; 
Mody et al., 2014). 
 
1.7.3 The choice of magnetic carrier and targeted delivery through enhanced 
permeability and retention (EPR)  
Despite several successful applications of MNP-based drug delivery in vitro and in vivo, 
there are technical barriers that need to be addressed such as the rapid decrease of magnetic 
field strength when the target tissue is deep into the body and limitations of bypassing 
intervening vasculature (Dobson, 2006a; Dobson, 2006b; Pankhurst et al., 2009;). In order 
to minimize these limitations and enhance attachment of the drugs, numerous studies have 
worked on the development of novel MNPs as described in section 1.6.2 that vary in size, 
multifunctional coatings, magnetic properties, which use high-moment materials and 
thermoresponsive hydrogels and/or particles (Corchero & Villaverde, 2009; Nishijima et 
al., 2007; McBain et al., 2008a; Muthana et al., 2008; Sanvicens & Marco, 2008; Staniland 
et al., 2009; Staniland, 2009; Xie et al., 2010).  
For example, particles ranging between 10-100 nm have been reported as optimal, as they 
have longer circulation times and are still able to penetrate through small capillaries (Singh 
et al., 2010; Mahmoudi et al., 2011). Such particle sizes allow for increased MNPs 
concentrations along with macromolecules, to be easier transported at the tumour target 
site and across the tumour endothelium, due to the tumour’s characteristic enhanced 
permeability and retention (EPR) effect with leaky vascular structures and poor lymphatic 
drainage (Figure 1.15) (Brannon-Peppas & Blanchette, 2004; Estelrich et al., 2015). For 
most human leaky tumours, particles with a mean size of approximately 100 nm are 
Chapter 1 – Literature Review 
 
 - 57 - 
 
attractive for tumour targeting and allow easier surface modifications to conformations that 
prevent serum opsonisation, in contrast with larger particles of approximately 400 nm that 
cannot easily enter the capillary gaps in tumour vasculature (Zhang et al., 2012).  
 
 
Figure 1.15 Schematic representation of magnetic nanoparticle-based drug targeting 
in tumour cells in vivo, highlighting enhanced permeability and retention effect. The 
externally applied magnetic field close to the target tissue promotes SPIONS localization at 
the tumour site, and via blood circulation around and/or inside the tumour endothelium, 
SPIONS extravasate from pores of leaky tumour blood vessel walls reaching the tumour 
site, a characteristic known as EPR effect (Adapted from Estelrich et al., 2015).    
 
In summary, magnetic drug targeting must be safe and effective, and be capable of 
delivering the maximum amount of therapeutic agent with the least possible amount of 
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magnetic particles
 
(Corchero & Villaverde, 2009; Pankhurst et al., 2009). Additionally, the 
most desirable magnetic carriers possess characteristics such as (Wahajuddin & Arora, 
2012);  
  Small size to allow insertion into the target area 
 A wide range of particle sizes to allow their selection depending on the specific 
application 
 A large biocompatible surface area and high capacity for transgene or therapeutic 
agent uptake 
 The ability to biodegrade, eliminating toxic by-products.    
 
Based on the MNP-based gene transfection principles explained here for magnetic 
drug/gene delivery and targeting purposes, the novel non-viral nanomagnetic gene 
transfection method is presented next.  
 
 
 
 
 
 
 
 
 
 
 
Chapter 1 – Literature Review 
 
 - 59 - 
 
1.8 MNP-based gene transfection: Nanomagnetic transfection 
1.8.1 Overview of principles and key parameters for nanomagnetic transfection  
Nanomagnetic gene transfection follows on from the general principle of magnetically 
directed gene delivery presented in section 1.7.1. As briefly introduced in Figure 1.4 about 
gene delivery approaches and Section 1.5.3 about hybrid systems, it combines both 
physical and chemical characteristics and has been effectively used with both viral and 
non-viral vector systems (Mah et al., 2000; Dobson et al., 2006; McBain et al., 2008b). 
Our group focuses on the technique that involves the coupling of MNPs with reporter or 
therapeutic genes (DNA or siRNA) to form complexes, which are applied in mammalian 
cell cultures and are taken up by endocytosis. Endocytosis is promoted further by the 
presence of a novel externally introduced oscillating magnet to assist and direct specific 
delivery of MNP/gene complexes on a single cell basis (Section 1.8.3) (McBain et al., 
2008b; Lim et al., 2012).  
 
In terms of the method’s background, MNP-based gene transfection (Figure 1.16), as the 
principle of nanomagnetic transfection, was introduced in 2000 by Mah et al. who first 
demonstrated the use of magnetic microparticles for gene transfection purposes and linked 
those to AAV encoding Green Fluorescent Protein (GFP) reporter gene. The complexes 
were magnetically targeted by static high-strength, high-gradient neodymium iron boron 
(NdFeB) magnets to a specific region of C12S HeLa-derived cells in vitro and in mouse 
models in vivo following intramuscular injection (May et al., 2000; May et al., 2002). The 
magnetic targeting enabled highly efficient uptake of GFP gene by HeLa cells localized at 
the site of the applied magnetic field. The method has generated great interest and based on 
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this idea many subsequent studies have applied the principle to non-viral systems that will 
be discussed in the following sections 1.8.2 and 1.8.3.   
 
 
Figure 1.16 Schematic representation of MNP-based gene transfection in vitro. The 
vector (here DNA) is attached to MNPs to form complexes, which are added to the cell 
culture. The high-gradient, rare-earth magnet is placed below the culture dish, and pulls the 
particles towards the magnetic field source. Fmag is the force exerted on the particles by the 
magnetic field.   
 
For nanomagnetic gene transfection, naturally the presence of a magnetic field and the 
choice of the MNPs to be used are of essential importance and these parameters need to be 
considered as part of the optimization of transfection efficiency.  
In regards to the magnetic field, during in vitro nanomagnetic transfection MNP/gene 
complexes are introduced into the cell culture, where the required field gradient is 
produced by the externally applied rare-earth magnets. Generally, neodymium iron boron 
(NdFeB) magnets are used and placed directly underneath the cell culture. The main 
advantage of this system is the ability to increase the speed of particle sedimentation onto 
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the cell surface and therefore significantly reduce the required time for cell transfection
 
(Figure 1.16) (Plank et al., 2003; Dobson, 2006a; Fallini et al., 2010). When SPIONs are 
used for nanomagnetic transfection, the fundamental mechanism by which the system 
works is determined by the equation:  
Fmag = (χ2 – χ1) x V x 1/μ0 x Β x (∇ Β) 
Where, Fmag is the force on the magnetic particle, χ2 is the volume magnetic susceptibility 
of the magnetic particle, χ1 is the volume of magnetic susceptibility of the surrounding 
medium, μ0 is the magnetic permeability of free space, V is particle volume, B is the 
magnetic flux density in Tesla (T), B is field gradient and can be reduced to ∂B/∂x, 
∂B/∂y, ∂B/∂z, of which ∂B/∂z plays the most critical role due to the geometry of the 
system
 
(Pankhurst et al., 2003). This results in a translational force on the MNP:gene 
complex in the direction of the magnetic field source, placed underneath the cell culture. 
For in vivo applications, following the magnetically targeted gene delivery model 
illustrated in the previous section 1.7.1 (Figure 1.14 and 1.15), the particles carrying the 
therapeutic gene could be intravenously injected and circulated by the blood stream until 
captured by externally applied magnets. These magnets could be focused close to the target 
tissue, to promote transfection and targeting of therapeutic genes to a specific site or organ 
of the body.  
 
In regards to the MNPs, the selection of the appropriate type, size and surface coating 
attributes some essential properties to the magnetic carrier/gene complexes (Section 1.6.2): 
(i) the use of SPIONS for their advantageous superparamagnetic properties provides strong 
magnetization for rapid complex sedimentation, which is lost once the magnetic field is 
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removed, preventing particle aggregation in vitro and in vivo (Sections 1.6.1 and 1.6.3) 
(Dobson et al., 2007; Ortega, 2012). (ii) the size of SPIONS in the range of 100 nm is 
advantageous for penetrating through small capillaries (Mahmoudi et al., 2011), and 
transfer of the MNP:gene complexes into the cells via a number of endocytic pathways 
(Section 1.6.3.1). 
(iii) the surface coating of MNPs (including SPIONS) is responsible for effective binding 
with plasmid DNA or siRNA, surface functionalization facilitating gene delivery, and 
minimizes toxicity once in contact with the target cells (Sections 1.5.2.2, 1.6.3 and 
1.6.3.2). Additionally, the choice of a charged polymer for the particle coating such as PEI 
promotes endosomal escape, as it allows exploitation of the changes in pH which occur 
within the internalized endosome activating the proton sponge effect mechanism (Figure 
1.9) with endosomes rupture, and release of the MNP:gene complex into the cell’s 
cytoplasm(Section 1.5.2.2) (Demeneix & Behr, 2005; Akinc et al., 2005; Midoux et al., 
2009; Richard et al., 2013).  
 
MNPs development is a continuous process and their investigation in tayloring the many 
requirements for transfection purposes has been reported in numerous studies. Several 
reviews have been published summarizing their current status (Mahmoudi et al., 2011; 
Markides et al., 2012; Prodan et al., 2013; Estelrich et al., 2015).  
In general, in order to avoid attachment with other external elements MNPs can be spread 
into a polymer matrix such as silica or can be enclosed within a polymer or metallic coat
 
(Plank et al., 2003). Other particles such as magnetoliposomes are similar to liposomes 
with a magnetic ferrite core structure enclosed within a spherical lipid membrane
 
(Gonzales & Kirshnan, 2005). Also, mesoporous silica nanoparticles which may consist of 
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up to 80% iron oxide have been used along with several molecules to promote uptake by 
the target cells and have been associated with N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-
trimethylammonium chloride (DOTAP chloride) to both prevent particle aggregation and 
promote uptake (Yiu et al., 2005; Dobson, 2006a;). A comparison between small (30-
60nm) and large (300-600nm) nanoparticles has shown that both types were transfected but 
the large nanoparticles were able to achieve higher transfection efficiencies, highlighting 
the importance of the size of the MNP/DNA complex for transfection efficiency 
(Schillinger et al., 2005). 
 
Once the MNP formation and consistency have been optimized, the coupling to the 
corresponding gene of interest follows. The gene of interest may be linked to naked DNA 
or enclosed into a vector. MNPs can be linked to their gene of interest via a viral or non-
viral vector and coupled through both electrostatic interactions and salt induced colloid 
aggregation as well as cross-linking
 
(Plank et al., 2003; Agora et al., 2013). Their 
therapeutic genes can be released by enzymatic cleavage of cross-linking molecules, pH 
charge interactions and polymer matrix degradation
 
(Dobson, 2006a; You & Auguste, 
2010). For several types of MNPs that can be embedded within a matrix such as a 
hydrogel, the release of the therapeutic gene is mediated by heating of the hydrogel carrier
 
(Pankhurst et al., 2009). 
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1.8.2 Nanomagnetic transfection studies using static magnet arrays in vitro and in vivo 
Over the past decade, and based on the idea of MNP-based  gene transfection as presented 
by Mah et al. in the previous section, significant progress has been made on further 
developing the technique by Plank, Rosenecker and others that coined the term 
‘magnetofection’. In this group’s studies magnetofection using static magnet arrays and 
therefore static magnetic fields, was used to importantly demonstrate the potential of the 
technique for non-viral transfection in vitro and in vivo in a variety of cell types using 
genetic material coupled to MNPs and/ or SPIONs with a magnetite core and an organic or 
inorganic coating (Scherer et al., 2002; Plank et al., 2003; Schillinger et al., 2005; 
Neuberger et al., 2005; Mykhaylyk et al., 2008).More specifically, Scherer et al. first used 
iron oxide nanoparticles coated with PEI associated with DNA vectors by electrostatic 
interaction, to show increased transfection efficiency in a number of transfection reagents 
in vitro (Scherer et al., 2002). In addition, reduction of tranfection duration was achieved 
due to the principal advantage of MNP-based gene transfection, the rapid sedimentation of 
MNP/gene complex onto the target area. Furthermore, the transfection efficiency obtained 
in vitro was reported similarly in vivo with magnetic field-guided local transfection in the 
gastrointestinal tract and blood vessels of rats. In the same study, adenoviral vectors were 
complexed with MNPs that enabled transduction of previously non-permissive cell types, 
indicating that the host tropism of adenoviral vectors can be extended with MNP-based 
transfection technologies (Scherer et al., 2002). 
Following on from this original study, the method has been used to transfect in vitro 
primary lung epithelial cells and whole tissue samples of airways (Gersting et al. 2004), 
and blood vessel endothelial cells (Krotz, Sohn et al., 2003). MNPs have also been used to 
Chapter 1 – Literature Review 
 
 - 65 - 
 
deliver antisense oligonucleotides in vitro and siRNA downregulating gene expression in 
vivo (Krotz, de Wit et al., 2003).  
In 2005, Schillinger et al. reported significant reduction of retrovirally mediated expression 
of luciferase in Hela cells by siRNA delivery (Schillinger et al., 2005). In the same study, 
the applicability of the method was tested further with MNPs associated with small and 
large nucleic acids transfecting in vitro primary cells such as keratinocytes, chondrocytes, 
osteoblasts and amniocytes. Furthermore, the group initiated a veterinary clinical study 
which reported in vivo therapeutic effect in feline fibrosarcoma using MNPs to deliver the 
gene encoding for human GM-CSF (granulocyte macrophage colony stimulating factor). In 
these experiments, an externally positioned magnet was fixed on the tumour in order to 
induce vector localization at the site of interest (Schillinger et al., 2005).  
In 2008, Mykhaylyk et al., using MNPs reported increased in vitro siRNA delivery in 
adherent mammalian cells compared with cationic lipids (Mykhaylyk et al., 2008). Two 
years later, the method was used to demonstrate efficient transfection of primary motor 
neurons (Fallini et al., 2010). This group has shown for the first time that the spinal 
muscular atrophy-disease protein Smn is actively transported along axons of live primary 
motor neurons, and that gene knockdown data using small hairpin (sh)RNA-based 
constructs showed significantly reduced Smn levels in both cell bodies and axons (Fallini 
et al., 2010). Following on, siRNA was successfully delivered in primary and immortalized 
mammalian fibroblasts and the method was compared with lipid-mediated delivery. The 
data reported high transfection efficiencies with both techniques and a gene silencing effect 
of approximately 80%. However, MNP-based transfection showed significantly lower 
cytotoxic effect post-transfection (Ensenauer et al., 2011). 
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More recently, Amin, Stevens et al., showed stimulation of chondrogenic differentiaton of 
adult human bone marrow-derived stromal cells following a 14-day application of a static 
magnet field. This work highlighted the importance of inducing chondrogenesis in 
precursor cells as it could benefit cases of Osteoarthritis (Amin et al., 2014). In 2016, Brett 
et al., used a prefabricated scaffold integrated with PEI-coated MNPs complexed with a 
plasmid encoding GFP and B-cell lymphoma 2 (Bcl-2) for in vivo transfection in mice with 
external magnetic field. It was demonstrated upregulation of Bcl-2 in implanted human 
adipose-derived stromal cells and bone regeneration enhancement (Brett et al., 2016). 
There was a comparison between magnetofection and nucleofection to reveal significantly 
more healing in the magnetofected groups.        
 
It is clear that MNP-based gene transfection has been used widely, and nanomagnetic 
transfection using static magnet fields, is a rapid and efficient non-viral technique for 
transfection in vitro with promising in vivo data to this day. However, the need for further 
investigating the method remains, in order to improve further transfection efficiency and/ 
or extend its potential and use in a wider range of biomedical applications. 
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1.8.3 Nanomagnetic transfection studies using oscillating magnet arrays in vitro and 
in vivo: Recent advancements   
In 2005, our group first introduced work on the oscillating magnetic fields in the x-y plane 
(Dobson, 2005; Dobson & Batich, 2005). Since then, a lot of research has been focused on 
the optimization of the technique by the use of oscillating magnet arrays, to enhance 
overall transfection efficiency of magnetofection-type approaches using static magnets and 
further decrease transfection duration, while maintaining the high cell viability that 
nanomagnetic gene transfection offers. 
In this novel system, MNP/gene complexes are added into the cell culture in the presence 
of a horizontally oscillating magnet array positioned beneath the cell culture plate, which 
introduces a lateral component to the motion of the MNP/gene complexes, further 
promoting endocytosis. The complexes are uptaken by the cells, often via clathrin-
mediated endocytosis when SPIONs are used, while generally this depends on the size of 
the MNPs, as described in section 1.6.3.1 (Figure 13) (Schillinger et al., 2005; Cores et al., 
2015). Once into the cytoplasm, the buffering capacity of the polymer coated MNPs (here 
PEI) induces the proton sponge effect, rupturing the endosome and releasing the DNA (in 
case of DNA transfection) as decribed in section 1.5.2.2 (Figure 1.9). Then, DNA nuclear 
transportation follows for the transcription of the target protein (Figure 1.17) (Fouriki et 
al.,2010; Restani et al., 2014). 
 
In regards to the mechanism and effect of the oscillating magnetic field; although MNPs 
will generally experience torque in a homogenous magnetic field, they will also undergo 
translational movement when exposed to a field gradient, which will be further influenced 
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by the magnet array horizontal displacement (Pankhurst et al., 2003). This lateral motion 
of the MNP/gene complexes is primarily perpendicular to the translational force exerted on 
the particles by the field gradient, which adds energy and mechanical stimulation to the 
system (Dobson, 2006; McBain et al., 2008a). Based on the above, we hypothesize that the 
energy and mechanical stimulation introduced onto the cell membrane by the MNP/gene 
complexes moving in the x-y plane under the influence of the oscillating magnet array, 
further promote MNP/gene complexes uptake by the cells improving transfection 
efficiency (McBain et al., 2008b; Fouriki et al., 2010; Lim & Dobson, 2012).    
 
Figure 1.17-: Principle of oscillating nanomagnetic transfection. Plasmid DNA or 
siRNA is attached to magnetic nanoparticles and incubated with cells in culture (left). An 
oscillating magnet array below the surface of the cell culture plate pulls the particles into 
contact with the cell membrane (i) and drags the particles from side-to-side across the cells 
(ii), mechanically stimulating endocytosis (iii). Once the MNP/DNA complex is 
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endocytosed, proton sponge effects rupture the endosome (iv) releasing the DNA (v) which 
then transcribes the target protein (vi)
 
(Fouriki et al., 2010).  
 
The concept of enhanced translocation of particles across the cell membrane stimulated by 
pulsating electromagnets with increased transfection efficiency was also presented in 2006 
by Kamau et al., although significant heating effect was produced requiring weaker field 
strengths and gradients (Kamau et al., 2006). Such heating effects in combination with an 
incubator’s conditions during transfection that could contribute additional heat to the cells, 
are not alarming with the use of the nanomagnetic oscillating system, as permanent high 
field/gradient magnets are used which hold major advantages in comparison to 
electromagnets (McBain et al., 2008b). The retention of excellent cell viability levels, 
comparable to untransfected controls, has been reported by all researchers work used the 
method and will be described next (McBain et al. 2008b; Fouriki et al. 2010; Pickard & 
Chari, 2010; Jenkins et al., 2011; Fouriki et al., 2012; Lim et al.,2012; Lim & Dobson, 
2012; Adams et al., 2013; Fouriki & Dobson, 2013; Jenkins  et al., 2013; Subramanian et 
al., 2013; Fouriki et al., 2014; Subramanian et al., 2017)       
 
The additional energy transferred from the oscillating field to the cells, promotes particle 
uptake and apart from transfection efficiency also increases protein expression levels as 
demonstrated in the following studies.  
In 2008, McBain et al., used iron oxide nanoparticles coated with PEI carrying the 
luciferase reporter gene for in vitro transfection of human airway epithelial cells. It was 
shown that at 2 hrs duration, a statistically significant increase in overall transfection 
efficiency in response to an oscillating magnet array, was two times greater compared to 
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both static field and four times greater that two different cationic lipids tested. Cell 
viability levels were similar to controls at 48 hrs post transfection indicating that the 
method was not harmful to the cells (McBain et al., 2008b). 
In 2010, using the same cell type and PEI coated SPIONS carrying the luciferase reporter 
gene, protein production was further investigated in vitro. It was observed enhanced 
transfection efficiency and by up to tenfold increase in protein production, in comparison 
to the use of both static field nanomagnetic gene transfection, as well as the most widely 
used cationic lipid-based technique, with no adverse effects on cell viability (Fouriki et al., 
2010). The above two initial studies by our group showed that transfection efficieny was 
also dependent on the magnetic field gradient, frequency and amplitude, with 40 mT, 2 Hz 
and 0.2 mm being the optimal for NCI-H292 cells.  
In addition, further experimental work has repeatedly demonstrated in vitro that 
nanomagnetic transfection using the oscillating magnet array can efficiently transfect a 
variety of cell systems, at shorter transfection times (usually 30 minutes) utilizing lower 
amounts of DNA than cationic lipid-based agents when used for comparison, showing no 
adverse effects in cell viability and morphology.  
In 2010, hard-to-transfect rat astrocytes were efficiently transfected with SPIONs and 
reporter gene, using the oscillating system that was shown to be frequency dependent. 
Following introduction of transfected astrocytes into a 3D neural tissue array, cells 
survived and were able to differentiate (Pickard & Chari, 2010). 
In 2011, it was shown that nanomagnetic transfection can safely mediate single and/or 
combinatorial in vitro gene delivery to nuclear precursor/stem cells. Combinatorial gene 
transfection significantly enhanced overall transfection with negligible toxicity, while no 
adverse effects were observed on stem cell proliferation and differentiation. The 
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transfected nuclear precursor/stem cells survived and differentiated in 3D neural tissue 
arrays post-transplantation (Pickard et al., 2011). In the same year, primary rat 
oligodendrocyte precursors were efficiently transfected for the first time with MNPs and 
reporter gene, with increased levels of transfection compared to lipofection and 
electroporation and significantly higher cell viability (Jenkins et al., 2011).    
In 2012, human osteosarcoma fibroblasts (MG-63s) were transfected with SPIONs 
carrying green fluorescent protein, showing increased transfection efficieny compared to 
static fields and statistically significant increase in comparison to both cationic lipids and 
electroporation (these data will be presented as part of this thesis) (Fouriki et al., 2012).  
In the same year, using the same nanomagnetic transfection concept, hard-to-transfect 
mouse embryonic fibroblasts (MEFs) and human umbilical vein endothelial cells 
(HUVECs), showed significantly higher transfection efficiency compared to both static 
magnet and lipid reagents (Lim & Dobson, 2012). Also in 2012, for the first time using the 
method, short interfering RNA (siRNA) was introduced against green fluorescent protein 
(GFP) or actin into stably-transfected GFP-HeLa cells or wild-type HeLa and rat aortic 
smooth muscle cells, respectively. This gene silencing technique occurred in a dose- and 
cell density- dependent manner, as reflected using fluorescence intensity and adhesion 
assays (Lim et al., 2012). 
In 2013, mouse embryonic fibroblasts (NIH3T3s) were transfected with SPIONs and green 
fluorescent protein, and shown to significantly enhance transfection efficiency compared to 
cationic lipids (these data will be presented as part of this thesis) (Fouriki & Dobson, 
2013). In the same year, human prenatal cardiac progenitor cells and adult cardiomyocytes 
were transfected with the same nanomagnetic transfection concept, and demonstrated 
significantly improved transfection efficieny compared to static fields, cationic lipids and 
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electroporation. Also, it was shown that seeding cells onto Collagen-I was further 
improved transfection effiency (Subramanian et al., 2013). In another study, investigating 
for the first time the potential of MNP-mediated reporter gene delivery in 
oligodendrocytes, it was shown that nanomagnetic transfection using both static and 
oscillating magnets were achieved, even though transfection efficiency was typically low. 
This study importantly demonstrated that within cells of a specific neural lineage, the 
amenability to transfection is dependent on the differentiation status of the cell (Jenkins et 
al.¸2013). 
Furthermore, interesting results were demonstrated by Adams et al., when MNPs and 
reporter gene were used for transfection of neural stem cells propagated in the neurosphere 
(suspension culture) model. It was shown that transfection efficiency was enhanced over 
two-fold by oscillating magnetic fields, while there was no effect on cell vialbility, stem 
cell marker expression and differentiation profile of cultures post transfection. This work 
demonstrated the first attempt in transfecting suspension cultures of neural cells with 
MNP-based technology (Adams et al., 2013). 
In 2014, human mesenchymal stems were transfected with SPIONs and green flurescent 
protein, showing increased transfection efficieny compared to both static fields and 
cationic lipids. In addition, it was observed that hMSC-specific cell surface markers CD44, 
STRO-1, CD90 and CD146 retained normal expression post transfection (these data will 
be presented as part of this thesis) (Fouriki & Dobson, 2014).  
More recently, efficient transfection of human neuroblastoma cells (SH-SY5Ys) as well as 
primary hippocampal and cortical neurons which are considered hard-to-transfect neuronal 
cell types, was demonstrated using oscillating nanomagnetic transfection and 
MNP/reporter gene complexes. Cell viability was reported high and there was no 
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interference with the cell physiology, such as differentiation and neurite growth, in both 
cell lines and primary neurons (Subramanian et al., 2017).  
 
All the above mentioned research works have been tested in vitro, showing the successful 
applicability of the method, but also highlighting the need for in vivo testing.     
So far, a preliminary in vivo work was presented in 2008, where Muthana, Dobson et al. 
trying to improve transfected monocytes’ ability to infiltrate tumours, designed a monocyte 
extravasation assay and demonstrated in vitro that transfected human monocytes were able 
to migrate across a human endothelial cell layer into a 3D tumour spheroid in a 
significantly increased rate, when the monocytes were pre-loaded with MNPs with the 
application of a magnetic field close to the tumour spheroid. In the same study, this 
magnetic targeting approach was applied in vivo, and the systemic administration of MNP 
pre-loaded monocytes in mice tumours demonstrated a marked extravasation increase 
(Muthana, Dobson et al., 2008).   
Ultimately, in future in vivo applications, based on the magnetically targeted gene delivery 
model illustrated in the previous section (Figure 1.14), the particles carrying the 
therapeutic gene could be intravenously injected and circulated by the blood stream until 
captured by externally applied magnets at the site of interest. These magnets could be 
focused close to the target tissue, to promote transfection and targeting of therapeutic genes 
to a specific site or organ of the body
 
(Dobson, 2006b).  
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1.9 Stem cells and cell lines used for in vitro transfection 
In order to meet a primary aim of this work, a variety of mammalian cell types relevant to 
regenerative medicine was employed for the nanomagnetic gene transfection experiments. 
In this way, the ability of the method to transfect different cells types was demonstrated 
and in parallel these results could be used to expand our understanding on how to achieve 
targeted gene delivery in vitro that would ultimately serve for regenerative therapy 
strategies through gene delivery and cell/tissue engineered-mediated approaches (Daar & 
Greenwood, 2007). The stems cells and cell lines used in this study are presented in the 
following paragraphs. 
1.9.1 Human mesenchymal stems cells 
Human mesenchymal stem cells (hMSCs) were first discovered within the bone marrow 
from the revolutionary work of Friedenstein and colleagues (Friedenstein et al., 1970). 
They are adult stem cells defined as multipotent, capable of differentiating into a limited 
number of phenotypes (Lee & Hui, 2006). MSCs are adherent and spindle-shaped, forming 
colonies in culture which are known as colony forming unit-fibroblasts (CFU-Fs) (Figure 
1.18). 
 
MSCs are nonhematopoietic stromal cells that can be ideal candidates for tissue 
engineering and reparative/regenerative medicine due to their characteristic properties to 
differentiate and help to regenerate multiple tissues such as bone, cartilage, muscle, 
ligament, tendon and adipose (Pittenger et al., 1999; Chamberlain et al., 2007; Chen et al., 
2008; Schop et al., 2009). 
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In culture, they are able to divide multiple times and retain their multipotent differentiation 
characteristics but their identification and characterisation can be challenging due to the 
lack of specific biomarkers. However, the established guidelines for MSC characterization 
require the positive expression of CD73, CD90, CD44, CD146, CD105 and STRO-1 
antigens (Simmons & Torok-Storb, 1991; Pittenger et al., 1999; Colter et al., 2001; 
Delorme et al., 2009) and negative expression of CD34, CD45, CD14, CD11b, CD19 or 
MHC class II antigen and show capability of tri-lineage differentiation into osteoblasts, 
chondrocytes and adipocytes (Dominici et al., 2006; Chamberlain et al., 2007; Chen et al., 
2008). 
 
 
Figure 1.18: Representative phase images of primary cells, hMSCs and hESCs. (A) 
Human bone marrow derived hMSCs at passage 1, showing the typical fibroblast like 
morphology of hMSCs. (B) hESCs (SHEF-1 cell line), showing the typical morphology of 
hESCs expanding as dense and tightly adherent colonies. Scale bar =100µm.  
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1.9.2 Human embryonic stem cells  
Human Embryonic Stem Cells (hESCs) represent perhaps the most important cell type for 
myriad potential biomedical applications in regenerative medicine, the development and 
investigation of human disease models, developmental biology studies and many other 
applications. Human ESCs are known for their immortality as a result of high telomerase 
activity (Wobus & Boheler, 2005; Thomson et al., 1998) unlimited in vitro self-renewal, 
pluripotency and differentiation capability to generate specialized cell types of three 
somatic germ layers; ectoderm, mesoderm and endoderm lineages (Gerecht-Nir & 
Itskovitz-Eldor, 2004).  
 
Human ESCs are derived from the inner cell mass (ICM) of pre-implantation blastocysts 
and various studies have characterized their undifferentiated phenotype. Their pluripotency 
is confirmed by the presence of specific surface markers such as SSEA-1, SSEA-4, TRA-
1-60, membrane bound receptors such as gp130, the expression of transcription factors 
such as Oct-4, hTERT, Nanog (Wobus & Boheler, 2005; Cryz et al., 2003; Mathew el al., 
2010; Miyazaki et al., 2008) and high levels of alkaline phosphatase activity (ALP) 
(O’Connor et al., 2008). During in vitro culture, hESCs are characterized by a rounded 
morphology with a large nucleus to cytoplasmic ratio and they expand as dense and tightly 
adherent colonies that diffuse together to form a confluent monolayer of undifferentiated 
cells (Figure 1.18) (Thomson et al., 1998). 
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1.9.3 Established Cell lines 
In this study apart from primary human stem cells, three more established cell lines were 
used as cell model for nanomagnetic gene transfection. Representative images from human 
osteosarcoma fibroblasts (MG-63), human lung mucoepidermoid carcinoma (NCI-H292) 
and mouse embryonic fibroblast (NIH-3T3) cell lines are shown below (Figure 1......). 
 
Figure 1.19 Representative phase images of typical morphology of MG-63, NCI-H292 
and NIH-3T3 cell lines. Scale bar =100µm.  
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1.10 Aims and objectives of this study  
Gene delivery and its wide potential and uses have been successfully attempted by (a) viral 
vectors with high transfection efficiency but also significant risks and/or limitations and (b) 
non-viral vectors comprising of physical and chemical approaches characterized by quite 
varied results in transfection efficiency and cell viability as presented in this chapter. 
However, magnetic nanoparticle-based gene transfection systems that generate significant 
interest in the gene delivery field have shown promise as they can combine considerable 
transfection efficiency with minimal effects on cell viability eliminating viral associated 
risks. 
 
Through this study, nanomagnetic gene transfection, as a novel non-viral gene delivery 
approach has attempted to pursue two main aims: 
Aim (1) Efforts have been made to optimize technical parameters of the method in order to 
further improve the efficiency of reporter gene delivery. At the same time  primary cells, 
hMSCs and hESCs, as well as the cell lines MG-63, NCI-H292 and NIH-3T3 were utilized 
to assess the improvements in transfection efficiency and to investigate the applicability of 
the technique in a wider variety of cell types used for regenerative purposes. Furthermore, 
the outcome of these experiments was not to compromise cell viability, morphology and 
phenotypic characteristics of these cells following treatment with the nanomagnetic gene 
transfection system. 
Aim (2) In parallel, and in order to assist in the overall evaluation of the method, 
transfection efficiency and cell viability results obtained by nanomagnetic gene 
transfection were directly compared with the widely used commercially available lipid-
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mediated gene delivery technique Lipofectamine (LF2000) and selectively and when 
possible with electroporation (AMAXA).  
 
Chapter 2 – Materials & Methods 
 
 - 80 - 
 
 
 
 
 
 
 
Chapter 2 
Materials and Methods 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 – Materials & Methods 
 
 - 81 - 
 
2.1 Cell lines 
The human primary cells hMSCs and hESCs (SHEF-1), along with the human NCI-H292, 
and MG-63, and mouse NIH-3T3 cell lines used for the transfection experiments of this study 
are listed in the table below (Table 2.1).  
 
Table 2.1: Primary cells and cell lines used for transfection. 
Cell lines Description Origin 
hMSC 
Human mesenchymal stem cells isolated 
from bone marrow aspirates 
Human bone marrow aspirates 
from Lonza, USA 
SHEF-1 Human embryonic stem cell line 
UK Stem Cell Bank with 
approval from the Steering 
Group.  
In collaboration with Keele 
University Stem Cell group 
MEFs 
Mouse embryonic fibroblasts isolated 
from 12.5-13.5 days gravid uteri of 
black CB1 hybrid mice 
Provided by the Stem Cell 
group, Keele University small 
animal facilities 
NCI-H292 
Human lung mucoepidermoid 
carcinoma epithelial cell line 
ATCC, USA 
MG-63 Human osteosarcoma fibroblast cell line ATCC, USA 
NIH-3T3 Mouse embryonic fibroblast cell line ECACC, UK 
Chapter 2 – Materials & Methods 
 
 - 82 - 
 
2.2 Cell culture  
The cell culture materials used for this study including media and other supplements are 
listed in table below (Table 2.2). 
 
Table 2.2: Media and other supplements for cell culture. 
Name Description Cat No Company 
DMEM 
Dulbeco’s Modified Eagle 
Medium 
21969 
Gibco, Invitrogen, 
Paisley, UK 
KO-DMEM Knock Out DMEM 10829 
Gibco, Invitrogen, 
Paisley, UK 
FBS Fetal Bovine Serum DE14-870F Lonza, Belgium 
KO-SR 
Knock Out Serum 
Replacement 
10828 
Gibco, Invitrogen, 
Paisley, UK 
PBS Phosphate Buffered Saline BE17-516F Lonza, Belgium 
RPMI 
Roswell Park Memorial 
Institute Medium 
LM-R1641 Biosera, UK 
Trypsin/EDTA Trypsin 10X with Versene BE02-007E Lonza, Belgium 
DMSO Dimethyl Sulphoxide  D2650 Sigma-Aldrich, UK 
L-glutamine L-Glutamine BE17-605E Lonza, Belgium 
NEAA Non Essential Amino Acid BE13-114 Lonza, Belgium 
Matrigel BD Matrigel Matrix 354234 BD, Bedford, MA, 
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USA 
bFGF Human FGF-basic 100-18B PeproTech, London 
PSA 
Penicillin-Streptomycin-
Amphotericin B 
17-745E Lonza, MD, USA 
β-mercaptoethanol 2-Mercaptoethanol 31350-010 
Gibco, Invitrogen, 
Auckland, NZ 
 
2.2.1 hMSC culture 
hMSC isolation:  
Human bone marrow aspirates (BMA) purchased from Lonza, USA were used to isolate from 
and expand hMSC following the previously published methodology of plastic adherent 
culture technique (D’Ippolito et al. 2004, Wimpenny et al. 2010). For this study 2 human 
BMA from 2 different donors were aspirated from iliac crest and the donors’ details were 
listed in Table 2.3. Whole bone marrow was seeded at a density of 10
5
 mononuclear cells/cm
2
 
on 10 ng/ml fibronectin-coated (Sigma, UK) T75 tissue culture flasks containing 20 ml of 
DMEM supplemented with 10% FBS, 1% L-glutamine, 1% PSA (Penicillin-Streptomycin-
Amphotericin B) and 1% NEAA that comprised the supplemented culture media and 
incubated at 37
0
C and 5% CO2. Each T75 flask containing a 10 ml fibronectin coating 
solution of 10 ng/ml in PBS was incubated for 2 hours at room temperature (RT). Before 
using the T75 flasks for BMA seeding, fibronectin solution was discarded and the culture 
media was added. A continuous culture of the whole bone marrow cells containing non-
adherent (mononuclear cells) and adherent cells (MSC) was maintained for three weeks in a 
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humidified incubator at 37
0
C and 5% CO2. Following a 7 day-culture half of media was 
removed and replaced with antibiotic-free fresh DMEM culture medium as described above. 
Cell culture continued and on week 2, whole media was discarded, cells were washed once 
with PBS and supplemented fresh media was added (20 ml/T75 flask). Finally, by week 3 a 
MSC-colony was formed (also known as CFU-F, colony forming unit- fibroblast). The 
adherent hMSC population was harvested with trypsin as described next and subsequently 
passaged for expansion. Before expansion, hMSC were seeded on 24-well plates for their 
characterisation and immunophenotyping which is described below in the fluorescent 
immunocytochemistry section 2.7.1. 
 
Table 2.3: Human BMA donor details. 
No BMA label Donor description Supplier 
1 BMA-8 Human Bone Marrow, Male, Age-35 years Lonza, USA 
2 BMA-11 Human Bone Marrow, Female, Age-26 years Lonza, USA 
 
Trypsinization for subculture:  
During trypsinization process a confluent T75 flask of cells was washed once with 10 ml of 
PBS (Phosphate-buffered saline) pre-equilibrated at 37
0
C and 5 ml of 0.05% trypsin/EDTA 
solution was added to the cells and incubated at RT for 3-5 minutes. The cells were checked 
under the microscope and once they looked rounded and detached from each other and the 
flask’s adherence surface the same volume (5 ml) of supplemented media was added to 
neutralise the action of trypsin. Cell suspension was centrifuged at 1200 rpm (conversion of 
rpm to gav is shown in Section 2.3.4) for 3 minutes to obtain a cell pellet. The supernatant was 
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discarded and the cell pellet was resuspended in fresh supplemented media for passage. 
Media was replaced twice in a week during the whole period of culture.  
 
hMSC expansion:  
hMSC were harvested by trypsinisation as described above, expanded in T75 tissue culture 
flasks and subcultured up to passage 3 by splitting at 1:5 to 1:10 ratios. The DMEM media 
used for cell culture was supplemented with 10% FBS, 1% L-glutamine, 1% PSA (Penicillin-
Streptomycin-Amphotericin B) and 1% NEAA that comprised the supplemented culture 
media and incubated at 37
0
C and 5% CO2. Passage 1-3 hMSC were utilised for all 
experimental work. 
 
hMSC cryopreservation:  
After isolation from BMA, a large number of hMSC was cryopreserved at Passage-1 for 
future use. Confluent T75 flasks of hMSC were harvested by trypsinisation and cells stored in 
the liquid nitrogen at -196
0
C in cryovials in freeze-media comprised of 10% DMSO 
(Dimethyl sulfoxide) in FBS (Foetal bovine serum). The cell content of one confluent T75 
flask was stored in each cryovial in 1 ml of freeze media. 
 
2.2.2 hESC culture 
hESC line SHEF-1 cells used in this study were obtained from the UK Stem Cell Bank after 
donation by the University of Sheffield, UK and with accompanying project approval from 
the Steering Group. hESC were cultured using a freeder-free culture system able to maintain 
undifferentiated hESCs for at least 130 population doublings (Xu et al., 2001). hESCs were 
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cultured on matrigel coated T25 tissue culture flasks and their conditioned culture media was 
prepared using mouse embryonic fibroblasts (MEFs) following the protocol described by Xu 
et al. 2001. 
 
hESC conditioned media (CM) preparation:  
MEFs that were used to condition hESC conditioned media (CM) were isolated from 12.5-
13.5 days gravid uteri of black CB1 hybrid mice at small animal facilities, Keele University 
and were provided by the Stem Cell Group, ISTM, Keele University. hESC CM was 
composed of KO (Knock out)-DMEM (Gibco, Invitrogen) media supplemented with 20% 
KO-SR (KO-Serum replacement) (Gibco, Invitrogen), 1% L-glutamine, 1% NEAA, 4ng/ml 
human bFGF (Basic fibroblast growth factor) and 0.1mM β-mercaptoethanol. hESCs CM 
was added and cultured/conditioned overnight on semi-confluent MEFs and then collected 
and further supplemented with 4ng/ml of bFGF and sterile filtered with 0.20 µm porous 
Millipore filtration unit (Millipore) before use. 
 
Matrigel coating:  
Cell culture surfaces of T25 tissue culture flasks were coated with 4 ml /T25 of cold matrigel 
solution diluted 1:100 in cold KO-DMEM and incubated at RT for 2 hours. Before use, 
matrigel containing flasks were incubated at 37
0
C for 30 minutes in an incubator, then 
matrigel solution was discarded and hESC culture media was added. Prepared matrigel 
coated culture flasks were stored at 4
0
C for later use. 
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hESC culture:  
A SHEF-1 cryovial (P-28) was taken from liquid nitrogen, equilibrated in a water bath at 
37
0
C and cells quickly thawed and stored in 10% DMSO in KO-SR solution. Then thawed 
cells were transferred into a matrigel coated T25 tissue culture flask containing 6 ml CM pre-
equilibrated 37
0
C and were incubated at 37
0
C and 5% CO2 in the humidified incubator. 
Media was replaced daily by 6 ml fresh hESC CM. When hESC became 70-80% confluent 
were harvested by trypsinisation and passaged into 2 to 4 T25 flasks at a split ratio of 1:2 to 
1:4. For trypsinisation, cells were washed with PBS and 2 ml of trypsin/EDTA solution was 
added and incubated for 1-3 minutes at RT. The cells were dislodged by tapping the flask and 
same volume of hESC culture media was added to the T25. The solution was centrifuged for 
3 minutes at 1200 rpm (conversion of rpm to gav is shown in Section 2.3.4) to obtain a cell 
pellet. Cell pellet was then resuspended in 10 ml of hESC CM and passaged as above split 
ratio. Cells were passaged every 3 to 7 days. 
 
hESC cryopreservation:  
When T25 flasks of hESC were 80-90% confluent they were harvested by trypsinisation and 
stored in the liquid nitrogen using 10% DMSO in KO-SR freeze media. The cell content of 
one confluent T25 flask was stored in each cryovial in 1 ml of freeze media. 
 
2.2.3 Cell lines culture 
Cell culture for  human NCI-H292 and MG-63 as well as mouse NIH-3T3 cell lines was 
performed according to the suppliers’ instructions.  
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2.2.3.1 MG-63 and NIH-3T3 cell culture 
MG-63 and NIH-3T3 cells were stored in the liquid nitrogen at -190
0
C in cryovials in freeze 
media comprised of 10% DMSO in FBS. Cells in cryovials were quickly thawed in a water 
bath at 37
0
C and resuspended in 10-15 ml of complete culture media that composed of 
DMEM supplemented with 10% FCS, 1% L-glutamine and 1% PSA.  
MG-63 and NIH-3T3 cell suspensions were then passaged into their correspondingly labelled 
T75 tissue culture flasks and incubated in the humidified incubator at 37
0
C and 5% CO2. 
Their media was replaced 24 hours later with 10-15 ml of fresh complete culture media (as 
described above). Both cell lines became confluent within 3-4 days. MG-63 and NIH-3T3 
cells were subcultured and cryopreserved as described previously (section 2.2.1).  
 
2.2.3.2 NCI-H292 cell culture 
NCI-H292 cells were stored in the liquid nitrogen at -190
0
C in cryovials in freeze media 
comprised of 10% DMSO in FBS. Cells in cryovials were quickly thawed in a water bath at 
37
0
C and resuspended in 10-15 ml of complete culture media that composed of RPMI 1640 
supplemented with 10% FBS, 1% L-glutamine and 1% PSA.  
NCI-H292 cell suspensions were then passaged into T75 tissue culture flasks and incubated 
in the humidified incubator at 37
0
C and 5% CO2. Their media was replaced 24 hours later 
with 10-15 ml of fresh complete culture media (as described above). NCI-H292 cells became 
confluent within 3-4 days. NCI-H292 cells were subcultured and cryopreserved as described 
previously (section 2.2.1).  
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2.3 In vitro nanomagnetic gene transfection with the magnefect-nano 
system  
2.3.1 The nanomagnetic gene transfection system components 
In this study, for the nanomagnetic gene transfection experiments the novel magnefect-nano 
system (nanoTherics Ltd, UK) was used to increase the MNP:DNA complexes sedimentation 
on the cell culture surface, stimulate endocytosis, andpromote further transfection of the 
complexes.  The basic components of the system included the magnefect-nano oscillating 
array (nanoTherics Ltd, UK), mounted onto a computer-controlled stepper motor to control 
the lateral sliding/oscillation of the magnet array (nanoTherics Ltd., UK), and the cell culture 
plates positioned directly above the magnet array holder, with cell culture surface being at 3 
mm distance above the magnet array. Following addition of the MNP:DNA complexes into 
the culture, the cell culture plate and magnefect-nano oscillating system were transferred into 
an incubator for the duration of transfection (Figure 2.1). 
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Figure 2.1 The magnefect-nano gene transfection system. The oscillating magnet array of 
the magnefect-nano system configured for multi-well cell culture plates was mounted to a 
computer-controlled stepper motor that was interfaced to computer software to control the 
duration, oscillation frequency and amplitude. For the duration of transfection experiments 
cell culture and stepper motor were incubated at 37
0
C and 5% CO2 to maintain optimal cell 
culture conditions.    
  
2.3.2 The magnet arrays 
Magnet arrays used for both static and oscillating transfections were configured for 96-well 
and 24-well tissue culture plate formats. (nanoTherics Ltd., UK), The magnet arrays were 
constructed arranging cylindrical stacks of rare earth magnet, an alloy of neodymium, iron 
and boron (NdFeB), with 6 mm and 15 mm diameter correspondingly on non-magnetic 
aluminium templates (Figure 2.2). Magnetic fields were mapped using the magnetic field 
scanner, Magtronics MagScan500 (Redcliffe Magtronics, UK).  
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Figure 2.2: Schematic representation of 96-well and 24-well plate formats of the magnet 
arrays. Cylindrical stacks of NdFeB magnets were used to assemble 96-well (left) and 24-
well (right) magnet array format used for static and oscillating transfections.   
 
2.3.2.1 The 96-well magnet array assembly 
As described above (Section 2.3.2) the magnet arrays were constructed arranging cylindrical 
stacks of NdFeB magnet discs on non-magnetic aluminium templates. Here, a detailed 
description of the 96-well magnet array assembly was provided (Figure 2.3), showing that 
each cylindrical well at 2 mm above the bottom of the well had a narrowing point, above and 
below which attracted magnet discs (6 mm diameter, 2 mm height) of opposing magnetic 
fields were positioned in order to secure the magnets’ position into the array. Then, an 
additional magnet disc (6 mm diameter, 2 mm height) was placed into the array on top of the 
previously inserted, to reach the top of the cylindrical well. Similarly, all wells of the non-
magnetic aluminium template were filled with the magnet discs and the 96-well magnet array 
was assembled.     
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Figure 2.3: Schematic representation of the 96-well magnet array assembly. (A) Top 
view of the nanoTherics 96-well aluminum plate, empty of magnets. Close up side views of: 
(B) a cylindrical well the bottom of which is open and the well periphery narrows at 2 mm 
above the bottom of the well; (C) two NdFeB magnet discs (2mm diameter) are positioned 
above and below the narrowing point; (D) magnet discs with opposing magnetic fields 
attracting each other to secure the magnet discs’ position; (E) an additional magnet disc 
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(2mm diameter) positioned on top and attracted by the magnet disc below. (F-G) Top and 
side view of the fully assembled nanoTherics 96-well magnet array.  
 
2.3.2.2 The magnet height rearrangement of the 96-well magnet array 
For the purpose of evaluating the magnetic field requirements for transfection and the 
resulting effect in transfection efficiency (Section 3.1), the 96-well magnet array format was 
rearranged in order to vary the distance between the magnet array and cell culture surface 
(bottom of the culture plate). In particular, the magnet height per column of the magnet array 
was adjusted in such way that in column 1, magnet discs were positioned directly beneath the 
cell culture surface of the 96-well plate at the closest of 3 mm. Following on, in columns 2, 3, 
4 and 5 the magnet discs were rearranged so the distance from the cell culture surface was 
increased at 4 mm, 5 mm, 6 mm and 7 mm correspondingly, increasing the distance between 
the magnet and cell culture surface by 1 mm at each time. Following on from the description 
of the basic 96-well magnet array assembly (Figure 2.3), the magnet height rearrangements 
were achieved by using the cylindrical NdFeB magnet discs (6 mm diameter) with a variety 
of heights (1 mm, 2 mm and 3 mm) (Figure 2.4). The rearranged magnet array used for both 
static and oscillating transfections was mapped for its magnetic field strength using the 
magnetic field scanner, Magtronics MagScan500 (Redcliffe Magtronics, UK).   
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Figure 2.4: Schematic representation of the magnet height rearrangement of the 96-well 
magnet array. For column 1, magnet discs are positioned directly beneath the cell culture 
surface of the 96-well plate, at the closest of 3 mm. For columns 2, 3, 4 and 5, magnet discs 
are rearranged increasing the distance between the magnet and cell culture surface by 1 mm 
at a time, and therefore keeping the magnets away from the cell culture surface at 4 mm, 5 
mm, 6 mm and 7 mm correspondingly.  
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2.3.3 The magnetic nanoparticles and plasmid DNA  
2.3.3.1 The choice of MNPs for transfection 
According to the manufacturers, the commercially available SPIONs nTMag (nanoTherics 
Ltd, UK) and PolyMag (OzBiosciences, France) (0.1mg/ml) used in transfection experiments, 
have magnetite cores with proprietary multi-layer PEI derivative dispersed in ddH2O aqueous 
solution. Also, they have a diameter of approximately 100 nm and are biocompatible and 
biodegradable when used according to manufacturer’s protocol. In addition, both SPIONs 
have been provided with accompanying quality control information that include in case of 
nTMag the pH value of suspension (7.0), particle size distribution (1.7) and zetapotential 
(+23.87mV), and in case of PolyMag the particle size distribution (1.5 to 2.0) and 
zetapotential (+25 mV to +28 mV). Their appropriate storage conditions were between 4 ˚C 
to 8 ˚C. The technical characteristics of nTMag and PolyMag as provided by their 
manufacturers are listed below in the Table 2.4.  
 
Table 2.4: Technical characteristics for commercially available nTMag and PolyMag 
SPIONs 
 SPIONs 
Product name nTMag PolyMag 
Description Aqueous dispersion in ddH2O 
Concentration 0.1mg/ml 
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Core Magnetite 
Type of magnetization Superparamagnetic 
Coating/ matrix PEI derivative, multi-layer 
Size (diameter) 100 nm 
Autoclaved Yes Unknown 
pH value of suspension 7.0 Unknown 
Particle size distribution 1.7 1.5 to 2.0 
Zeta-potential +23.87mV +25 mV to +28 mV 
Storage 4 - 8 ˚C 
 
2.3.3.2 The plasmid DNA as a reporter 
The 4.7 kb eukaryotic expression plasmid pEGFP-N1 (Figure 2.5) (Clontech, California, 
USA) containing a cytomegalovirus (CMV) immediate early promoter/enhancer and gene 
expressing enhanced Green Fluorescent Protein (EGFP) was used as reporter in this study. 
The endotoxin free plasmid DNA, purified using EndoFree Plasmid Purification kit (Qiagen, 
UK) and maintained at -80 ˚C in endonuclease-free water (Sigma, UK), was kindly provided 
by nanoTherics Ltd. The working concentration of pEGFP-N1 plasmid used for all 
transfection experiments was 0.2mg/ml. 
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Figure 2.5: Schematic representation of plasmid map of pEGFP-N1 vector. pEGFP-N1 
encodes a red-shifted variant of wild type GFP which has been optimized for brighter 
fluorescence and higher expression in mammalian cells, with excitation maximum at 488 nm 
and emission maximum at 507 nm. EGFP coding sequence is located before the PCMV that 
represents the cytomegalovirus immediate early promoter responsible for driving expression 
in mammalian cells. Sequences flanking EGFP have been converted to a Kozak (Kozak 
consensus translation initiation site) to further increase the translation efficiency in eukaryotic 
cells. SV40 polyadenylation (poly A) signals protect the mRNA from degradation by 
exonucleases. F1 ori is the origin of replication for single-stranded DNA production. SV40 
ori is the simian virus 40 origin for replication in mammalian cells. Kanamycin/Neomycin 
resistance and polyadenylation signals from Herpes simplex virus thymidine kinase (HSV TK 
poly A), allow stably transfected eukaryotic cells to be selected. pUC ori is the origin of 
replication for propagation of Escherichia coli (E. coli) (Adapted from Yang et al., 1996 and 
www.clontech.com).  
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2.3.4 Investigation of MNP:DNA binding 
In order to investigate whether the SPIONs to be used for transfection experiments were able 
to bind pEGFP-N1 containing the gene encoding for enhanced green fluorescent protein 
(EGFP), MNP:DNA binding curves were performed in DMEM media using 
spectrophotometry.  
A range of different MNP volumes with a concentration of 0.1mg/ml and DMEM media were 
mixed with 30 μl fixed volume of pEGFP-N1 plasmid (0.2mg/ml) to add up to 60 μl in total 
which was the total spectrophotometry cuvette sample volume, as shown in Table 2.5. The 
proportion of DNA that remained unbound (i.e. still in solution after centrifugation) was then 
determined. A sample containing only plasmid DNA and DMEM but no MNP was assayed 
as a control. Following mixing of the particles and DNA at RT for 15 min, samples were 
centrifuged at 14,000 rpm (conversion of rpm to gav is shown below) for 5 min to induce 
sedimentation of the MNP and/or MNP:DNA complexes. The absorbance of the supernatant 
containing the unbound DNA was measured for each sample at 260 nm and compared with 
the DMEM blank sample. In order to determine the proportion of unbound (free) plasmid 
DNA, spectrophotometry absorbance readings were expressed as percentages of the 
absorbance of the DNA-only (blank) control and results were plotted in a curve. 
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Table 2.5: Preparation of spectrophotometry cuvette samples for nTMag and PolyMag 
MNPs with DNA for binding curves. 
nTMag/ PolyMag 
(μl)  
original solution 
nTMag/ PolyMag 
(μl)  
1:10 dilution/ 
original solution. 
DNA  
(μl) 
DMEM  
(μl) 
Total Volume 
(μl) 
Cuvette sample 
0 0 30 30 60 
0,1 1 30 29 60 
0,25 2,5 30 27,5 60 
0,5 5 30 25 60 
0,75 7,5 30 22,5 60 
1 10 30 20 60 
 
Conversion between rpm to gav 
The centrifugation conditions for experiments are represented in rpm (revolutions per 
minute). Additionally, the conversion between rpm to gav (g), i.e. relative centrifugal force 
(RCF) expressed in units of gravity, is shown next. 
Revolutions per minute refer to the acceleration applied to the samples during centrifugation. 
When rpm unit is used the force of acceleration varies with the radius of the instrument, as 
the bigger the radius the higher the acceleration. On the contrary, RCF (g) is the same across 
all instruments. When the value of the radius of the instrument is known, the force of 
acceleration can be calculated using the formula below: 
RCF (or g) = (1.118 x 10
-5
) x rpm
2
 x r 
RCF represents the Relative Centrifugal Force, rpm represents the rotational speed in 
revolutions per minute, and r is radius of the instrument’s rotor in centimeters.   
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2.3.5 MNP:DNA complexes dose response optimization  
In order to test a wide range of MNP volumes complexed with different DNA concentrations 
and to facilitate optimization of transfection efficiency in different cell types, a MNP:DNA 
dose response experiment was designed to allow for multiple rations to be tested 
simultaneously (Figure 2.6). The experiment was designed in a 96-well plate format 
accommodating duplicate samples of 36 different MNP:DNA ratios. Following this 
experiment, and observing the expression of GFP under the microscope, the most appropriate 
MNP:DNA transfection ratio for each cell type we selected. 
 
2.3.5.1 The MNP:DNA dose response protocol  
Step 1: Six different DNA concentrations (1.2 μg, 2.0 μg, 3.0 μg, 4.0 μg, 5.0 μg, 6.0 μg) were 
mixed with 200 μl serum free (SF) media contained in six tubes labeled correspondingly. In 
parallel, in a 48-well plate 2 μl of MNP were pipetted into wells A1 to A6. The six DNA 
solutions were added to the six wells of the 48-well plate correspondingly and incubated at 
RT for 15 min (Step 1, Figure 2.6).  
Step 2: Continuing at the 48-well plate, MNP:DNA complexes were diluted to the working 
concentration by adding 300 μl of supplemented media into all six wells (A1-A6). 250 μl of 
supplemented media was added into all the remaining wells of the 48-wel plate in columns 1-
6. Serial dilutions were performed transferring 250 μl from well A1 below to well B1, mixing 
well and continuing from B1 to C1 similarly for the remaining wells of column 1. This step 
was repeated from all 6 columns (Step 2, Figure 2.6).  
Step 3: Following serial dilutions at the 48-well plate, 100 μl (in duplicates) of MNP:DNA 
complex from well A1 (of the 48-well serial dilutions plate) was transferred into wells A1 
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and A2 of a 96-well tissue culture plate were cells have been seeded for the experiment 24 
hours ago. This step was repeated for the remaining wells in the 48-well plate. Then the 96-
well tissue culture plate was placed above the oscillating magnet of the magnefect-nano 
system and was set for 30 min transfection, at 2 Hz frequency and 0.2 mm amplitude (Step 3, 
Figure 2.6).  
Step 4: Following transfection and 48 hours standard incubation of the tissue culture plates, 
the cells were observed under the microscope for GFP expression and by the use of the table 
in illustrated in Step 4 the optimal MNP:DNA ratio was determined (Step 4, Figure 2.6).  
 
Following the determination of the optimal MNP:DNA ratio in the 96-well format, and if the 
transfection experiment was to performed in 24-well plate format (in the case of hESCs) then 
the surface area of the wells were taken into account. In particular, the surface area of a 24-
well plate well (1.9 cm
2
) is six times larger than equivalent for a 96-well plate well (0.32 
cm
2
). In that case the optimal MNP:DNA ratio obtained by the dose response experiment was 
scaled up by a factor of 6. The same principle can be applied for the seeding densities in 
larger tissue culture plates. 
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Figure 2.6: Schematic representation of the experimental steps for  MNP:DNA dose 
response optimization. Step 1 illustrates the MNP:DNA complexes preparation of the 6 
solutions containing the highest volume/concentration of MNPs and DNA in a 48-well plate. 
Step 2 explains the serial dilution steps in the 48-well plate, for the preparation of complexes 
with gradually lower volumes/concentrations of MNPs and DNA, and in adequate numbers 
for the transfer and transfection at a 96-well tissue culture plate. Step 3 shows the addition of 
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previously prepared MNP:DNA complexes into the 96-well tissue culture plate, containing 
cells seeded 24 hrs before. Finally, Step 4 lists all the available MNP:DNA ratios tested 
during the optimization, and the corresponding wells of the 96-well plate that were added into 
(Adapted from nanotherics protocols, www.nanotherics.com).  
 
2.3.6 In vitro nanomagnetic gene transfection: The protocol 
All primary cells (hMSCs and hESCs) and cells lines (NCI-H292, MG-63 and NIH-3T3) 
used during the experiments were transfected using the oscillating magnefect-nano system 
(nanoTherics Ltd., UK) and the standard nanomagnetic transfection protocol as described 
here. All cell type-specific transfection requirements and/or deviations from the standard 
transfection protocol are described in each cell type-specific paragraph below (Section 
2.3.6.1) and summarized in Table 2.6.             
 
Protocol: Cells were seeded onto 96-well or 24-well tissue culture plates at approximately 
70% confluency and incubated at 37
0
C and 5.0% CO2 for a period of 24 hours before 
transfection, to allow cells to adhere to the bottom of the wells. At the transfection 
experiment day, 24 hrs after seeding, MNP:DNA complexes were composed of 100 μl (in 
case of 96-well plate) and 400 μl (in case of 24-well plate) of non-supplemented, serum free 
(SF)  cell type-specific media, pEGFP-N1 DNA from a working concentration of 0.2mg/ml 
and nTMag and/or PolyMag MNPs from an original MNP concentration of 0.1mg/ml for 
both MNP types used. Following the addition of MNP:DNA complexes to the cell culture, 
samples were transferred into an incubator at 37
0
C and 5% CO2, and placed over the 
magnefect-nano oscillating magnet array for 30 min, at 2 Hz horizontal oscillation frequency 
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and 200 μm amplitude. At 30 min post transfection, cell culture plates were removed from 
the magnefect-nano system and transfection complexes were replaced with 100μl (in case of 
96-well plate) and 400 μl (in case of 24-well plate) of supplemented cell type-specific 
medium. All samples in tissue culture plates were transferred back into an incubator for 48 hr 
before data analysis. In the cases of static field experiments, the cell culture plates were 
placed directly above the magnet array but the oscillation option was not selected and then 
transferred into an incubator for the duration of transfection as previously described. 
 
The drive system: For oscillating field experiments with the magnefect-nano system, the cell 
culture plates were placed directly above the magnet array holder that was mounted onto a 
computer-controlled stepper motor (nanoTherics Ltd., UK) and interfaced to a computer 
running a software to control the magnet array’s horizontal lateral oscillation (nanoTherics 
Ltd., UK). The cell culture plate and magnefect-nano oscillating system were transferred into 
an incubator and remained interfaced to control electronics outside the incubator for the 
duration of transfection (Figure 2.1). The oscillating field transfection experiments were 
performed at 2 Hz horizontal oscillation frequency and 200 μm amplitude.
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Table 2.6: Cell type-specific transfection parameters for nanomagnetic gene transfection.  
Transfection 
Parameters 
(differing from standard 
nanomagnetic transfection 
protocol 2.3.6) 
Cell Type 
 NCI-H292 MG-63 NIH-3T3 hMSC  hESC 
Medium type 
9
6
-w
el
l 
p
la
te
 f
o
r
m
a
t 
RPMI 1640 DMEM DMEM DMEM 
2
4
-w
el
l 
p
la
te
 f
o
r
m
a
t 
KO-DMEM 
SPIONS:DNA complexes- 
nTMag and/or PolyMag:  
pEGFP-N1 
0.1 μl: 0.1 μg 0.2 μl: 0.3 μg 0.6 μl: 0.6 μg 
Transfection volume (μl) 100 400 
Seeding density 2 x 10
4
 1 x 10
4
 1 x 10
4
 5 x 10
3
 5 x 10
4
 
Replacement volume  
(post transfection) 
100 400 
Magnets NdFeB 96-well array format 
NdFeB 24-well 
array format 
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2.3.6.1 Cell type-specific transfection requirements 
NCI-H292 cell line:  
 Transfection complexes were composed of 100 μl of SF RPMI 1640 media, 0.1 μg of 
pEGFP-N1 DNA and 0.1μl nTMag MNPs per 96-well tissue culture plate well. All other 
experimental conditions were as per protocol (Section 2.3.6) and cell culture conditions 
(Section 2.2.3.2).  
 
MG-63 and NIH-3T3 cell lines:  
Transfection complexes were composed of 100 μl of SF DMEM medium, 0.1 μg pEGFP-N1 
DNA and 0.1 μl nTMag and/or PolyMag MNPs per 96-well tissue culture plate well. In the 
case of MG-63 cell line transfections both nTMag and PolyMag MNPs were used, while only 
nTMag MNPs were used for NIH-3T3 cell line transfections. All other experimental 
conditions were as per protocol (Section 2.3.6) and cell culture conditions (Section 2.2.3.1).  
 
hMSCs: 
hMSCs used for transfection experiments were ranging from 1-3 population doublings. 
Transfection complexes were composed of 100 μl of SF DMEM medium, 0.3 μg pEGFP-N1 
DNA and 0.2 μl nTMag MNPs per 96-well tissue culture plate well. All other experimental 
conditions were as per protocol (Section 2.3.6) and cell culture conditions (Section 2.2.1). 
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hESCs:  
hESCs used for transfection experiments were ranging from 46-56 population doublings. 
Transfection complexes were composed of 400 μl of KO-DMEM medium, 0.6 μg DNA and 
0.6 μl nTMag MNPs per 24-well tissue culture plate well. All other experimental conditions 
were as per protocol (Section 2.3.6) and cell culture conditions (Section 2.2.2).  
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2.4 In vitro lipid-mediated gene transfection 
All primary cells (hMSCs and hESCs) and cells lines (NCI-H292, MG-63 and NIH-3T3) 
used during the experiments were transfected using the best currently available cationic 
lipids, Lipofectamine 2000 (LF2000) (Invitrogen, UK), for the comparison with 
nanomagnetic transfection. Lipofectamine and nanomagnetic transfections were performed in 
parallel with identical complex formation conditions, and all other transfection parameters as 
summarized in Table 2.6. In this section, the exact compositions of Lipofectamine:DNA 
complexes for each cell type are summarized in Table 2.7. All cell type-specific 
Lipofectamine transfection requirements and/or deviations from the standard Lipofectamine 
transfection protocol are described in each cell type-specific paragraph below (Section 2.4.1) 
 
Protocol: Cells were seeded onto 96-well or 24-well tissue culture plates at approximately 
70% confluency and incubated at 37
0
C and 5.0% CO2 for a period of 24 hours before 
transfection, to allow cells to adhere to the bottom of the wells. At the transfection 
experiment day, 24 hrs after seeding, LF2000:DNA complexes were composed of non-
supplemented, serum free (SF) cell type-specific media, pEGFP-N1 DNA from a working 
concentration of 0.2mg/ml and LF2000 lipid-based agent. Following the addition of 
LF2000:DNA complexes to the cell culture, samples were transferred into an incubator at 
37
0
C and 5% CO2 for 6 hrs as per manufacturers protocol. At 6 hrs post transfection, 
transfection complexes were removed from samples and replaced with supplemented cell 
type-specific medium. All samples in tissue culture plates were transferred back into an 
incubator for 48 hr before data analysis. 
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The major point of difference in the protocol execution with lipid-mediated transfection, is 
the requirement for prolonged Lipofectamine:DNA complexes incubation with the cells (6 
hrs). This requirement lies on the different mechanism of Lipofectamine:DNA complex 
uptake by the cells, and the lack of a magnetic component of the complex and a magnet to 
induce rapid complex sedimentation.   
 
Table 2.7: Cell type-specific composition of Lipofectamine:DNA complexes for 
transfection. 
Transfection 
Parameters 
(As shown in Table 2.6) 
Cell Type 
 
NCI-
H292 
MG-63 NIH-3T3 hMSC  hESC 
Lipofectamine:DNA 
complexes- 
LF2000: pEGFP-N1 
 9
6
-w
el
l 
p
la
te
 
fo
rm
a
t 0.3 μl: 
0.1 μg 
0.3 μl: 
0.1 μg 
0.5 μl:  
0.2 μg 
0.5 μl:  
0.2 μg 
2
4
-w
el
l 
p
la
te
 
fo
rm
a
t 1.8 μl:  
0.6 μg 
 
2.4.1 Cell type-specific transfection requirements 
NCI-H292 cell line:  
Transfection complexes were composed of 100 μl of SF RPMI 1640 media, 0.1 μg of 
pEGFP-N1 DNA and 0.3 μl LF2000 per 96-well tissue culture plate well. All other 
experimental conditions were as per protocol (Section 2.4) and cell culture conditions 
(Section 2.2.3.2).  
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hMSCs and MG-63 and NIH-3T3 cell lines:  
Transfection complexes were composed of 100 μl of SF DMEM medium, 0.1 μg pEGFP-N1 
DNA and 0.3 μl LF2000 for MG-63 cells, and  100 μl of SF DMEM medium, 0.2 μg pEGFP-
N1 DNA and 0.5 μl LF2000 for hMSCs and NIH3T3 cells, per 96-well tissue culture plate 
well. All other experimental conditions were as per protocol (Section 2.4) and cell culture 
conditions (Sections 2.2.1 and 2.2.3.1).  
 
hESCs:  
Transfection complexes were composed of 400 μl of KO-DMEM medium, 0.6 μg pEGFP-N1 
DNA and 1.8 μl LF 2000 per 24-well tissue culture plate well. All other experimental 
conditions were as per protocol (Section 2.4) and cell culture conditions (Section 2.2.2). 
 
2.5 Electroporation of MG-63 cells 
In the MG-63 experiments the magnefect-nano system also was compared with the Amaxa 
Nucleofector (Lonza, UK) electroporation method. MG-63 cells were maintained as 
described previously and following manufacturers protocol 2 x 10
6
 cells were used for a 
single Amaxa sample. Following electroporation, cell count was performed to determine cell 
viability and finally samples were seeded onto 96-well tissue culture plates and transferred 
back into an incubator for 48hr before analysis. 
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2.6 Fluorescent microscopy  
After transfection experiments with the magnefect-nano system, lipid agents and 
electroporation and following a standard 48 hr incubation, fluorescent microscopy was 
performed for all transfected samples to visualise GFP-expressing cells. Phase and 
fluorescent images of transfected cells were captured using a Nikon Eclipse Ti fluorescent 
microscope. 
 
2.7 Fluorescent Immunocytochemistry  
Fixation protocol:  
Samples were fixed with 4% PFA (Fisher Scientific, UK) for 30 minutes, washed with PBS 
once and permeabilized with 0.5% Triton-X 100 (Sigma, UK) for 5 minutes at RT.  
 
Blocking protocol:  
Samples were then washed with PBS twice and blocked with 3% BSA for 1 hour at RT. After 
blocking, samples were washed with PBS once and treated with primary antibodies (Table 
2.8) in 0.1% BSA in PBS buffer for 24 hours at 4
0
C. The next day samples were washed with 
PBS twice and secondary antibodies were added and incubated for 2 hours in the dark at RT. 
For secondary antibody control, samples were treated with secondary antibody (IgG) only. 
Samples were washed with PBS twice and were immersed in Phalloidin solution at 250 ug/ml 
PBS for 30 minutes in the dark at RT for actin filament stain. Then samples were washed 
with PBS once and immersed in DAPI solution (at 1:500) in PBS, for nuclear counter 
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staining, for 10 minutes in the dark at RT. Samples were then washed three times with PBS 
and examined under a fluorescent microscope. 
 
2.7.1 Characterisation of hMSCs 
5 x 10
3
 hMSC (P-1) were seeded on each well of a 96-well plate and grown to 80-90% 
confluency for immunophenotyping. Cells were fixed with 4% PFA, permeabilised with 
0.5% Triton-X 100 and blocked with 3% BSA as described above (Section 2.7). Fixed hMSC 
cells were characterised using the human MSC characterisation kit containing anti-human 
mouse anti-CD44, anti-CD90, anti-CD146, anti-CD14, anti-CD19 and anti-STRO-1 primary 
antibodies at 1:500 dilution (Millipore). Cells were incubated with primary antibodies at 4
0
C 
overnight. Secondary antibodies were anti-mouse IgG-NL557 for all except STRO-1 and 
anti-mouse IgM-NL493 for STRO-1 (both at 1:200 dilutions) (NorthernLights, R & D 
System). DAPI was used for nuclear staining. Images were acquired by a fluorescent 
microscope Nikon Eclipse Ti. 
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Table 2.8: List of primary antibodies used for immunocytochemistry. 
Antibody Description Dilution Company 
CD44 
Anti-H-CAM antibody 
Mouse monoclonal (IgG2a) 
1:500 
Millipore, USA 
Cat No- CBL154-20UL, 
Component of Cat No- 
SCR067 
CD90 
Anti-THY-1 antibody 
Mouse monoclonal (IgG1) 
1:500 
Millipore, USA 
Cat No- CBL415-20UL, 
Component of Cat No- 
SCR067 
CD146 
Anti-MCAM antibody 
Mouse monoclonal (IgG1) 
1:500 
Millipore, USA 
Cat No- MAB16985-
20UL, Component of Cat 
No- SCR067 
CD14 
Anti-CD14 antibody 
Mouse monoclonal (IgG1) 
1:500 
Millipore, USA 
Cat No- MAB1219-
20UL, Component of Cat 
No- SCR067 
CD19 
Anti-CD19 antibody 
Mouse monoclonal (IgG1) 
1:500 
Millipore, USA 
Cat No- MAB1794-
20UL, Component of Cat 
No- SCR067 
STRO-1 
Anti-STRO-1 antibody 
Mouse monoclonal (IgM) 
1:500 
Millipore, USA 
Cat No- MAB4315-
20UL, Component of Cat 
No- SCR067 
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2.8 Fluorescence activated cell sorting (FACS) 
In order to quantitatively determine the transfection efficiency following transfection 
experiments with the magnefect-nano system, LF2000 and Amaxa 48 hr after transfection 
cells were washed with PBS, trypsinized off their culture plates and resuspended in their 
corresponding supplemented media. Cell suspension was transferred into FACS tubes that 
were spun down at 1200 rpm (conversion of rpm to gav is shown in Section 2.3.4) for 5 min. 
The supernatant was discarded and cell pellets were resuspended in FACS buffer (0.1% 
BSA/PBS). FACS tubes were transferred in an ice bath until the processing. Samples 
containing at least 20,000 cells (per FACS sample) were counted using a FACSort flow 
cytometer (Beckton Dickinson, UK) and data was analysed using the CellQuest software 
package (BD Biosciences, UK).  
 
2.9 Microscopy cell count of transfected cells 
Following transfection at 48 hrs during data analysis, transfection efficiency of the gene 
delivery methods used was estimated by microscopy counts, for cells expressing GFP where 
no FACS count was performed. Based on the fluorescence microscopy images obtained, both 
the number of GFP-expressing cells and the total number of cells were counted, and 
expressed as a percentage of transfection efficiency by the following calculation.  
 
Transfection Efficiency (%) = (no. of GFP-expressing cells / total no. of cells) x 100 
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2.10 Reverse transcription-PCR (RT-PCR) 
Semi-quantitative RT-PCR analysis was performed to determine the mRNA expression of 
Oct-4, hTERT, Nanog, AFP, ACTC1, SOX1 and ACTB as the house keeping gene in hESC. 
The primers were designed using human gene sequences from NCBI Map Viewer and Primer 
3. Designed primers were evaluated in NCBI Primer-BLAST to check specificity and 
customised primer sets were purchased from Invitrogen, USA. Primers are tabulated below 
(Table 2.9). RT-PCR was performed with a one-step protocol. 
 
Table 2.9 Primer sequences. Forward and reverse primers are listed in 5' to 3' orientation. 
All primers were obtained from Invitrogen, USA. 
Gene Primers (5’-3’) 
Annealing 
temp (
0
C) 
Amplicon 
size (bp) 
POU5F1 
(Oct-4) 
F GCAATTTGCCAAGCTCCTGAAGCAG 
55 536 
R CATAGCCTGGGGTACCAAAATGGGG 
TERT 
(hTERT) 
F GCAGCTCCCATTTCATCAGC 
53 343 
R CAGGATGGTCTTGAAGTCTG 
NANOG 
(Nanog) 
F GGTGGCAGAAAAACAACTGGC 
55 300 
R TGCAGGACTGCAGAGATTCC 
AFP 
F CAGAAAAATGGCAGCCACAGC 
54 400 
R TGGCAGCATTTCTCCAACAGG 
ACTC1 
F CATCCTGACCCTGAAGTATCCCATC 
56 315 
R CCCTCATAGATGGGGACATTGTGAG 
SOX1 F CCAGGAGAACCCCAAGAGGC 56 206 
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R CGGCCAGCGAGTACTTGTCC 
ACTB 
(β-actin) 
F GCCACGGCTGCTTCCAGC 
55 505 
R AGGGTGTAACGCAACTAAGTC 
 
 
RNA extraction:  
Total RNA was extracted using the QIA RNeasy Mini Spin Column (Qiagen, Germany) 
according to the manufacturer protocol. For RNA extraction preparation adherent hESC were 
harvested by trypsinisation, cells washed with PBS once and pellets were formed by 
centrifugation. Cell pellets were lysed with RLT lysis buffer (350 µl RLT buffer + 3.5 µl β-
mercaptoethanol per sample). Cell lysates were transferred into the upper column of the QIA 
Shredder, centrifuged for 3 minutes at 13,000 rpm (conversion of rpm to gav is shown in 
Section 2.3.4) then collected in the collection tube and stored at -80
0
C. For RNA extraction, 
previously stored cell lysates were thawed on ice and 350 µl of 70% ethanol added. The cell 
lysate-ethanol solution (700 µl total) was transferred into the upper column of QIA RNeasy 
Mini Spin Column and centrifuged for 25 seconds at 6000 rpm (conversion of rpm to gav is 
shown in Section 2.3.4). Flowthrough was discarded and 700 µl of RW1 buffer was added 
and centrifuged for 25 seconds at same speed. Then flowthrough was discarded again and 
500 µl of RPE buffer was added into the upper column and centrifuged for 25 seconds. This 
step was repeated with 2 minutes of centrifugation at maximum speed. Collection was 
discarded and the upper column was transferred into a fresh collection tube and further 
centrifuged for 1 minute at maximum speed. Into this 20 µl of RNAse/DNAse-free dH2O was 
added and allowed to stand vertically for 1 minute. Column was centrifuged for 1 minute at 
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maximum speed and this step was repeated once for maximum yield of RNA. The extracted 
RNA was collected into the eppendorf. The quality and quantity of RNA yield were 
determined by measurement of absorption at 260 and 280 nm using NanoDrop ND-1000 
spectrophotometer (NanoDrop, USA). The ratio of optical density at 260 and 280nm was 
>1.8 in all cases.  
 
One-step RT-PCR:  
One-step RT-PCR was performed using SuperScript
®
 III One-Step RT-PCR System with 
Platinum
®
 Taq High Fidelity kit (Invitrogen, USA) and amplified in DNA Engine
®
 Thermal 
Cycler (MJ Research, USA) in a single tube according to the manufacturer protocol. In short, 
10 ng RNA of each sample was mixed with 6.25 μL 2X Reaction Mix, 3 μL RNAse-free 
water, 1 μL of each primer (10 μM) and 0.25 μL of Platinum® Taq polymerase enzyme.  
 
 
The thermal cycling protocol steps comprised an initial reverse transcription at 50
0
C for 30 
minutes, pre-denaturation at 94
0
C for 2 minutes followed by 30 cycles of denaturation at 
94
0
C for 15 seconds, primer specific annealing temperatures (depending on primers as shown 
in table 2.9) for 30 seconds and extension at 68
0
C for 1 minute followed by a final extension 
at 64
0
C for 5 minutes. RT-PCR products were separated by 2% agarose gel electrophoresis 
(Fisher Scientific, USA) and visualized by ethidium bromide staining (Sigma, USA) under 
UV light. Primers for β-actin were used as a loading control. Imaging of the RT-PCR 
products was performed with Gene Snap software. 
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Agarose gel protocol:  
The RT-PCR products were separated by electrophoresis on 2% agarose gel. For the gel 
preparation 2 g of agarose powder (Fisher Scientific, USA) was dissolved in 100 ml of 1X 
TAE (Tris Acetate-EDTA) buffer in the microwave oven until completely dissolved. Then 5 
µl of ethidium bromide (10 mg/ml) was added and mixed properly and the hot agarose 
solution was then immediately poured onto an agarose gel case and a comb was placed to 
make pockets. After 45 minutes at RT, the gel was formed and loaded with samples. The 
agarose gel was placed on the electrophoresis machine (Bio-Rad DNA Sub Cell) and covered 
in 1X TAE buffer. Each sample (RT-PCR product) was mixed with 2 µl of loading buffer. 6 
µl of PCR product was then loaded per well. 6 µl of DirectLoadTM wide range DNA marker 
(Sigma) was loaded into two wells to determine product size after electrophoresis. 
Electrophoresis was performed for 45 minutes with 100 volts constant current. 
 
2.11 Cell Viability 
Following 48 hr incubation post-transfection, samples were assayed with the Cytotox-ONE 
Homogeneous membrane integrity assay (Promega, UK) for their cell viability as per the 
manufacturer’s protocols. This method was used to assess membrane integrity of the cells as 
a proxy for viability following transfection by measuring LDH release from cells into the 
culture medium. In brief, for 96-well plate formats, assay plates were equilibrated at RT. 
Lysis solution (2 μl) was added to the cells that would serve as positive control (100% cell 
death). CytoTox-ONE reagent (100 μl) was added in each well, cell culture plate was gently 
shaken for 30 seconds and incubated at RT for 10 minutes. Stop solution (50 μl) was added to 
Chapter 2 – Materials & Methods 
 
 
 - 119 - 
 
all wells and plate was shaken for 10 seconds. Fluorescence with an excitation wavelength of 
560 nm and an emission wavelength of 590 nm was recorded by a Biotech Synergy plate 
reader (Biotech, USA).  
 
2.12 Statistical analysis  
Data from transfection efficiency and cell viability were analysed for statistical significance 
using the GraphPad Prism
® 
(version 5.00 for windows) (GraphPad Software, USA) statistical 
analysis package. Statistical significance of compared data sets were analysed by a one-way 
ANOVA using a Tukey-Kramer multiple comparison test and a ‘p’ value less than 0.05 
(<0.05) was considered indicative of statistical significance. In vitro data are presented as 
mean ± standard error of mean (SEM), and at least three separate repeats were performed for 
each experimental design which is referred as ‘n’ number.  
 
2.13 Study approval 
Human tissue research was approved by the Guy Hilton Research Centre, Institute for 
Science and Technology in Medicine, Keele University, Genetic Modification of 
Microorganisms safety committee. All research involving hESC was performed within a UK 
Human Tissue Authority licensed premises. 
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3.1 Evaluation of the magnetic field requirements for nanomagnetic gene 
transfection  
3.1.1 Objectives of this study  
As described in the introduction chapter (section 1.7.1), an applied magnetic field must 
have a gradient in order to generate a force on the MNP, as in the presence of a 
homogeneous field the particle will experience no force. In this study, the effects of the 
distance (and by proxy, magnetic field strength) between the magnet and the cell culture 
surface on transfection efficiency results were investigated for static and oscillating field 
transfection in order to: (i) evaluate the magnetic field gradient that could create a 
threshold above which the magnetic field force rapidly increases MNPs sedimentation 
accelerating endocytosis of MNPs by the cells, and (ii) investigate whether cellular 
morphology and viability are affected following transfection and exposure to different 
magnetic field  levels during transfection.  
3.1.2 Study design 
Previous work by our group showed that protein production increased significantly, 
showing an up to 10-fold increase, as a result of transfection efficiency in relation to the 
oscillating magnetic field strength (Fouriki et al., 2010). 
In this work we investigated the capacity of nTMag MNPs to bind pEGFP-N1 plasmid 
DNA that contained the gene encoding for enhanced green fluorescent protein (EGFP), and 
transfected NCI-H292 cells with nTMag:DNA complexes  on a 96-well plate format for 2 
hours using static and oscillating magnetic fields. Transfection with the oscillating field 
(magnefect-nano system) was performed at 2 Hz frequency and 0.2 mm amplitude. In 
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addition, and in order to determine to optimal distance between the magnet and cell culture 
surface the 96-well format magnet array was rearranged so that the distance between the 
magnet array and the cell culture would increase by 1 mm in each column of the magnet 
array. Furthermore, this experiment would enable us to visualize the transfection efficiency 
results by fluorescent microscopy and to determine whether the application of 
nTMag:DNA complexes and static and oscillating magnetic fields had any adverse effects 
on the morphology and viability of our samples following treatment using Cytotox-ONE 
cell viability assay. 
3.1.3 Results 
3.1.3.1 Determination of the magnetic field strength 
In order to determine the optimal working distance between the magnet (and by proxy, the 
magnetic field strength) and cell culture for the improvement of transfection efficiency in 
NCI-H292 cells the magnet arrays were rearranged as described in chapter 2, sections 
2.3.2.1 (Figure 2.3) and 2.3.2.2 (Figure 2.4) in the following format: In column 1 magnet 
discs were positioned directly beneath the cell surface of the 96-well plate (at 3mm). 
Following, in columns 2, 3, 4 and 5 the magnet discs were rearranged so the distance 
between the magnet and the cell surface (bottom of the culture plate) was at 4mm, 5mm, 
6mm and 7mm correspondingly and therefore increasing the distance between the magnet 
and cell surface by 1 mm at a time. The rearranged magnet array used for both static and 
oscillating transfections was mapped for its magnetic field strength as shown in Figure 3.1. 
The cylindrical stacks were assembled to align with 96-wel plates produced magnetic 
fields of up to ~101 millitesla (mT) at the cell surface. 
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Figure 3.1: Redcliffe MagScan image of a nanoTherics Ltd. Magnet array obtained at 3 
mm distance between the scanning probe and the magnet surface. This magnet array has 
been rearranged for the purposes of the experiment as described earlier, to gradually 
increase the distance between the magnet array and the cell culture between 3mm to 7mm. 
At the centre of the wells in column 1 (at 3 mm distance) the highest magnetic field was 
obtained reaching 101 mT (Image redrawn after Fouriki et al., 2010).       
 
 
 
 
 
 
Chapter 3 – Results 
 
 - 125 - 
 
3.1.3.2 MNP:DNA binding and transfection of NCI-H292 cells 
As described in chapter 2, section 2.3.4, SPIONs nTMag and pEGFP-N1 were used for the 
binding curve investigation before transfection. 
 
Figure 3.2: Typical DNA binding curve showing the nTMag MNPs: pEGFP-N1 
plasmid ratio of binding. Particle saturation levels were reached nearly at 0.1 μl nTMag 
MNPs and 0.1 μg DNA. 
  
A binding assay demonstrated that nTMag MNPs and pEGFP-N1 DNA were efficiently 
bound and formed complexes as shown in Figure 3.2. The optimal nTMag MNP:DNA 
ratios used to form the transfection complexes for NCI-H292 transfection were those that 
nearly reached particle saturation levels (0.1 μl nTMag MNPs and 0.1 μg DNA). 
Once transfection complexes were formed and added to the cell culture, static and 
oscillating magnets (F = 2 Hz and amplitude = 0.2 mm) were applied beneath using the 
rearranged magnet array from Figure 3.1 for 2 hours. Following 48 hours of incubation 
Chapter 3 – Results 
 
 - 126 - 
 
fluorescent microscopy images demonstrated an increase in GFP-expression levels 
between the samples transfected with nTMag MNPs exposed to the oscillating field for 2 
hours, in comparison to those transfected with nTMag MNPs in the presence of no field or 
static field. In addition, the fluorescent images show a small but gradual decrease in GFP-
expressing cells as the magnetic field strength decreases, and hence when the distance 
between the magnet array and the cell culture increases (Figure 3.3).    
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Figure 3.3 Fluorescent microscopy images of NCI-H292 cells expressing GFP 
following transfection at different magnet array distances from the cell culture 
surface. (A) Untreated, (B) transfected with 100 nm nTMag MNPs coated with pEGFPN1 
plasmid DNA; in the absence of a magnetic field, for 2hr (C), in the presence of a static 
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field (nanoTherics static array) for 2 hr (D) and an oscillating field (nanoTherics 
magnefect-nano array at F = 2 Hz and amplitude = 0.2 mm), for 2 hr. Cell seeding density 
was 2x10
4
/ 96-well, incubation period 48 hr (at 37 ˚C, 5 % CO2) post transfection and scale 
bar = 100μm in (A-D). 
 
3.1.3.3 Cell viability studies following transfection of NCI-H292 cells 
At 48 hr post transfection, the cell viability and the corresponding toxicity of the nTMag 
MNPs:DNA complexes for no field, static and oscillating field conditions were tested 
using a Cytotox-ONE Homogeneous membrane integrity assay that measures LDH release 
from cells with non-intact cell membranes. From the cell viability/toxicity bar chart it can 
be seen that cell viability of transfected NCI-H292 cells using nTMag MNPs at no field, 
static and oscillating magnetic field conditions at 2 hours were similar, and marginally 
lower relative to untreated controls (statistically insignificant) showing that treatment with 
nTMag MNPs:DNA complexes and magnetic fields had no significant effect on cell 
viability (Figure 3.4). In regards to samples transfected at various distances from applied 
the magnetic cell viability remained unaffected indicating that the magnetic field strength 
had no adverse effect cell viability, however it might improve transfection efficiency. 
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Figure 3.4 Cell viability of transfected NCI-H292 cells. Bar chart showing combined 
average percentage for viable and non viable cells following treatment with nTMag 
MNPs:DNA complexes and ‘no field’, ‘static field’ (F=0Hz) and ‘magnefect-nano’ 
(F=2Hz) transfections at 2hr, at 48hrs post transfection. n=9 for all test samples.   
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3.2 Efficient Transfection of MG-63 Osteoblasts Using Magnetic 
Nanoparticles and Oscillating Magnetic Fields 
 
3.2.1 Objectives of the study 
In this study the potential of MNPs in transfecting human osteosarcoma fibroblasts (MG-
63) was examined as well as the effects of the novel non-viral oscillating nanomagnetic 
gene transfection system (magnefect-nano™) in enhancing transfection efficiency at 
shorter transfection times (30 min transfection duration). The nanomagnetic gene 
transfection method was performed using two different type of superparamagnetic iron 
oxide MNPs and it was also compared with lipid mediated gene delivery and 
electroporation techniques. 
 
3.2.2 Study design 
MG-63 cells were transfected using MNPs coupled with a GFP-carrying plasmid. The 
magnefect-nano system was evaluated for transfection efficiency at shorter transfection 
times and fluorescent microscopy was used to visualize GFP-expressing cells following 
transfection. The method was compared with lipid mediated gene delivery (cationic lipids) 
(6 hour duration) and electroporation according to the manufacturers protocol. 
Furthermore, cell viability studies were used to determine whether the application of the 
nTMag/  and PolyMag MNPs:DNA complexes and static and oscillating magnetic fields 
had any potential associated effects on cell viability following treatment using Cytotox-
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ONE cell viability assay and compared with the equivalent results from lipid mediated 
gene delivery and electroporation. 
 
3.2.3 Results 
3.2.3.1 Determination of the magnetic field strength 
In order to determine the magnetic field strength, the magnet arrays were rearranged as 
described in chapter 2, sections 2.3.2.1 (Figure 2.3) in the following format: In all columns 
magnet discs were positioned directly beneath the cell surface of the 96-well plate (at 
3mm). The magnet array used for both static and oscillating transfections was mapped for 
its magnetic field strength as shown in Figure 3.5. The cylindrical stacks were assembled 
to align with 96-wel plates produced magnetic fields of up to ~101 millitesla (mT) at the 
cell surface. 
 
Figure 3.5: Redcliffe MagScan image of scale colours of magnetic field mapping for 
the nanoTherics Ltd. 96-well format magnet array. Magnet array obtained at 3 mm 
distance between the scanning probe and the magnet surface. At the centre of each well (at 
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3 mm distance) the highest magnetic field was obtained reaching 101 mT (Fouriki et al., 
2010).       
 
3.2.3.2 MNP:DNA Binding and Transfection of MG-63 cells 
As described in chapter 2, section 2.3.4, two types of SPIONs, nTMag and PolyMag, were 
associated with pEGFP-N1 for the binding curve investigation before transfection. 
nTMG/plasmid binding curve was described in Figure 3.2. Furthermore, PolyMag/plasmid 
binding curve is decribed here (Figure 3.6). 
 
 
Figure 3.6: Typical DNA binding curve showing the PolyMag MNPs: pEGFP-N1 
plasmid ratio of binding. Particle saturation levels were reached nearly at 0.1 μl nTMag 
MNPs and 0.1 μg DNA. 
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Binding assays demonstrated that nTMag and PolyMag MNPs could efficiently bind 
pEGFP-N1 DNA as shown in Figure 3.2 and Figure 3.6 (as described in section 2.3.2). The 
optimal nTMag/ and PolyMag MNP:DNA ratios used to form the transfection complexes 
for MG-63 cells transfection were those that nearly reached particle saturation levels for 
both particles that demonstrated very similar binding curves (0.1 μl MNPs and 0.1 μg 
DNA). 
 
Once transfection complexes were formed and added to the cell culture, static and 
oscillating magnet arrays (F = 2 Hz and amplitude = 0.2 mm) were placed beneath the cell 
culture for 30 min. In parallel, transfection with lipid mediated gene delivery 
(Lipofectamine 2000, LF2000) and electroporation were performed as described in 
methods section. Following 48 hours of incubation fluorescence microscope images clearly 
show the highest GFP-expression levels in the samples exposed to magnetic fields, both 
static and oscillating (Figure 3.7). Electroporation and lipid-based transfection were not as 
effective. Some transfection was seen when using the nTMag particles even in the absence 
of an applied field. For both static and oscillating magnet conditions, nTMag particles 
appeared to provide more efficient transfection. 
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Figure 3.7: Transfection of MG-63 cells. (A) Light image of untreated human MG-63 
cells. (B-J) EGFP expression in MG-63 cells; transfected with 100 nm nTMag and 
PolyMag MNPs coated with pEGFPN1 plasmid DNA in the absence of a magnetic field, 
for 30 min (B-C), in the presence of a static field (nanoTherics static array) for 30 min (D-
E) and an oscillating field (nanoTherics magnefect-nano array at F = 2 Hz and amplitude = 
200 µm), for 30 min (H-I). Transfected with Lipofectamine 2000TM, for 30 min (F), for 6 
hr (G) and electroporated with Amaxa nucleofector system (5x10
5 
/ sample) (J). Incubation 
period (48 hr, 37 ˚C, 5 % CO2) post transfection and electroporation were identical for all 
samples. Cell seeding density was 1x10
4
/well (A-I). Scale bar = 200μm in (A-J). Data 
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represent at least three independent experiments (N=3). (Image taken from Fouriki et al., 
2012). 
 
3.2.3.3 Quantitative Analysis of transfection efficiency (FACS) 
Quantitative analysis of transfection efficiency obtained using Fluorescence-Activated Cell 
Sorting (FACS) provided confirmation of the qualitative results seen via fluorescence 
microscopy (Figure 3.7). In the bar chart, the effect of the oscillating magnet arrays (F=2 
Hz) using both nTMag and PolyMag MNPs at 30 min was compared to “no field” and 
“static field” (F=0) conditions (at 30 min), as well as lipid-mediated gene transfection and 
electroporation methods.  
 
Again, some GFP expression (12%) representing the transfection efficiency was observed 
in the presence of nTMag MNPs:DNA complexes even in the absence of a magnetic field. 
However, a dramatic increase in GFP-expressing MG-63 cells (49%) was demonstrated 
when nTMag MNPs:DNA complexes were introduced to a static magnetic field, and an 
even greater transfection efficiency (53%) was shown when introduced to the oscillating 
magnetic field (magnefect-nano system, nanoTherics). The increase in transfection 
efficiency observed between the no field and both the static and oscillating field conditions 
was found to be statistically significant (***p<0.001). In addition, transfection efficiency 
using both static and oscillating magnetic fields (at 30 min) was shown to significantly 
outperform Lipofectamine
 
2000 at both 30 min (7%) and 6 hr (24%) as well as Amaxa 
Nucleofector (21%) (***p<0.001). 
 
Chapter 3 – Results 
 
 - 136 - 
 
However, when PolyMag MNPs:DNA complexes were used to transfect MG-63 cells at 
both static (24%) and oscillating (20%) field conditions, overall transfection efficiency was 
significantly lower than the nTMag for the same conditions (***p<0.001) (Figure 3.5). 
 
Figure 3.8: Bar chart of quantitative analysis of MG-63 transfection. Average of 
FACS data from transfection efficiency of GFP-expressing MG-63 cells transfected with 
nTMag and PolyMag MNPs coated with pEGFPN1 DNA in the absence of a magnetic 
field (n=9), in the presence of the nanoTherics static magnetic array (n=7) and the 
nanoTherics magnefect-nano™ oscillating magnetic array (200 µm amplitude, 2 Hz) (n=9) 
for 30 min, in comparison with lipid-based transfection (LF2000, for 30 min and 6 hr) 
(n=9) and electroporation (Amaxa) methods (n=8). Data represent the mean ±SD of at least 
three independent experiments (N=3). During transfection cells were incubated at 37˚C and 
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5% CO2. At 30min post transfection the magnets were removed and cells were incubated 
for 48 hr before analysis. (Image taken from Fouriki et al., 2012) 
 
Following Figure 3.8, summarizing the average of FACS data from transfected MG-63 
cells, next figure (Figure 3.9) shows the GFP expression data, from which Figure 3.8 was 
compiled. 
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Figure 3.9: GFP expression following transfection of MG-63 cells using flow 
cytometry. MG-63 cells transfected with nTMag and PolyMag MNPs coated with 
pEGFPN1 DNA in the absence of a magnetic field, in the presence of the nanoTherics 
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static magnetic array and the nanoTherics magnefect-nano™ oscillating magnetic array 
(200 µm amplitude, 2 Hz) for 30 min, in comparison with lipid-based transfection 
(LF2000, for 30 min and 6 hr) and electroporation (Amaxa) methods. Data represent the 
mean ±SD of at least three independent experiments (N=3). 
 
3.2.3.4 Magnetic nanoparticle toxicity and cell viability  
At 48 hr post transfection, the cell viability and the corresponding toxicity of the particles 
for no field, static and oscillating field conditions were tested using a Cytotox-ONE 
Homogeneous membrane integrity assay (Promega) that measures LDH release from cells 
with non-intact cell membranes. These results were compared with the equivalent data for 
Lipofectamine
 
and electroporation (Amaxa) using the same cell viability assay. The 
Amaxa cell viability data were obtained by manual cell counting in order to determine the 
number of cells remaining viable immediately after electroporation and 48 hr post-
transfection. The percentage of transfected cells was determined by FACS analysis of the 
transfected cell count from the cell population that originally survived electroporation. The 
actual transfection efficiency of the starting population is therefore lower. Viability of cells 
transfected using static and oscillating magnetic field conditions with nTMag, PolyMag 
and Lipofectamine
 
at 30 min were comparable, and marginally lower relative to controls 
(Figure 3.6).  
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Figure 3.10: Cell viability of MG-63 cells following transfection. Bar chart showing 
combined average percentage for viable and non-viable cells following treatment with 
nTMag and PolyMag MNPs and ‘no field’, ‘static field’ (F=0) and ‘magnefect-nano’ 
(F=2Hz) transfections at 30 min, compared with Lipofectamine at 30 min and 6hr and 
Amaxa, at 48hrs post transfection and electroporation. n = 12 for all groups, except Amaxa 
(n = 8). Data represent the mean ±SD of at least three independent experiments (N=3). 
(Image taken from Fouriki et al., 2012) 
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3.3 Nanomagnetic Gene Transfection for Non-Viral Gene Delivery in 
Mouse Embryonic Fibroblasts (NIH-3T3)  
3.3.1 Objectives of the study 
The objective of this work was to examine the potential of nTMag MNPs in transfecting 
NIH3T3 mouse embryonic fibroblasts and to investigate the effects of a novel non-viral 
oscillating nanomagnetic gene transfection system (magnefect-nano™) in enhancing 
transfection efficiency at shorter transfection times. The results obtained were compared 
with the equivalent from lipid mediated gene delivery and cell viability assays were 
performed to investigate whether the nTMag MNPs:DNA complexes had any toxic effects 
in the cell cultures.    
 
3.3.2 Study design 
NHI-3T3 cells were transfected using nTMag MNPs coupled with a GFP-carrying plasmid. 
The magnefect-nano™ system was evaluated for transfection efficiency at shorter 
transfection times (30 min transfection duration) and fluorescent microscopy was used to 
visualize GFP-expressing cells following transfection. The method was compared with 
lipid mediated gene delivery (cationic lipids) (6 hour transfection duration). Furthermore, 
cell viability studies were used to determine whether the application of the nTMag 
MNPs:DNA complexes and the use of static and oscillating magnetic fields had any 
associated toxic effects on cell viability following treatment using Cytotox-ONE cell 
viability assay and compared with the equivalent results from lipid mediated gene delivery.   
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3.3.3 Results 
3.3.3.1 DNA Binding and Transfection 
Binding assays demonstrated that nTMag MNPs could efficiently bind pEGFP-N1 DNA as 
shown in Figure 3.2 (as described in section 2.3.2). The optimal nTMag MNPs:DNA ratios 
used to form the transfection complexes for NIH-3T3 cells transfection were those that 
nearly reached particle saturation levels for both particles that demonstrated very similar 
binding curves (0.2 μl MNPs and 0.2 μg DNA). In addition, nTMag MNPs:DNA dose 
response experiments were performed as described in 2.3.3 section to obtain the optimal 
nTMag MNP:DNA ratios used to form the transfection complexes that confirmed findings 
from the nTMag MNPs:DNA binding curves. It was shown that the ratio of 0.2μl nTMag 
MNPs and 0.2μg pEGFP-N1 DNA was the most effective for 1x104 NIH-3T3 per 96-well. 
 
Once transfection complexes were formed and added to the cell culture, the magnet array 
used for static and oscillating transfections (F = 2 Hz and amplitude = 0.2 mm) shown in 
Figure 3.5, was placed beneath the cell culture for 30 min. In parallel, transfection with 
lipid mediated gene delivery (Lipofectamine 2000, LF2000) was performed as described in 
methods section. Following 48 hours of incubation fluorescence microscope images show 
a clear increase and similar GFP-expression levels between the samples transfected with 
nTMag MNPs exposed to magnetic fields, both static and oscillating (magnefect-nano™) 
for 30min, in comparison to those transfected in the absence of a magnetic field and with 
Lipofectamine 2000 for 30min and 6 hr (Figure 3.11).  
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Figure 3.11: Fluorescent microscopy images of transfected NIH3T3 cells expressing 
GFP. NIH-3T3 cell were labelled with Phalloidin for actin stain of the whole cell 
population. (A-B) Untreated (C-L) transfected with 100 nm nTMag MNPs coated with 
pEGFPN1 plasmid DNA; in the absence of a magnetic field, for 30 min (C-D), in the 
presence of a static field (nanoTherics static array) for 30 min (E-F) and an oscillating 
field (nanoTherics magnefect-nano™ array at F = 2 Hz and amplitude = 200 µm), for 30 
min (G-H), Lipofectamine 2000
TM
 for 30 min (I-J) and Lipofectamine 2000
TM
 for 6 hr (K-
L). Cell seeding density was 1x10
4
/ 96-well, incubation period (48 hr, 37 ˚C, 5 % CO2) 
post transfection and scale bar = 100μm in (A-L). Data represent at least three independent 
experiments (N=3). GFP: green fluorescent protein; nTMag MNPs: nanoTherics nTMag 
magnetic nanoparticles; F: oscillation frequency. (Image taken from Fouriki et al., 2013) 
 
3.3.3.2 Quantitative Analysis of transfection efficiency (FACS)  
Quantitative analysis of transfection efficiency obtained using Fluorescence-Activated Cell 
Sorting (FACS) provided analogous results to those obtained via fluorescence microscopy. 
In the bar chart, the effect of the oscillating magnet array (F=2 Hz) using nTMag MNPs at 
30 min was compared to “no field” and “static field” (F=0) conditions (at 30 min), as well 
as lipid-mediated gene transfection method at 30 min and 6 hr (Figure 3.12). 
 
Some GFP expression representing transfection efficiency (2%) was observed in the 
presence of nTMag MNPs:DNA complexes even in the absence of a magnetic field. 
However, a clear increase in GFP-expressing NIH3T3 cells (25%) was demonstrated when 
nTMag MNPs:DNA complexes were introduced to the oscillating magnetic field 
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(magnefect-nano system, nanoTherics) and to a static magnetic field (22%). The increase 
in transfection efficiency observed between the no field and both the static and oscillating 
field conditions was found to be statistically significant (***p<0.001). Furthermore, the 
use of both the static and oscillating field conditions significantly increased transfection 
efficiency in comparison to Lipofectamine 2000 at 30 min (***p<0.001), but found to have 
analogous results to Lipofectamine 2000 at 6 hr (22%) highlighting further the efficiency 
of the magnetic field systems at shorter transfection times. 
 
 
Figure 3.12: Transfection efficiency of NIH-3T3 cells. Average of FACS data from 
transfection efficiency of GFP-expressing NIH3T3 cells transfected with nTMag MNPs 
coated with pEGFPN1 DNA in the absence of a magnetic field, in the presence of the 
nanoTherics static magnetic array and the nanoTherics magnefect-nano™ oscillating 
magnetic array (200 µm amplitude, F= 2 Hz) for 30 min, in comparison to lipid-based 
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transfection (LF2000, for 30 min and 6 hr). During transfection cells were incubated at 
37˚C and 5% CO2. At 30min post transfection the magnets were removed and cells were 
incubated for 48 hr before analysis. n=6 for all samples. Data represent the mean ±SD of at 
least three independent experiments (N=3). GFP: Green fluorescent protein; F: oscillation 
frequency. (Image taken from Fouriki et al., 2013) 
 
 
Following Figure 3.12, summarizing the average of FACS data from transfected NIH-3T3 
cells, next figure (Figure 3.13) shows the GFP expression data, from which Figure 3.12 
was compiled. 
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Figure 3.13: GFP expression following transfection of NIH-3T3 cells using flow 
cytometry. NIH3T3 cells transfected with nTMag MNPs coated with pEGFPN1 DNA in 
the absence of a magnetic field, in the presence of the nanoTherics static magnetic array 
and the nanoTherics magnefect-nano™ oscillating magnetic array (200 µm amplitude, F= 
2 Hz) for 30 min, in comparison to lipid-based transfection (LF2000, for 30 min and 6 hr). 
During transfection cells were incubated at 37˚C and 5% CO2. At 30min post transfection 
the magnets were removed and cells were incubated for 48 hr before analysis. n=6 for all 
samples. Data represent the mean ±SD of at least three independent experiments (N=3). 
GFP: Green fluorescent protein; F: oscillation frequency. 
 
3.3.3.3 Magnetic nanoparticle toxicity and cell viability  
At 48 hr post transfection, the cell viability and the corresponding toxicity of the MNPs for 
no field, static and oscillating field conditions were tested using a Cytotox-ONE 
Homogeneous membrane integrity assay that measures LDH release from cells with non-
intact cell membranes. These results were compared with the equivalent data for 
Lipofectamine 2000
 
at 30 min and 6 hr, using the same cell viability assay. From the cell 
viability/toxicity bar chart it was demonstrated that cell viability of transfected NIH3T3 
cells using nTMag MNPs at no field, static and oscillating magnetic field conditions at 30 
min were very similar to the untreated controls retaining high cell viability (Figure 3.14). 
 
Transfected NIH3T3 cells with Lipofectamine 2000 at 30 min were found analogous with 
all the MNP-treated and untreated samples, however, significantly lower cell viability / 
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higher toxicity was obtained when comparing these samples with transfected NIH3T3 cells 
with Lipofectamine 2000 for 6 hr (**p<0.01).  
 
 
Figure 3.14: Cell viability of transfected NIH-3T3 cells. Bar chart showing combined 
average percentage for viable and non-viable cells following treatment with nTMag MNPs 
and ‘no field’, ‘static field’ (F=0Hz) and ‘magnefect-nano’ (F=2Hz) transfections at 30 
min, compared with Lipofectamine 2000 at 30 min and 6hr, at 48hrs post transfection. n = 
9 for all groups. Data represent the mean ±SD of at least three independent experiments 
(N=3). (Image taken from Fouriki et al., 2013) 
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3.4 Oscillating Magnet Array-Based Nanomagnetic Gene Transfection of 
Human Mesenchymal Stem Cells 
3.4.1 Objectives of the study 
The primary objective of this work was to investigate the potential of nanomagnetic gene 
transfection to transfect for the first time primary human mesenchymal stem cells (hMSCs) 
and the effects of a novel non-viral oscillating magnet array system (magnefect-nano™) in 
enhancing transfection efficiency at shorter transfection times (30 min transfection 
duration). The nanomagnetic gene transfection method was compared with lipid mediated 
gene delivery and cell viability assays were performed to investigate for any potential 
adverse effects of the MNP:DNA complexes in the primary cell cultures. Finally, samples 
from both methods used were examined for their ability to retain the hMSC phenotypic 
characteristics and expression of hMSC surface antigens. 
 
3.4.2 Study design 
Primary hMSC cells, that are considered hard to transfect, were transfected using nTMag 
MNPs coupled with a GFP-carrying plasmid that were previously shown to be more 
effective than PolyMag MNPs. The magnefect-nano system was evaluated for transfection 
efficiency at shorter transfection times and fluorescent microscopy was used to visualize 
GFP-expressing cells following transfection. The method was compared with lipid 
mediated gene delivery (cationic lipids) (6 hour duration) according to the manufacturers 
protocol. Furthermore, cell viability studies were used to determine whether the application 
of the nTMag MNPs:DNA complexes had any adverse effects on cell viability following 
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treatment using Cytotox-ONE cell viability assay and compared with the equivalent results 
from lipid mediated gene delivery. Finally it was important to investigate if the phenotype 
of the hMSCs was altered in the level of expression of surface antigens.   
 
3.4.3 Results 
3.4.3.1 hMSCs isolation and characterization 
hMSCs were isolated from human bone marrow aspirates and cultured as described in 
chapter 2, section 2.2.1. Before experimentation hMSCs were characterized as described in 
chapter 2, section 2.7.1, in order to confirm positive expression of CD44, STRO-1, CD90, 
CD146 and negative expression to haematopoietic markers CD14 and CD19. Cell nuclei 
were stained with DAPI and phase and F-actin network images were stained with 
fluorescent Phalloidin to facilitate visualization of typical morphology of hMSCs (Figure 
3.15). 
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Figure 3.15: Fluorescent images of human MSC phenotypic antigenic markers. 
Human MSC demonstrate positive expression of CD44, STRO-1, CD90, CD146 and 
negative expression to haematopoietic markers CD14 and CD19. Nuclei are stained with 
DAPI. Phase and F-actin network images (stained with fluorescent Phalloidin) show 
typical morphology of hMSCs. Scale bar = 100µm. Passage 1.  
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3.4.3.2 DNA Binding and Transfection 
Binding assays demonstrated that nTMag MNPs could efficiently bind pEGFP-N1 DNA as 
shown in Figure 3.2 (as described in section 2.3.2). In addition nTMag MNPs:DNA dose 
response experiments were performed as described in 2.3.3 section to obtain the optimal 
nTMag MNP:DNA ratios used to form the transfection complexes. It was shown that the 
ratio of 0.2μl nTMag MNPs and 0.3μg pEGFP-N1 DNA was the most effective for 5x103 
hESCs per 96-well . 
 
Once transfection complexes were formed and mixed with the cell culture, static and 
oscillating magnet arrays (F = 2 Hz and amplitude = 0.2 mm) (shown Figure 3.5) were 
placed beneath the cell culture for 30 min. In parallel, transfection with lipid mediated gene 
delivery (Lipofectamine 2000, LF2000) was performed as described in methods section. 
Following 48 hours of incubation fluorescence microscope images clearly showed the 
highest GFP-expression levels in the samples exposed to the oscillating magnetic field 
(Figure 3.16). Transfection with Lipofectamine appeared quite limited.  
No accurate quantification method was performed, a limitation that will be dicussed in 
chapter 4, due to the limited available hMSCs cell polulations. However, fluorescent 
microscopy images provided a qualitative estimation and a representative overview of 
transfection efficiency (Figure 3.16).    
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Figure 3.16: Transfection of hMSCs. Fluorescent microscopy images of hMSCs 
expressing GFP and correspondingly labelled with Phalloidin for actin stain of the whole 
cell population. (A-B) Untreated, (C-H) transfected with 100 nm nTMag MNPs coated 
with pEGFPN1 plasmid DNA; in the absence of a magnetic field, for 30 min (C-D), in the 
presence of a static field (nanoTherics static array) for 30 min (E-F) and an oscillating field 
(nanoTherics magnefect-nano array at F = 2 Hz and amplitude = 200 µm), for 30 min (G-
H), and Lipofectamine 2000 for 6 hr (I-J). Cell seeding density was 5x10
3
/ 96-well, 
incubation period 48 hr (at 37 ˚C, 5 % CO2) post transfection and scale bar = 100μm in (A-
J). hMSCs: human mesenchymal stem cells; GFP: green fluorescent protein; nTMag 
MNPs: nanoTherics nTMag magnetic nanoparticles; F: oscillation frequency. Data 
represent at least three independent experiments (N=3). (Image taken from Fouriki et al., 
2014) 
 
3.4.3.3 Magnetic nanoparticle toxicity and cell viability  
At 48 hr post transfection, the cell viability and the corresponding toxicity of the MNPs for 
no field, static and oscillating field conditions were tested using a Cytotox-ONE 
Homogeneous membrane integrity assay that measures LDH release from cells with non-
intact cell membranes. These results were compared with the equivalent data for 
Lipofectamine 2000. From the cell viability/toxicity bar chart it can be seen that cell 
viability of transfected hMSCs using nTMag MNPs at no field, static and oscillating 
magnetic field conditions at 30 min were similar, and marginally lower relative to 
untreated controls (statistically insignificant) showing that treatment with MNPs and 
magnetic fields had no significant effect on cell viability (Figure 3.17). 
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However, significantly lower cell viability/higher toxicity was obtained when using 
Lipofectamine 2000 to transfect hMSCs (**p<0.01) (Figure 3.18). Finally, when 
comparing the three conditions (‘no field’, ‘static field’ and ‘oscillating field’) treated with 
nTMag MNPs no statistical significance in cell viability was obtained, highlighting further 
that the magnetic field improves transfection efficiency but does not affect cell viability. 
 
Figure 3.17: Cell viability of transfected hMSCs. Bar chart showing combined average 
percentage for viable and non viable cells following treatment with nTMag MNPs and ‘no 
field’ (n=9), ‘static field’ (F=0Hz) (n=6) and ‘magnefect-nano’ (F=2Hz) (n=9) 
transfections at 30 min, compared with Lipofectamine 2000 at 6hr (n=9), at 48hrs post 
transfection. Data represent the mean ±SD of at least three independent experiments (N=3). 
(Image taken from Fouriki et al., 2014) 
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3.4.3.4 Immunophenotyping of transfected hMSC  
Immunocytochemistry was performed in order to investigate if transfection with the 
magnefect-nano system and Lipofectamine 2000 has altered the hMSC multipotent 
phenotype (as described in section 2.7). Immunophenotyping showed the previously 
characterized hMSCs (Figure 3.15), retained positive expression for all four cell surface 
markers present on hMSCs that included antibodies directed against cell-surface 
molecules: CD44, STRO-1, CD90 and CD146. These results indicated that the hMSCs 
retained their cell-specific marker expression following treatment (Figure 3.9). 
 
Figure 3.18: Immunophenotyping of hMSCs on isolated MSCs. hMSC transfected with 
the magnefect-nano system and Lipofectamine 2000 were positive for surface antigens 
CD44, STRO-1, CD146, and CD90 and negative for haematopoietic markers CD14 and 
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CD19. DAPI was used for nuclear counter staining. Scale bar, 100 µm. (Image taken from 
Fouriki et al., 2014) 
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3.5 Nanomagnetic Gene Transfection for Non-Viral Gene Delivery in 
Human Embryonic Stem Cells 
 
3.5.1 Objectives of the study  
The aim of this work was to investigate the potential for efficient transfection of hESCs 
using the non-viral nanomagnetic transfection. Additionally and following 48 hrs from 
transfection, hESCs were evaluated for the method’s impact on cell viability and capacity 
to retain expression of key stem cell markers for pluripotency and lineage differentiation.  
 
3.5.2 Study design 
Primary hESC cells, that have not been transfected before, were transfected using nTMag 
MNPs coupled with the GFP-carrying plasmid pEGFP-N1. The magnefect-nano system 
was evaluated for transfection efficiency at shorter transfection times and fluorescent 
microscopy was used to visualize GFP-expressing cells following transfection. The method 
was compared with lipid mediated gene delivery (cationic lipids, LF2000) (6 hour 
duration) according to the manufacturers protocol. Furthermore, cell viability studies were 
used to determine whether the application of the nTMag MNP:DNA complexes had any 
adverse effects on cell viability following treatment using Cytotox-ONE cell viability 
assay and compared with the equivalent results from lipid mediated gene delivery. Finally, 
it was important to investigate for potential post transfection alterations in gene expression 
of pluripotency associated key stem cell markers by performing semi-quantitative RT-PCR 
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analysis for the genes Oct-4, Nanog and hTERT, as well as for lineage differentiation 
markers Sox-1, ACTC1 and AFP expression. 
For this purpose semi-quantitative RT-PCR was performed for the three pluripotency 
markers Oct-4, Nanog and hTERT as well as the lineage differentiation markers 
differentiation markers Sox-1, ACTC1 and AFP following all transfection methods.  
 
3.5.3 Results 
3.5.3.1 Determination of the magnetic field strength 
In order to determine the magnetic field strength, the magnet arrays were rearranged as 
described in chapter 2, sections 2.3.2.1 (Figure 2.3) in the following format: In all columns 
magnet discs were positioned directly beneath the cell surface of the 24-well plate (at 
3mm). The magnet array used for both static and oscillating transfections was mapped for 
its magnetic field strength as shown in Figure 3.19. The cylindrical stacks were assembled 
to align with 24-wel plates produced magnetic fields of ~300 mT at the cell surface. 
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Figure 3.19: Redcliffe MagScan image of scale colours of magnetic field mapping for 
the nanoTherics Ltd. 24-well format magnet array. Magnet array obtained at 3 mm 
distance between the scanning probe and the magnet surface. At the centre of each well (at 
3 mm distance) the highest magnetic field was obtained reaching 304 mT. 
 
3.5.3.2 DNA Binding and Transfection 
Binding assays demonstrated that nTMag MNPs could efficiently bind pEGFP-N1 DNA as 
shown in Figure 3.2 (as described in section 2.3.2). In addition nTMag MNPs:DNA dose 
response experiments were performed as described in 2.3.3 section to obtain the optimal 
nTMag MNP:DNA ratios used to form the transfection complexes. It was shown that the 
ratio of 1.8μl nTMag MNPs and 1.2μg pEGFP-N1 DNA was the most effective for 5x104 
hESCs per 24-well. For the 24-well plate format of the experiment the 24-well format 
magnet array was used (Figure 3.19).  
 
Once transfection complexes were formed and added to the cell culture, static and 
oscillating magnet arrays (F = 2 Hz and amplitude = 0.2 mm) (shown in Figure 3.19) were 
placed beneath the cell culture for 30 min. In parallel, transfection with lipid mediated gene 
delivery (Lipofectamine 2000, LF2000) was performed as described in methods section. 
Following 48 hours of incubation fluorescence microscope images were obtained clearly 
showed the highest GFP-expression levels in the samples exposed to the oscillating 
magnetic field (Figure 3.20).  
No accurate quantification method was performed, a limitation that will be dicussed in 
chapter 4, due to the limited available hMSCs cell polulations at the time of 
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experimentation. However, fluorescent microscopy images provided a qualitative 
estimation and a representative overview of transfection efficiency (Figure 3.20).    
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Figure 3.20: Transfection of hESCs. (A) Fluorescent image of untreated hESCs and (B) 
labelled with Phalloidin for actin stain of the whole cell population; (C,D) EGFP 
expression and Phalloidin labeling in hESCs transfected with 100 nm nTMag MNPs coated 
with pEGFPN1 plasmid DNA in the absence of a magnetic field for 30 min; (E,F) in the 
presence of a static field (nanoTherics static array) for 30 min; (G,H) in the presence of an 
oscillating field (nanoTherics magnefect-nano array at f = 2 Hz and amplitude = 200 µm), 
for 30 min; (I,J) and transfected with Lipofectamine 2000
TM
 for 6 hr.  
Cell seeding density was 5x10
4
/ 24-well, incubation period (48 hr, 37 ˚C, 5 % CO2) post 
transfection and scale bar = 100 μm. hESCs: human embryonic stem cells; GFP: green 
fluorescent protein; nTMag MNPs: nanoTherics nTMag magnetic nanoparticles; F: 
oscillation frequency. Data represent at least three independent experiments (N=3). 
 
3.5.3.3  Magnetic nanoparticle toxicity and cell viability  
At 48 hr post transfection, cell viability was tested using the Cytotox-ONE Homogeneous 
membrane integrity assay that measures LDH release from cells with non-intact cell 
membranes. Cell viability of transfected hESCs using nTMag MNPs at no field, static and 
oscillating magnetic field conditions at 30 min were comparable, to untreated controls 
(Figure 3.21). 
 
However, significantly higher toxicity was seen when comparing untreated cells with 
Lipofectamine 2000 transfected hESCs (***p<0.001). In addition, Lipofectamine 2000 had 
significantly lower cell viability / higher toxicity in comparison to nTMag no field 
(***p<0.001), as well as in comparison to both static (*p<0.05) and oscillating magnetic 
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field (***p<0.001) (Figure 3.21). Finally, when comparing the three conditions (no field, 
static field and oscillating field) treated with nTMag MNPs no statistical significance in 
cell viability was obtained, further highlighting that the magnetic field improves 
transfection efficiency but does not significantly affect cell viability. 
 
 
Figure 3.21 Bar chart showing combined average percentage for viable and non viable 
cells following treatment with nTMag MNPs and ‘no field’, ‘static field’ (F=0Hz) and 
‘magnefect-nano’ (F=2Hz) transfections at 30 min, compared with Lipofectamine 2000 at 
6hr, at 48hrs post transfection. n = 9 for all groups. Data represent the mean ±SD of at least 
three independent experiments (N=3). 
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3.5.3.4 Nanomagmetic transfection does not alter pluripotent gene expression in hESCs 
To investigate whether hESCs retain expression of pluripotency and differentiation specific 
stem cell markers following transfection with nTMag MNPs at no field, static field, 
oscillating field (magnefect-nano system) as well as Lipofectamine 2000, the expression 
levels of hESCs pluripotent markers Oct-4 (POU5F1), h-TERT and Nanog and 
differentiation markers Sox-1, ACTC1 and AFP as well as the housekeeping gene b-actin 
(ACTB) was investigated by semi-quantitative RT-PCR. All three pluripotency markers 
and the housekeeping gene (Figure 3.22) as well as the differentiation markers (Figure 
3.33) were detected at different intensities following all transfection methods.  
 
 
Figure 3.22 Semi-quantitative RT-PCR on transfected hESCs for pluripotency 
markers expression. A semi-quantitative RT-PCR analysis of hESCs POU5F1, h-TERT, 
Nanog pluripotency markers and the ACTB house keeping gene were assayed. Total RNA 
was extracted at 48hr post transfection and used for the analysis. (1) Untreated hESCs, (2-
5) Transfected hESCs; with nTMag MNPs coated with pEGFPN1 plasmid DNA in the 
absence of a magnetic field, for 30min (2), with Lipofectamine 2000 for 6hr (3), with 
nTMag MNPs coated with pEGFPN1 plasmid DNA: in the presence of a static magnetic 
Chapter 3 – Results 
 
 - 167 - 
 
field (f = 0 Hz) (4), and water control (6), and in the presence of an oscillating magnetic 
field (nanoTherics magnefect-nano array, f = 2 Hz, amplitude = 200 µm), for 30min (5). 
 
 
 
Figure 3.23 Semi-quantitative RT-PCR on transfected hESCs for differentiation 
markers. A semi-quantitative RT-PCR analysis of hESC differentiation markers. AFP as 
an endoderm marker, ACTC1 as a mesoderm marker and Sox-1 as an ectoderm marker 
were assayed at 48hr post transfection. (1) Untreated hESCs, (2-4) Transfected hESCs; 
with Lipofectamine 2000 for 6hr (2), with nTMag MNPs coated with pEGFPN1 plasmid 
DNA in the absence of a magnetic field, for 30min (3) and in the presence of an oscillating 
magnetic field (nanoTherics magnefect-nano array, F = 2 Hz, amplitude = 200 µm), for 
30min (4), and water control (5).  
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4. Discussion 
Gene therapy, the method used to introduce new genetic materials to hosts, is a promising 
tool for the study of gene function and its regulation in disease initiation and progression, for 
establishing various disease models, acquiring DNA-based immunization, and exploring 
potential therapeutic applications to various acquired or inherited diseases including 
neurodegenerative conditions, cardiovascular diseases, various tumours such as osteosarcoma 
and lung cancer, hemophilia, AIDS and asthma. As previously mentioned, the method was 
initially performed in 1990 in the USA for the treatment of adenosine deaminase (ADA)-
deficient SCID (severe combined immune deficiency disease) patients by ex vivo retroviral-
mediated introduction of the normal ADA gene into T lymphocytes (Blaese, 1993). This 
advancement actually led to the successful treatment of more than 30 patients since 2000 with 
no adverse effects related to the gene transfer technology having been observed (Ferrua et al., 
2010; Ginn et al., 2013). Since then, several gene therapy success stories have been reported 
as described in Chapter 1 (section 1.2.2).   
In recent years, there has been an increasing effort to develop new technologies for efficient 
gene delivery for clinical and/or scientific research purposes, which also do not adversely 
affect cell viability (Cho et al., 2007; Kersting et al., 2007; Lamoureux et al., 2007). 
Recombinant viruses, including retrovirus, lentivirus, adenovirus, adeno-associated virus, and 
herpes simplex virus have been used as transfection (transduction) agents and there have been 
numerous clinical trials with successful outcomes (Walther & Stein, 2000; Morgan et al., 
2006; Cartier et al., 2009; Simonelli et al., 2010; Kalos et al., 2011; Robbins et al., 2011; 
Tuddenham, 2012; Ginn et al., 2013; Hammoudi et al., 2015).  
Chapter 4 - Discussion & Conclusions 
 
  170 
 
However, over the past decade there has been an increasing shift towards the use of non-viral 
gene transfection. Several physical, chemical or hybrid approaches combining both physical 
and chemical characteristics have become available as described in Chapter 1 (section 1.5). 
Non-viral vectors are preferred due to concerns about the use of viruses, mostly related to 
safety, such as induced inflammatory response, target tissue specificity and insertional 
mutagenesis. Additionally, there are significant limitations in the plasmid packaging capacity 
of the different viral vectors and in the efficiency of transfecting the plasmid into suspension 
cell lines (Lu, 2001; Spack & Sorgi, 2001; Bhattarai et al., 2008; Mintzer & Simanek, 2009; 
Pickard & Chari, 2010; Naldini et al., 2011; Mingozzi and High, 2013; Kotterman & 
Schaffer, 2014; Cox et al., 2015).  
So far, it has been demonstrated that non-viral vectors can proficiently transfect cells in 
culture, the most frequently used being the cationic lipid agents and cationic polymers, but 
still a lot of evidence is needed to obtain efficient nanomedicines. Some concerns include the 
strong interaction of cationic delivery vehicles with blood components, toxicity, targeting 
ability of the carriers to the cells of interest, the need for higher transfection efficiency 
compared to viral vectors. 
In this study two primary aims were pursued. The first aim was the further optimization and 
assessment of improvements in transfection efficiency of the novel non-viral nanomagnetic 
gene transfection method (magnefect-nanoTM system) in hESCs and hMSCs primary cells, 
as well as in MG-63, NCI-H292 and NIH-3T3 cell lines in both static and oscillating 
conditions. The outcomes would help evaluate the applicability of the method in a variety of 
cell systems used for regenerative purposes. The second aim was to evaluate the efficiency of 
the method in comparison to the widely used lipid-mediated (Lipofectamine 2000TM) gene 
delivery (and selectively electroporation when possible). In parallel, cell viability and toxicity 
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assays were performed and morphologic and phenotypic characteristics of the cells after 
transfection were evaluated to determine any adverse effects of the MNP/DNA complexes’ 
addition into the cell cultures.   
4.1 Barriers of non-viral vector-mediated cell DNA delivery 
The most important and difficult challenge in gene transfection is successful delivery and 
most efforts have been concentrated on developing safe and effective nanoparticles for 
systemic gene delivery In order to be efficiently used clinically, non-viral vector-mediated 
delivery of DNA to cells in culture has to overcome several anatomical and cellular barriers 
restricting the overall efficiency of gene transfer.  
As it will be evident in the following sections, it has been shown by our work and the work of 
others that nanomagnetic transfection can significantly overcome most of these hurdles. 
These include vector-cell contact, transport across the cell membrane, endosomal escape in 
cases when the vectors are internalized within vesicles, as well as transport to and DNA 
delivery into the nucleus (Godbey & Mikos, 2001; Bergen et al., 2008; Zhang et al., 2012). 
Vector-cell contact is principally limited by diffusion for nanoscale vectors, such as viruses 
and most synthetic alternatives including MNPs, and great effort has been made to facilitate 
more rapid vector-cell contact (Bunnell et al., 1995; Luo & Saltzman, 2000).  
Crossing of the plasma membrane is typically achieved through endocytosis, the vectors 
being contained within endosomes, which may be subject to acidification, and trafficking to 
lysosomes for enzymatic digestion of the contents, preventing gene delivery. Endosomal 
escape can be achieved through the ‘proton sponge effect’ (Behr et al., 1997; Creusat et al., 
2010; Lian et al., 2014; Yin et al., 2014), which is made possible through functionalizing 
particles with highly cationic molecules. The positive charge aids cellular uptake but also 
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promotes nonspecific interactions with non target cells and extracellular components such as 
serum proteins and extracellular matrix.  
The most common way to decrease nonspecific interactions is to shield the nanoparticle 
surface with hydrophilic, uncharged polymers such as polyethylene glycol (PEG). Surface 
PEG coating sterically hinders the interaction and binding of blood components with the 
nanoparticle surface and prevents opsonisation and recognition by phagocytes of the RES, 
resulting in prolonged nanoparticle circulation in the blood. PEG coating, however, can 
inhibit fusion with the cell or endosomal membrane reducing the potential for particle cellular 
uptake and endosomal escape, decreasing transfection efficiency in case of DNA or silencing 
effect in case of siRNA (Zhang et al., 2012), although several strategies have been employed 
in an effort to handle this limitation (Walker et al., 2005; Hatakeyama et al., 2007; 
Hatakeyama et al., 2011). 
As described analytically in Chapter 1 (section 1.7.3), in case of tumours, transport of 
macromolecules across the tumour endothelium is more efficient than that of normal 
endothelium because the tumour has a leaky and discontinuous vascular structure with poor 
lymphatic drainage. This is referred to as the “enhanced permeability and retention (EPR) 
effect” (Seymour, 1992). The tumour endothelium thus allows the penetration of 
macromolecules and most nanoparticles. The EPR effect can be enhanced by PEGylation 
because the amount of blood that circulates through the tumour is usually far less than that of 
the RES organs, and only the nanoparticles that are not rapidly cleared from the circulation 
have a chance to encounter the leaky tumour vasculature. But not all tumours are equally 
leaky. Thus, nanoparticles with small size (less than 30 nm) are desirable for tumours with 
less leaky vasculature, whereas larger nanoparticles (around 100 nm) are efficient for most 
tumours. The latter allow easier surface modification with PEG arranged in a brush mode. 
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This arrangement successfully prevents serum opsonization. Small particles are also prone to 
renal excretion through the glomeruli in the kidney, and their large surface curvature makes 
PEG shielding difficult (Schipper et al., 2009; Tseng et al., 2009; Li & Huang, 2010). 
However, although PEGylation may protect nanoparticles from protein agglomeration and 
macrophage capture, controlling their biodistribution and tumour accumulation, the PEG 
coating prevents the formation of essential nonbilayer intermediates and inhibits fusion with 
the cell and/or the endosomal membrane, thus reducing the potential of nanoparticle cellular 
uptake and cargo release from endosomes, decreasing silencing or transfection efficiency 
(Drummont et al., 2000).  
As already discussed in Chapter 1, PEI is considered one of the most effective polymer-based 
transfection agents and its ability to promote gene transfection in vitro and in vivo was first 
demonstrated in 1995 (Boussif et al., 1995). This acidification process occurs as endosomal 
membrane pumps import protons into the endosome. The endosomal proton pumps continue 
to import protons, resulting in osmotic swelling and rupture of the endosome, releasing the 
vectors into the cytosol. On the other hand, not much is known about how vectors are 
transported into the nucleus. Trafficking of PEI has been shown to be mediated by 
microtubule transport (Pichon et al., 2010). It is not known, however, whether this transport 
involved PEI within vesicles, and thus may not apply to free PEI or PEI-coated MPs (Suh et 
al., 2003).  
 
4.1.1 Cells could potentially be more amenable to transfection during mitosis 
In terms of DNA entrance to the nucleus for transgene expression to occur, in non-dividing 
cells the aforementioned process is regulated by nuclear pore complexes, and thus smaller 
DNA molecules gain entry more efficiently. Dividing cells on the other hand undergo nuclear 
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membrane breakdown (Van der Aa et al., 2006), during which nucleic acids can potentially 
gain entry, and that explains why proliferative populations are frequently reported to be more 
amenable for transfection (Bettinger et al., 2001; Brunner et al., 2000; Kim et al., 2006). As it 
will be discussed in further detail in section 4.6, certain cells, in our case hMSCs, are really 
hard to transfect using non-viral methods that result in really low transfection efficiency and 
reduced viability. This can be due to the fact that hMSCs have a very slow cell division cycle, 
which might possibly affect cellular and/or nuclear entry.  
According to the currently presented data, the use of oscillating magnetic fields (magnefect-
nanoTM system) for 30 min, or even shorter, transfection times at 2Hz frequency and 200 μm 
amplitude significantly enhanced overall transfection efficiency in comparison with absent or 
static magnetic fields, as well as the 6 hr treatment with lipid-based agents that demonstrated 
nearly complete inability to transfer hMSCs. In parallel, cell viability studies reconfirmed the 
very high cell viability results retained following transfection. This was not the case with 
Lipofectamine 2000TM where statistically significant decrease in cell viability following 
treatment was demonstrated. Similar results were obtained with MG-63 cells.  
 
4.2 Nanomagnetic gene transfection 
Magnetic microparticle (MP) - based gene transfection was first demonstrated in early 2000. 
In these experiments, magnetic microspheres with green fluorescent protein (GFP) - carrying 
recombinant adeno-associated virus linked to the microspheres via heparin sulfate were used. 
The complex was then magnetically targeted to a specific region within a culture of HeLa 
cells. The magnetic targeting actually enabled highly efficient uptake of the GFP gene into 
HeLa cells localized at the site of the applied magnetic field (Mah et al., 2000; Mah et al., 
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2002). This magnetic nanoparticle-based gene transfection method was followed by the 
development of multiple different MNPs, coated with charged polymers to which plasmids 
(DNA or siRNA) are coupled for non-viral nanomagnetic gene transfection, also known as 
magnetofection (Scherer et al., 2002; Plank et al., 2003; Krotz et al., 2003a&b; Dobson, 
2006a&b).  
As already extensively discussed in Chapter 1 (section 1.8), this technique relies on a high-
field, high-gradient, permanent magnetic field placed beneath a culture plate, increasing the 
rate of MNP/DNA complex sedimentation, and thus enhancing transfection efficiency by 
exploiting the magnetic properties of these particles (Plank et al., 2003). This technique has 
actually been successfully used to target cells carrying reporter genes, which are replaced by 
apoptosis genes for therapeutic applications, to tumors in vivo (Muthana et al., 2008). 
Although the method originally employed/used a static magnetic field, oscillation of the array 
of magnets beneath the culture plate, while the plate remains stationary, has been shown to 
enhance transfection efficiency (McBain et al., 2008b; Fouriki et al., 2010; Pickard and 
Chari, 2010; Jenkins et al., 2011; Lim et al., 2012; Adams et al., 2013; Subramanian et al., 
2013), an observation that will be discussed in further detail in the following paragraphs, 
since, as already shown, it was one of the main findings of the presented work. 
 
4.2.1 The importance of MNPs choice and the safety of magnetic fields 
In order to be suitable for biomedical applications, SPIONS have to possess several key 
characteristics, as described in Chapter 1 (sections 1.6.2 & 1.6.3), such as biocompatibility, 
biodegradability, low toxicity and be physiochemically stable for storage and physiological 
conditions (Mahmoudi et al., 2011; Wahajuddin & Arora, 2012). For the purpose of this 
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thesis two commercially available SPIONs were used, nTMag and PolyMag, which actually 
share all the aforementioned advantageous characteristics of SPIONs for gene delivery. 
According to their manufacturers, they both share the same physiochemical specifications in 
terms of shape, size and surface coating. As already extensively described in Chapter 2 
(section 2.3.3.1), they both have magnetite cores with proprietary multi-layer PEI derivative 
dispersed in ddH2O. Additionally, they have a diameter of approximately 100 nm and are 
biocompatible and biodegradable.     
The use of MNPs and nanomagnetic transfection techniques compare favourably with the 
transfection efficiencies achieved using electroporation and other non-viral methods, such as 
lipid-mediated gene delivery (lipofectamine), their major advantages being high speed of 
transfection (up to 30 min), high cell viability post-transfection, stability and cost 
effectiveness. In other frequently used techniques, such as electroporation, transient pores are 
produced in the cell membrane, through which transfection vectors enter the cell (Leclere et 
al., 2005; Villemejane & Mir, 2009). However, this disruption of the cell membrane 
frequently results in extensive cell death and damage of the surviving cells (Gao et al., 2007; 
Weill et al., 2008; Villemejane & Mir, 2009).  
On the contrary, MNPs do not disturb the membrane, as they make use of the natural 
endocytotic mechanisms of cells, and thus highly cell viability is achieved. This is a very 
important point when talking about their potential use in the clinical practice, as introducing 
dead/dying cells into a patient can have detrimental effects, such as an inflammatory response 
caused by the necrotic release of the cell contents (Chen et al., 2008). In addition, when cells 
are cultured in large scale for clinical applications, a high rate of cell attrition may add to the 
cost of production, especially in cases where availability of primary tissue sources is limited. 
Furthermore, MNPs can be a great tool for therapeutic and diagnostic (‘theragnostic’) 
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applications, as their multimodality enables therapeutic effects to be combined with 
diagnostic functionality, an example being the non-invasive imaging of MP-labelled cells 
(Shubayev et al., 2009). Thus, in summary, the advantages of nanomagnetic transfection 
using both static and oscillating magnets in vitro on various cell systems, as demonstrated by 
numerous studies, include: (a) low amounts of transfection complexes, (b) high cell viability, 
(c) high transfection efficiency, (d) little or no interference with cell proliferation and 
differentiation, (e) low cost (Scherer et al., 2002; Dobson et al., 2006a&b; Mykhaylyk et al., 
2007; Plank & Rosenecker, 2009; Jenkins et al., 2011; Pickard et al., 2011; Sapet et al., 2011; 
Subramanian et al., 2013; Subramanian et al., 2017).  
The ultimate goal of gene therapy and cell transplantation therapies remains the functional 
recovery, or at least the inhibition of disease progression. What though is of absolutely vital 
significance is the investigation of all possible indications of toxicity or abnormality due to 
MNP and magnetofection applications. No obvious effects of magnetic field application on 
the cells used in the currently presented experiments were observed, as discussed in the next 
paragraphs. The safety of magnetic field use, which is unlikely to disrupt normal cellular 
function via nanomagnetic activation, has been further supported by numerous other studies 
(Scherer et al., 2002; Huth et al., 2004; Schillinger et al., 2005; Dobson et al., 2008; Pickard 
& Chari, 2010; Subramanian et al., 2013).  
There have, however, been a few reports were it was shown that in certain cases the 
application of a magnetic field affects the cells. An example of such a case was the alignment 
of the cytoskeletal protein F-actin when human fibroblasts were exposed to 350 mT for 30 
min (Berry 2009). However, in most of those studies, prolonged field exposures (up to 60 h) 
were investigated and often greater field strengths were applied (up to 8T) (Smith et al., 
2010). However, as a further proof of concept it would be of great interest to further explore 
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this by, for example, performing microarray analysis of magnetofected cells and study any 
possible effects on gene expression. Similar analyses could be performed for the oscillating 
compared to static magnetic field application, although no obvious changes were observed by 
any phenotypic analysis performed.  
4.2.2 Oscillating magnet arrays: possible underlying mechanisms of enhanced 
transfection 
The work presented as part of this thesis has clearly demonstrated that oscillating magnet 
arrays of the magnefect-nanoTM system enhanced nanomagnetic gene transfection compared 
to static magnetofection in NIH 3T3 mouse embryonic fibroblasts (Fouriki et al., 2010; 
Fouriki & Dobson, 2013), MG-63 osteoblasts (Fouriki et al., 2014), human mesenchymal 
stem cells (hMSCs) (Fouriki & Dobson, 2014) and human stem cells (hESCs). However, the 
exact mechanisms underlying this effect still remain elusive. Better understanding could help 
to further improve these effects either by modifying the current protocols and/or by 
modifying the actual nanomagnetic transfection device (magnefect-nanoTM oscillating field 
system). 
The primary mechanism underlying magnetic - nanoparticle based gene transfection is the 
attraction of the magnetic particle to the magnetic field source. This results in a translational 
force on the particle/gene complex in the direction of the magnetic field source, which is 
generally placed under the culture dish. The horizontally oscillating magnet array introduces 
a component of lateral motion as the particles are pulled towards the field source. The extra 
energy and mechanical stimulation associated with this lateral motion of the particles have 
been shown to promote increased particle sedimentation and stimulate uptake, thus improving 
the transfection efficiency compared to static fields. Thus, compared to static oscillating 
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magnet arrays show promise for further enhancing nanomagnetic transfection and gene 
delivery (Dobson, 2006a&b). As discussed next, the improved transfection ability of 
nanomagnetic transfection using oscillating magnet arrays has been demonstrated in several 
cell types. However, further testing in additional cell systems would be needed.  
Oscillation appears to facilitate endocytosis-mediated cellular uptake of complexes during 
MNP-mediated transfection (Kami et al., 2011). Additional transfection studies from our and 
other research groups have demonstrated similar findings using oscillating nanomagnetic 
transfection on mouse embryonic fibroblasts (MEFs) (Lim & Dobson, 2012), neural stem 
cells (Adams et al., 2013), human umbilical vein endothelial cells (HUVEC) (Lim & Dobson, 
2012), rat oligodendrocyte precursor cells (Jenkins et al., 2011), rat astrocytes (Pickard & 
Chari, 2010), and cardiac progenitor cells (Subramanian et al., 2013).  
In all these studies a frequency-dependent increase in transfection efficiency was shown, 
which actually demonstrated the versatility of the frequency-displacement based-
nanomagnetic transfection technology as well its efficiency over a range of primary, 
differentiated and undifferentiated cells, and cell lines. However, the observed enhancement 
in transfection efficiency appears to be highly dependent on the cell type as it was shown to 
be quite modest in some in vitro systems, such as astrocytes (Pickard & Chari, 2010), adult 
cardiomyocytes (Subramanian et al., 2013), SH-SY5Y neural cell line, and primary neurons 
(Subramanian et al., 2017).  
The reason behind frequency-displacement dependent transfection remains elusive. However, 
increased cytosolic Ca2+ transients and enhanced Ca2+ oscillations have been observed with 
increasing pacing frequency in adult mouse myocytes (Lim et al., 2000). Additionally, shear 
stress has been shown to induce cytosolic Ca2+ transients in different cell types (Schwarz et 
al., 1992; Wei et al., 2012). Subramanian et al. thus suggested that the frequency-
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displacement dependent transfection they observed in cardiac cells may depend on the 
cytosolic Ca2+ oscillations, which is reported to interfere with the transfection and gene 
expression of cells (Dolmetsch et al., 1998; Preuss et al., 2000). The same could possibly 
apply to other cell systems where similar observations have been made.  
Static nanomagnetic transfection does not alter the mechanisms of vector uptake by the cells, 
but significantly reduces the time taken for particles to come into contact with adherent cells 
and prolongs contact time as during magnetic exposure the NPs/DNA complexes gather onto 
the cell culture surface (Laurent et al., 2011; Plank et al., 2011). Endocytosis still remains the 
main suggested method for cellular uptake leading to gene delivery (Scherer et al., 2002). 
There are thus various theories, based on the above, that could provide a possible explanation 
for the enhanced transfection efficiency observed in oscillating nanomagnetic transfection.  
First, an oscillating magnetic field may result in a more uniform dispersion of particles since 
it may simply move the MNPs laterally and so particles in a cell-free area are brought into 
contact with cells, thus increasing the likelihood that each particle comes into contact with a 
cell within a given time. In 2008, a static magnetic field model predicted that magnetic 
particles accumulate at the centre of a culture well, due to the radial component, potentially 
with an annulus of slightly greater accumulation surrounding it, due to the axial component 
(Furlani & Ng, 2008).  
However, that was neither experienced during our experiments nor it has been reported by 
other groups. In addition, the applied oscillating field may lead to the distortion of MNPs or 
to the stimulation of the cell membrane in a way that endocytosis is more likely to occur 
(Dobson, 2008; Fouriki et al., 2010). It could also be possible that the applied oscillating field 
alters intracellular processing of MNPs by, for example, disrupting endosomal processing and 
facilitating endosomal escape (McBain et al., 2008). This notion is further supported by the 
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currently presented work on NCI-H292 cells and could possibly be linked to the very high 
protein production observed (Fouriki et al., 2010).  
Finally, as aforementioned, the mechanical stimulation associated with the lateral motion of 
the particles could actually promote enhanced particle sedimentation and stimulate uptake, 
thus increasing the transfection efficiency compared to static fields.  
Kamau and coworkers performed experiments using HeLa cells and showed that the 
application of a pulsating electromagnetic field (amplitude: 27 mT, field gradient: 10 T/m) 
greatly enhanced MP-mediated transfection. A pulsed field is thought to produce both 
horizontal and vertical oscillation of the MPs. The particle movements induced by these 
oscillations are presumed to underpin the mechanism via which the pulsed field increases 
transfection efficiency. These effects were observed following a 10 min exposure to magnetic 
fields. Taken together these findings support the idea that membrane stimulation by MPs in a 
dynamic magnetic field leads to enhanced cellular uptake, rather than post-uptake 
intracellular events. It is interesting to note that following a 5 min exposure to the magnetic 
field, the authors noticed that the temperature at the surface of the device had risen from 
37oC to 42.5oC. Although this could be potentially damaging for the cells, the authors did 
not report any toxicity data (Kamau et al., 2006). During the protocols used during the work 
presented here, no similar heating effects were observed. 
 
4.3 Evaluation of the magnetic field requirements for nanomagnetic gene 
transfection 
As part of the optimization of magnetic nanoparticle - based transfection technique, it was 
initially necessary to understand the effects of magnetic field strength and distance on 
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transfection efficiency and protein production. For these experiments human lung 
mucoepidermoid carcinoma cells (NCI-H292) were used. In order to determine the optimal 
working distance between the magnet and the cell culture for the improvement of transfection 
efficiency in NCI-H292 cells, magnet arrays were rearranged, as previously described in 
detail in Chapter 2 (Section 2.3.2), to gradually increase the distance between the magnet 
array and the cell culture between 3 and 8 mm. The highest magnetic field reached was 101 
mT. Based on the presented data of fluorescent microscopy images (Figure 3.2) it appears 
that the highest luciferase expression levels of NCI-H292 cells following 2 h transfection 
were achieved at the closest spacing between the magnet and the cells (3 mm). However, the 
difference in luciferase expression was not statistically significant when compared to 4 mm, 5 
mm and 6 mm distances, providing scope for potentially transfecting cultured tissue explants 
with this technique. It was actually demonstrated by these results that there is a plateau effect 
beyond which transfection efficiency is not improved (Fouriki et al., 2010).  
This demonstrated correlation between the magnetic field strength and transfection efficiency 
then formed the basis for the way the magnet arrays were assembled for the studies that 
followed, meaning that cell cultures were positioned in the closest proximity with the magnet 
array.  It is of great importance to mention that regardless of the magnet distance luciferase 
activity using the oscillating field was statistically significantly enhanced compared to both 
static field and Lipofectamine 2000TM after both 2 and 6h transfection (Fouriki et al., 2010). 
These results were in line with earlier studies of oscillating magnetic systems where increases 
in luciferase activity and in transfection efficiency using GFP have been reported (Kamau et 
al., 2006; McBain et al., 2008; Pickard et al., 2010). It should also be noted that in our 
experiments the luciferase activity was not directly related to the number/ percentage of cells 
transfected, but rather was a proxy for protein/ enzyme production (Fouriki et al., 2010).  
Chapter 4 - Discussion & Conclusions 
 
  183 
 
Furthermore, cell viability studies demonstrated unaffected cell viability levels, comparable 
to untreated samples, following transfection with the MNPs/DNA complexes and magnetic 
fields eliminating any concerns about MNP toxicity. 
Data from NCI-H292 cells also revealed one of the main advantages of the method. As the 
forces generated on the particle/plasmid complex were in the picoNewton range, the effects 
on the cell membrane integrity were negligible. Based on findings from previous studies of 
magnetic ion channel activation (Cartmell et al., 2002; Dobson et al., 2006; Dobson et al., 
2008), the primary mechanism for uptake is likely to be via increased endocytosis due to 
mechanical stimulation (Fouriki et al., 2010). Although this mechanical stimulation can 
potentially affect downstream protein production in mechanoresponsive cells, reporter 
constructs such as luciferase and GFP are dependent on cell entry and transcription rather 
than anomalous protein expression (Cartmell et al., 2002).   
 
4.4 Nanomagnetic gene transfection for non-viral gene delivery in NIH-3T3 
mouse embryonic fibroblasts (MEFs) 
The potential of this transfection method was also investigated in NIH-3T3 MEFs. Based on 
the data presented, in this case the oscillating nanomagnetic gene transfection method had 
similar transfection efficiency results (25%) with the static array (22%), still slightly more 
improved. The increase in transfection efficiency observed between the no field, and both the 
static and oscillating field conditions was found to be statistically significant (***p < 0.001). 
Additionally, the use of both the static and oscillating field conditions significantly increased 
transfection efficiency compared to Lipofectamine 2000TM at 30 min (***p <0.001), but 
was found to have analogous results to Lipofectamine 2000TM at 6h (22%). These results 
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demonstrate the efficiency of the magnetic field systems at shorter transfection times using 
lower reagent doses. Furthermore, during these experiments, excellent cell viability levels 
were retained comparable to untreated samples and significantly higher cell viability was 
observed compared to Lipofectamine 2000TM at 6h (Fouriki and Dobson, 2013).  
An interesting finding in the course of these experiments was that Lipofectamine 2000TM-
transfected cells glowed less brightly compared to cells transfected with the magnefect-
nanoTM system. This observation further supports the idea suggested in the previous section 
and what has since been shown by other studies (McBain et al., 2008; Fouriki et al., 2010; 
Pickard and Chari, 2010), that protein production is enhanced in the magnefect-nanoTM 
system.   
Taken together the presented data have shown the potential of nanomagnetic transfection to 
be a fast and efficient method for nonviral transfection of MEFs for use in regenerative 
medicine and tissue engineering research applications.  
 
4.5 Transfection of MG-63 Osteoblasts using magnetic nanoparticles and 
oscillating magnetic fields 
Osteosarcoma is the most common malignant bone tumour and occurs mainly in children and 
adolescents (Klein and Siegal, 2006; Liang et al., 2009). Conventional therapies have so far 
provided limited, if any, improvement and thus increasing emphasis has alternatively been 
given on gene therapy approaches (Cho et al., 2007; Kersting et al., 2007; Lamoureux et al., 
2007). In order to examine the potential of the magnefect-nanoTM transfection system we 
used the human osteoblastic/osteosarcoma cell line MG-63, which has been extensively used 
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in various studies of bone tissue engineering, regenerative medicine and the metastatic 
mechanism of bone cancers (Shi et al., 2005).  
The method (both static and oscillating magnetic fields) resulted in higher transfection 
efficiency (49% and 53% respectively) than lipid-based reagents (7%) and electroporation 
(21%). Cell viability was found to be relatively unaffected, mainly in comparison to 6h lipid 
transfection and electroporation, and cell morphology appeared normal after transfection. The 
highest levels of transfection (53%) were achieved using nTMag nanoparticles with an 
oscillating magnet array running at a frequency of 2 Hz and amplitude of 200 μm (Fouriki et 
al., 2014). These frequencies were significantly lower than those used for magnetic fluid 
hyperthermia, which was aimed at tumor ablation or induction of apoptosis (Pankhurst et al., 
2003).  
These methods rely on coupling high frequency fields to magnetic nanoparticles to heat the 
particles or mechanically disrupt the cell membrane. At the frequencies used in the current 
experiments, neither mechanism occurred, thus the effects on cell viability were negligible. It 
is also important to notice that the magnefect-nanoTM system demonstrated a 2-fold increase 
in transfection efficiency in 30 min compared to Lipofectamine 2000TM subjected to 6 h 
duration (24%). Similar was the significance of improved transfection in comparison to 
electroporation.  
Interestingly, some transfection was seen when using the nTMag particles even in the 
absence of an applied field; while for both static and oscillating magnet conditions, nTMag 
particles appeared to provide significantly enhanced transfection efficiency than PolyMag 
(24% for static and 20% for oscillating). Taken together, these results showed that 
nanomagnetic transfection provides a fast and efficient method for non-viral gene 
transfection (or delivery) that outperforms both lipid-mediated gene delivery and 
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electroporation. They also demonstrated that nanomagnetic gene transfection has great 
potential for use as an effective, non-viral transfection agent for MG-63s for use in tissue 
engineering and cancer research applications (Fouriki et al., 2014).  
 
 
4.6 Oscillating magnet array-based nanomagnetic gene transfection of 
human Mesenchymal Stem Cells (hMSCs) 
hMSCs are non-hematopoietic stromal cells, critically important for both stem cell and gene 
therapy studies. They can be ideal candidates for tissue engineering and regenerative 
medicine applications due to their differentiation capacity and ability to regenerate multiple 
tissue types, such as bone, cartilage, muscle, ligament, tendon and adipose tissue (Pittenger et 
al., 1999; Chamberlain et al., 2007; Chen et al., 2008; Schop et al., 2009). The challenge in 
using hMSCs is that they are particularly hard to transfect using non-viral methods as cationic 
lipid reagents result in low TEs and slightly reduced viability, while electroporation results in 
relatively low cell viability. In addition, hMSCs have a very slow cell division cycle, which 
might affect cellular and/or nuclear entry. As part of this study, the potential of nanomagnetic 
gene transfection in the presence of oscillating magnetic fields for hMSCs transfection was 
explored.  
It was shown that the use of the magnefect-nanoTM system for 30 min transfection at 2 Hz 
frequency and 200 μm amplitude significantly enhanced overall transfection efficiency in 
comparison with absent or static magnetic fields, as well as the 6 h treatment with lipid-based 
agents that demonstrated nearly complete inability to transfect hMSCs. In parallel, membrane 
integrity assays determined that treatment with MNPs and oscillating or static magnetic fields 
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retained high cell viability comparable with untreated hMSCs following transfection. This 
was not however the case with Lipofectamine 2000TM-treated samples which were 
characterized by statistically significant decrease in cell viability and increased toxicity 
following treatment (Fouriki & Dobson, 2014).  
hMSCs divide multiple times and retain their multipotent differentiation characteristics in 
culture. The fact that hMSCs retained their phenotypic characteristics following treatment 
was confirmed by the positive expression of four cell-surface specific markers present on 
hMSCs: CD44, CD90, STRO-1, and CD146 (Fouriki & Dobson, 2014). This was further 
confirmed by the negative expression of hematopoietic cell surface markers CD14 (present 
on leukocytes) and CD19 (present on B-lymphocytes) (Chamberlain et al., 2007; Chen et al., 
2008), which actually demonstrated there was no hematopoietic cell contamination (Fouriki 
& Dobson, 2014). Additional negative markers include CD45, CD34 (Chamberlain et al., 
2007; Chen et al., 2008). 
An interesting observation made during these experiments was the significantly enhanced 
accumulation of DAPI staining in the oscillating magnet samples compared to the static ones. 
Although this could be a random finding, it could also have another explanation. It is not 
clear from the staining whether this increased accumulation is inside or outside of the cell. If 
this is indeed the case, then this could be attributed to compromised ability of the plasmid to 
enter the nucleus or the cell respectively. Although being a cell entry problem is still possible, 
it is highly unlikely, as there is no reference suggesting that hMSCs cell membrane could not 
be permeable with this method. Being a nuclear entry problem is most likely, also based on 
the fact that hMSCs are slow dividing cells and similar to all non-dividing cells they are very 
hard to transfect based on the fact they have a very slow division cycle and as already 
discussed in section 4.1.1 cells are more amenable to transfection during mitosis. However, 
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further experiments, including live monitoring and electron microscopy would be needed in 
order to verify it is a nuclear entry problem.  
Another observation during the hMSCs experiments was the presence of protein RAFTS, 
shown as pigmented dots in untreated hMCs characterization. This could be in support to the 
theory that genes are highly expressed in particular places, known as protein RAFTS, which 
are a group of organized protein (Lucero & Robbins, 2004).  
The currently presented work on hMSCs was limited by the fact that FACS analysis was not 
performed due to low number of cells. Samples were thus assessed by microscopy and 
manual counting was performed. These data, although mostly qualitative, are in agreement 
with and support the rest of the data pointing towards the effectiveness of oscillating 
magnetofection in hMSCs transfection. Undoubtedly, future FACS experiments on these cells 
are needed to further verify the findings presented here and provide a more accurate 
quantification of transfection efficiency.  
Taken together, these data demonstrate that nanomagnetic transfection provides a fast and 
efficient method for non-viral transfection of hMSCs and could be of great potential as an 
effective, non-viral transfection system for this type of cells.  
 
4.7 Nanomagnetic Gene Transfection for Non-Viral Gene Delivery in 
Human Embryonic Stem Cells (hESCs) 
This study represented the first demonstration of nanomagnetic transfection of hESCs using 
both static and oscillating magnet arrays. In recent studies cationic lipids have been used to 
transfect ESCs with both DNA and siRNA, however, transfection efficiencies have been 
relatively low and toxicity has been a great concern [Ma et al., 2011]. Fluorescent microscope 
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images obtained 48 hr post pEGFP-N1/MNP complex introduction into the cell culture, 
showed that hESCs were efficiently transfected and visual inspection of the image indicated 
that magnet arrays oscillating at 2 Hz appeared to enhance transfection when compared to 
cationic lipids, though this result should be considered preliminary. 
Cell viability of hESCs following treatment with magnetic nanoparticles and both static and 
oscillating nanomagnetic transfection appeared unaffected relative to untreated controls. 
Significantly higher toxicity was observed when comparing untreated cells with 
Lipofectamine 2000TM – transfected hESCs (***p < 0.001); while Lipofectamine 2000TM 
had significantly lower cell viability/higher toxicity in comparison to nTMag no field (***p < 
0.001), as well as in comparison to both static (*p < 0.05) and oscillating magnetic field 
(***p < 0.001). Finally, no statistical significance in cell viability was observed when 
comparing the three conditions (no field, static field and oscillating field), further 
highlighting that the magnetic field improves transfection efficiency but does not 
significantly affect cell viability. 
 Furthermore, following transfection, the expression of the specific transcriptional factors 
Oct-4 and Nanog (Cruz et al., 2003) and h-TERT, as a confirmation of high telomerase 
activity (Wobus & Boheler, 2005; Mathew et al., 2010), indicated that the cells retained 
expression of specific pluripotency markers. Analysis of the expression of Sox-1 (ectodermal 
layer marker) (Wobus & Boheler, 2005), ACTC1 (mesodermal layer) (Abeyta et al, 2004) 
and AFP (endodermal layer) (Osafune et al., 2008) also demonstrated that the cells expressed 
specific differentiation markers from all three somatic germ layers. However, the data are 
preliminary and reconfirmation is required, including the elimination of any possible 
experimental errors.   
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The data presented here provides some preliminary evidence that nanomagnetic transfection 
provides a rapid and efficient method for non-viral transfection of hESCs. In 30 min, the 
technique achieved transfection efficiencies similar to those obtained with a 6 hr treatment 
using lipid-based reagents, with significantly higher cell viability. Additionally, preliminary 
results have indicated that stem cell morphology, pluripotency and differentiation potential 
remained unaffected post-transfection. qPCR results for markers of multipotency 
demonstrated that these are expressed post-transfection. However, these experiments were 
carried out using extracted RNA from the whole cell population (transfected and non-
transfected cells) and one could possibly claim that expression of these transcription factors 
was actually observed in the non-transfected cells. Further experiments, during which cells 
will be sorted by FACS prior to gene expression analysis, will provide a definite confirmation 
on whether this is the case or not.  
Though this study reports our initial results of hESC transfection, oscillating array-based 
nanomagnetic gene transfection efficiency using magneto-mechanically stimulated 
particle/DNA (or siRNA) uptake has the potential to be improved further by systematically 
investigating a wider range of frequencies and amplitudes (Jenkins et al., 2011).  
 
4.8 Summary of thesis findings and conclusion 
Based on the data presented in this thesis, nanomagnetic transfection provides a fast and 
efficient method and has significant potential for use as an effective, non-viral transfection 
agent for a variety of primary human stem cells and different cell lines. Taken together these 
results exhibit its diverse use and potential in regenerative medicine and tissue engineering 
research applications. 
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Gene transfection and transient GFP expression was examined. It is understood that stable 
gene expression is governed by different requirements and mechanisms which need to be 
further investigated. It was shown that the use of oscillating field surpasses transfection 
efficiency levels compared to the static one; this difference being statistically significant in 
most cases. The magnet distance was also examined and the threshold at which transfection 
efficiency increased and marked protein production was stimulated was identified. Compared 
to other methods, magnetofection is time and reagent efficient, can potentiate the efficacy of 
a given vector and allows magnetic-field guided targeting in vivo. The principal advantage of 
the MNP-based method was shown to be the rapid sedimentation of the MNP/gene complex 
onto the target area which significantly reduces both time and dose of vector for efficient 
transfection. The application could be used in gene therapy for the nucleic acid delivery itself 
as the heart of the therapeutic strategy, in basic research and in commercial scale 
biotechnology approaches where nucleic acid/ gene delivery only serves as a tool for 
answering scientific questions. Importantly, cell viability was excellent throughout in all 
experiments with different types of cells.  
In conclusion nanomagnetic gene transfection provides efficient non-viral delivery of 
MNP/DNA complexes into a wide range of cells using static and oscillating magnet arrays. 
The technique consistently surpasses transfection efficiency levels of the best cationic lipid 
agents at shorter transfection times and lower reagent doses. Cell viability and morphology of 
transfected cells remained unaffected. In case of primary stem cell use, hMSCs surface 
marker expression of CD44, STRO-1, CD90 and CD146 was retained post transfection 
indicating retention of phenotypic characteristics post transfection, and preliminary 
experiments demonstrated that hESCs retained expression of certain pluripotency (Oct-4, 
Nanog and hTERT) and differentiation (Sox-1, ACTC1 and AFP) markers. 
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4.9 Limitations of the study 
A part of the work presented here is somehow limited by the fact it was carried out in cell 
lines. This is because cell lines possess an altered morphology compared with the 
corresponding primary cells. Cell lines are highly homogeneous and exhibit high survival and 
proliferation rates, in addition to resistance to adverse stimuli, such as cell death signals. 
Thus, their properties may not represent biological variations that exist in vivo, mainly in 
terms of cell proliferation and differentiation. Most importantly, cell lines allow for 
continuous passage which, if carried out without robust quality control, increases the risk of 
chronic contamination by mycoplasma, which can in turn alter cell structure, metabolism and 
growth, thus affecting the interpretation of the data (Freshney 2002). These concerns 
combined with the risk of cellular aneuploidy, can make cell lines a relatively poor model for 
toxicity testing (Freshney 2002; Hughes et al., 2007), which is currently an important issue in 
nanotechnology. 
In addition, the proposed method in the current study was not tested enough in vivo. As 
already discussed in Chapter 1 (section 1.8.2), small animal studies with nanomagnetic 
transfection with either static or oscillating magnets have already shown great potential 
(Pulfer et al., 1999; Alexiou et al., 2000; Goodwin et al., 2001; Krotz de Wit et al., 2003; 
Schillinger et al., 2005; Muthana et al., 2008; Brett et al., 2016). However, magnetic targeting 
in larger animals including humans is more challenging. This is mainly due to the fact that 
sites of interest are further away from the magnet source and are considerably more difficult 
to target. As the magnetic field strength and gradient rapidly decay when the magnet source is 
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not close enough to the target site, a high-gradient which is necessary for capturing the 
MNP/DNA complexes cannot be accomplished (Dobson, 2006). 
Although it is up to the experimental objective whether stable or transient expression is 
needed, in regards to stable transfection, one should be cautious and the whole process needs 
to be well controlled in order to avoid insertional mutagenesis and switching on/off a gene 
via an activated oncogene or tumour suppressor gene respectively.    
 
4.10 Future perspectives 
Theoretically, an ideal gene therapy vector could combine characteristics of both viral and 
non-viral systems in order to meet the many gene delivery challenges. Several properties of 
these systems would need to be brought together as the vector has to be efficient, specifically 
targeted, biodegradable or easy to remove, stable in the bloodstream and non-toxic (Munoz et 
al., 2012). In addition, it is very important that the vector is safe and initiates no inflammatory 
or immunogenic response, and that is it is able to protect genetic materials against 
degradation during transport and be stable for storage (Kay et al., 2009; Grigsby and Leong, 
2010; Kay et al., 2011). We have shown that in the cell systems studied, the method used had 
most of these characteristics, and similar results have been demonstrated by studies on other 
various cells. However, the method could be further ameliorated in order to enhance 
transfection efficiency even further. 
A way to achieve that would include adaptations in the cell culture conditions. It was recently 
shown that transfection efficiency in HUVEC cells using both static and oscillating magnet 
systems was dramatically increased by pre-incubating the cells in serum-free conditions 2 h 
prior to transfection using nTMag particles. It was suggested that this could be due to the 
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dissociation of complexes in the presence of serum suggesting weak binding of plasmid to 
nanoparticles (Lim & Dobson, 2012). The same was observed in HeLa, KB and 11293 cell 
lines using cationic PEI-polyplexes (Liu & Zhang, 2011; Lim and Dobson, 2012). This could 
be due to better DNA incorporation into polyplexes or onto nTMag particles in the absence of 
serum. The effects of serum starvation could possibly be advantageous for other cell systems. 
In a recent study, where the same method was used in human prenatal cardiac progenitor cells 
and adult cardiomyocytes, it was shown that transfection efficiency can be enhanced by 
coating the wells with collagen I. Oscillating magnetofection, when used for an adherent cell 
transfection, then seeding/ adhering parameters are key for the technique and it is likely that 
the increased efficiency observed in cells seeded onto rat tail collagen I was due to efficient 
adherence as collagen type-I is one of the fibrous proteins within extracellular matrix and, 
being a structural protein, it is highly biocompatible. In the cardiomyocytes, this led to 
increased adhesion and improved transfection efficiency with the oscillating system 
(Subramanian et al., 2013). Cell adhesion assays could thus possibly be used to further 
improve transfection efficiency. In the same study, as well as in subsequent ones on neural 
cells, the Neuromag MNPs were used, which was shown to also further enhance transfection 
efficiency. Although, this system was initially proposed to target neural cells, it was 
demonstrated to efficiently transfect cardiac progenitor cells and cardiomyocytes 
(Subramanian et al., 2013; Subramanian et al., 2017). It would be interesting to study in the 
future the applicability of this system on the cell systems used in the current study. 
 
Further work could also be performed towards the optimization of the delivery of therapeutic 
gene sequences. Importantly, nanomagnetic gene transfection using mechanically stimulated 
particle/DNA uptake may be further improved by systematically investigating a wide range 
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of oscillation frequencies and amplitudes, as part of the optimization for each cell type. 
Additionally, although the method used is based on endocytic mechanisms thus allowing the 
uptake of large plasmids, further optimization could still be beneficial.  
For example, transfection efficiency could possibly be further enhanced by minimizing the 
overall size of the plasmids. For this the plasmids could be engineered to produce constructs 
containing only the therapeutic gene sequences and the elements necessary for transcription. 
Furthermore, future studies could focus on identifying physiochemical parameters that may 
allow for the attachment and the delivery of larger plasmids and/or higher copy numbers. To 
achieve that, biologists should work in collaboration with material scientists and need to 
understand in detail the chemical interactions occurring at the organic-inorganic hybrid 
interface of magnetic particles and biomolecules. An example of that is the understanding of 
the different association of large and small plasmids with the particle surface and the 
implication this has on DNA attachment and intracellular release.  
Nanomagnetic transfection optimization is also influenced by the properties of the MNPs 
used. The attractive force is directly proportional to the volume of magnetic material in the 
particle, magnetic field strength/ gradient of the magnet array and magnetic properties 
(susceptibility) of the particle (Dobson, 2006). While it is true that increases in the magnetic 
content (volume of magnetic material) of the particles increases the magnetic force, generally 
the particles used for these studies are iron oxide/ polymer composite particles. Increasing the 
hydrodynamic diameter is not always associated with a proportional increase in magnetic iron 
oxide as the polymer represents the bulk of the particle’s volume. Different sized 
nanoparticles have been demonstrated to use different receptor-mediated endocytosis 
mechanisms to enter the cells. For example, it was shown that 100 nm MNPs were 
endocytosed through caveolae-mediated endocytosis (Lim et al., 2012), 200 nm MNPs 
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through clathrin- or caveolae-mediated endocytosis (Huth et al., 2004) and 300 nm MNPs 
through micropinocytosis and clathrin-mediated endocytosis (Pickard et al., 2011). Different 
entry mechanisms may be associated with increased or decreased transfection efficiency. 
Additionally, suitable biocompatible and biodegradable polymer coating/matrices are also 
important for enhancing transfection, alongside size and magnetic properties of the 
nanoparticles (Kami et al., 2011).  
Another field where non-viral magnetic nanoparticle based transfection has been successfully 
used is in the generation of iPS cells. In 2011, Lee and coworkers demonstrated that 
nanofection-mediated iPS cells exhibited ES cell-like characteristics, including expression of 
endogenous pluripotency genes, differentiation of three germ layer lineages, and formation of 
teratomas (Lee et al., 2011). Our method could potentially be tried to further enhance 
efficiency of virus-free iPS cells generation, something very crucial for clinical applications 
in the field of regenerative medicine. Additionally, radioactive labeling of DNA could be 
used to determine more accurately the binding capacity of MNPs. It has been demonstrated 
by the experiments presented as part of this thesis that the method has significant potential for 
use as an effective, non-viral transfection agent for hMSCs, as well as for multiple primary 
cells and cell lines. These results show its diverse use and potential in regenerative medicine 
and tissue engineering research and applications.    
One major finding presented here, which should be further explored in the near future, is the 
always enhanced protein production under the magnetic field (both static and oscillating), 
which was first observed in NCI-H292 cells (Fouriki et al., 2010). Further experiments 
should help uncover the mechanisms behind this upregulation, which could be of high 
significance and applicability in future translational assays.  
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Finally, although it currently appears there is a lot of promising evidence for the future use of 
these systems for gene therapy, there are still some extremely difficult cases which remain a 
challenge. The lateral motion of the MNP/gene complex, which is primarily perpendicular to 
the translational force exerted on the MNPs by the field gradient, may prove useful for 
promoting efficiency in such cases, including the penetration of the mucus lining in the lung 
and delivery of the therapeutic genes for cystic fibrosis (Ferrati et al., 2004; McBain et al., 
2008). As already discussed in Chapter 1, there is no available cure for cystic fibrosis yet and 
it is considered a good candidate for gene therapy (Mason & Dunhill, 2008). Studies 
addressing the issue using both viral and non-viral vectors have not been successful 
(Griesenbach et al., 2006; Flotte, 2007; Mueller et al., 2008; Mimoto et al., 2010) and the 
same was the case in a very preliminary experiment using our method. However, since this 
method keeps overpassing most of the barriers for successful and efficient transfection, it is 
possible that with the right adaptations it will also prove successful in this case.  
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